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1.1. Introduction: Towards a system-based pharmacology 
approach to predict developmental changes in renal drug 
clearance in children
The response to drugs may be different in children compared to adults. 
Notwithstanding these differences, to date, evidence-based drug dosing algorithms 
are often lacking in the pediatric age range [1-4]. This can be explained by ethical, 
practical and economical issues which may seriously impede the design and 
implementation of pediatric clinical trials [2, 4, 5]. Consequently, drug doses for children 
are often empirically derived from adult dosing guidelines based on bodyweight or 
age, irrespective the physiological differences due to developmental changes [1, 3, 
6-8]. Despite the shortcomings of empirically scaling from adult dosing regimen to 
children, it is still the most commonly used approach which may result in therapeutic 
failure [9] or occurrence of toxic effects [10-13].
These differences in drug response between children and adults may be caused by 
differences in pharmacokinetics (PK), pharmacodynamics (PD) or both. While a child 
grows, differences are seen in body composition, maturation of drug metabolizing 
enzymes, cardiac output, blood flow and functionality of the drug eliminating organs 
liver and kidneys. All these differences are seen as potential sources influencing 
the pharmacokinetics of drugs [14]. Furthermore, developmental changes in the 
functionality and expression of receptors and differences in disease status may alter 
the pharmacodynamics and therefore the pharmacological response to drugs [14, 
15]. In order to develop rational evidence-based dosing schemes in children, these 
developmental changes in pharmacokinetics and pharmacodynamics need to be 
characterized. 
To counterbalance the lack of information on PK and PD of drugs in children, 
the Pediatric Regulation (EMA) came into force in Europe [16]. The main aim of this 
regulation was to facilitate the development and availability of drugs for children. 
Furthermore, funding by the European Union became available to promote research 
of off-patent drugs in children. As a result a large increase was seen in the number 
of PK and/or PD studies in children, potentially leading to evidence-based and 
individualized dosing schemes in children. However, despite the efforts of the industry 
and academia to perform research in children, most of the drugs in pediatrics are still 
used in off-label or unlicensed manner [1, 3, 4].
Performing PK/PD studies in the pediatric age range is very challenging. Besides 
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the fact that only a limited number of children is available, since studies are only 
performed in children suffering from a particular disease, also ethical, practical and 
economical issues occur (e.g. limited number and volume of blood samples). In addition 
to the use of very sensitive analysis techniques which require only a very small blood 
volume, advanced statistical tools are needed so that the burden for each child is kept 
to a minimum while still addressing the study objective: the development of rational, 
evidence-based and individualized dosing regimens in children. Consequently, the 
population approach using non-linear mixed effect modeling is the preferred approach 
since all data of all patients are simultaneously analyzed while still taking into account 
that different observations originate from different patients. An important advantage 
of this approach is that it allows the analysis of dense but also sparse and unbalanced 
data, which is often encountered in clinical practice. Furthermore by using this 
approach both the inter- and intra-individual variability can be estimated separately 
[17, 18]. Finally specific predictors of variability also called covariates, in PK or PD can 
be identified which subsequently can be used to determine new evidence-based and 
individualized dosing regimens [19-22].  
However, if for each drug, models needs to be developed and validated over the 
entire pediatric age range to obtain rational, evidence-based and individualized dosing 
guidelines, a tremendous amount of time and costs will be involved. Therefore the 
objective of the research described in this thesis was to describe the developmen-
tal changes in renal function by using a more system-based pharmacology approach 
[23]. This means that the developmental changes of the various subprocesses that 
contribute to renal clearance (glomerular filtration, tubular secretion and tubular 
reabsorption) need to be characterized. 
Renal clearance is responsible for the elimination of a large number of wa-
ter-soluble drugs and their metabolites. Various mechanisms contribute to the renal 
clearance: glomerular filtration, tubular secretion and tubular reabsorption. Each 
of these processes exhibit different rates of maturation in an independent way [24]. 
Although renal clearance is well defined in adults, limited information is available on 
the developmental changes in renal function in the pediatric age range. It is known 
that nephrogenesis starts at week 5-6 of gestation and continues until 36 weeks of 
gestation [14, 25, 26]. Development of tubular processes starts from 36 weeks of gestation 
and continues during childhood. During the first weeks of life, a rapid increase is 
seen in glomerular filtration and tubular functions due to haemodynamic changes [24]. 
Moreover, development in tubular processes seems to be delayed in comparison with 
glomerular filtration. For the glomerular filtration rate, it is known that adult levels 
are reached at approximately 6-12 months of age when corrected for body surface 
area. Meanwhile the development of tubular processes is more gradual since adult 
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levels are not reached until 1-5 years of age [24]. Since the renal elimination of most 
of the drugs is covered by glomerular filtration and only a limited number of drugs 
is undergoing tubular secretion or reabsorption, the primary focus in this thesis was 
to describe the developmental changes in glomerular filtration. Moreover, once the 
developmental changes in GFR are characterized, this can be used to describe the 
maturation of tubular processes. 
To estimate GFR, different methods can be used. First, GFR can be measured by 
determination of the inulin clearance which is considered to be the gold standard 
because inulin is an exogenous substance that is completely filtered by the glomer-
ulus and not secreted or reabsorbed by the renal tubules [27]. Although simplified 
methods have been proposed to determine GFR from the decrease of the inulin con-
centration in plasma rather than from 24 hour urine collection, still some limitations 
are linked to this technique. These can make the routine application cumbersome in 
paediatric and certainly in neonatal clinical practice. Some of the constraints are the 
limited commercial availability of inulin, the burden caused by collection of additional 
blood samples and the advanced assay methodology that is required to measure 
inulin concentration in blood [28-30]. A second method to assess GFR is by measuring 
creatinine clearance. There is however a number of factors that must be taken into 
account when using creatinine clearance as a substitute for glomerular filtration. 
First of all creatinine is not only filtered by the glomerular filtration but also in part 
secreted by the tubular secretion [24, 31]. Moreover, the formation of creatinine is 
determined by age, muscle mass and gender and this complicates the estimation of 
creatinine clearance in children on the basis of plasma concentrations. In addition, 
in the first days of life, serum creatinine concentrations reflect maternal creatinine 
concentrations [25, 32, 33]. Furthermore, serum creatinine concentrations are known to 
increase with a peak in the second part of the first week of life with a subsequent 
progressive decrease throughout neonatal life making it difficult to interpret the 
renal function based on creatinine in the first week of life. The peak creatinine con-
centration is most pronounced in the most immature neonates and is due to passive 
back leak of creatinine through renal tubular leaky cells [33]. Although the Schwartz 
formula based on creatinine concentrations and body length is often used to estimate 
GFR, it often leads to overprediction of GFR [34]. Due to the reasons mentioned 
above, it is preferred not to use creatinine as a marker to measure GFR in children 
and certainly not in neonates. A third method to measure GFR is by injection of 
radioisotopes [28, 29]. This method is also not recommended in children for the same 
reasons mentioned as with inulin. 
Therefore, the most pragmatic method, which has been proposed before, is to 
assess GFR in the pediatric age range by determining the clearance of a drug which 
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is exclusively eliminated by GFR [35-37]. Moreover, when evaluating GFR by describing 
the clearance of renally excreted drugs, information can directly be obtained during 
clinical practice. Finally, in the context of the system-based pharmacology approach, 
it will also be evaluated whether information on the developmental changes in the 
clearance of one drug can be used to describe clearance of other drugs eliminated 
by the same route. This implicates that a distinction is made between system-specific 
and drug-specific properties to evaluate whether the system-specific properties 
derived from one drug describing the underlying physiological changes, can be ex-
trapolated to other drugs, eliminated through the same route. 
1.2. Developmental changes in glomerular filtration in preterm 
and term neonates by describing the pharmacokinetics of 
renally excreted antibiotics
In Section II of this thesis a system-based pharmacology approach is used to 
describe the developmental changes in GFR in preterm and term neonates. Using 
this approach, the pharmacokinetics of one specific aminoglycoside, i.c. amikacin, a 
drug which is almost entirely eliminated by GFR, are first described in preterm and 
term neonates. To characterize these developmental changes, a systematic covariate 
analysis is performed in which all potential covariates are tested for significance 
and included in the model when they are sufficiently predictive of the variability 
in amikacin clearance. Based on the model, including the model covariates, a new 
model-based dosing algorithm can be developed for amikacin in neonates. Secondly, 
to extrapolate information from one drug to another drug, a distinction is made 
between system-specific and drug-specific information in the derived model. In this 
respect, the pediatric covariate model can be considered to contain system-specific 
information on the developmental changes in GFR and therefore the covariate model 
can be extrapolated to the other renally excreted drugs [23, 38, 39].
In chapter 3, the developmental changes in GFR were quantified in 874 preterm 
and term neonates aged between 1-30 days by describing maturation in clearance of 
amikacin. In a systematic covariate analysis the influence of birth bodyweight, current 
bodyweight, postmenstrual age, gestational age, postnatal age, co-administration of 
ibuprofen and creatinine was studied. To ascertain that the model was able to describe 
the data without bias, the model was both internally and externally validated [40, 41]. 
The internal validation was based on two different methods: a bootstrap analysis and 
a normalized prediction distribution error (NPDE) analysis. For the external valida-
tion two different datasets were used. Finally simulations were performed to obtain a 
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new optimized and individualized dosing algorithm for amikacin in preterm and term 
neonates which would result in achieving target peak and trough concentrations in 
each individual neonate.
In chapter 4 the new-model based dosing regimen for amikacin in neonates 
was tested in a prospective clinical trial including 579 preterm and term neonates. In 
this study it is assessed whether the proposed dosing regimen for amikacin resulted 
in the expected concentrations and whether further dose adjustments need to me 
made. 
In chapter 5 the system-based pharmacology approach is applied for between 
drug extrapolations. In this chapter it is illustrated how information of one drug 
is extrapolated to other drugs eliminated through the same route. Using this 
approach, it is hypothesized that covariate models contain quantitative information 
on the developmental changes in the underlying physiological pathways [23]. To test 
this hypothesis, the covariate model of amikacin, describing the developmental 
changes in GFR in preterm and term neonates, was directly extrapolated to four 
other renally excreted drugs: netilmicin, tobramycin, vancomycin and gentamicin. 
Meanwhile, the population values describing the absolute values of parameters like 
clearance and volume of distribution are still estimated in the population analysis as 
they are considered to be drug-specific. The descriptive and predictive performance 
of the models using the amikacin covariate model was compared to the independent 
reference models which were developed for each dataset based on a systematic 
covariate analysis. This approach in which information of one drug is extrapolated 
to another drug can be considered a semi-physiological approach which may lead 
to optimization of sparse data analysis in children. Furthermore another not 
unimportant advantage is the large reduction in both time and costs when models 
can be developed using information of one drug to another drug. 
1.3. Developmental changes in renal function (GFR and tubu-
lar processes) in preterm and term neonates by describing 
the pharmacokinetics of cefazolin
Renal function consists of glomerular filtration, active and passive tubular 
secretion and reabsorption. Cefazolin is a drug which is eliminated by both GFR 
and active tubular secretion [42, 43]. In chapter 6, the pharmacokinetics of cefazolin 
are described in preterm and term neonates. On the basis of both total and free 
cefazolin concentrations in 36 neonates, a one compartment pharmacokinetic model 
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was developed in which non-linear protein binding was taken into account. In a sys-
tematic covariate analysis, all potential covariates (age and weight related covariates, 
albumin, creatinine, free fatty acids, bilirubin, gender) were tested for significance. 
In addition, based on the final model, Monte Carlo simulations were performed to 
illustrate the exposure to cefazolin following currently used dosing regimens and to 
derive an optimal dosing regimen in preterm and term neonates.
To be able to quantify the developmental changes in tubular secretion in neonates, 
it was hypothesized that when clearance of cefazolin was higher than the clearance 
through GFR, it is due to clearance by tubular processes. In the previous section, 
the developmental changes in GFR were quantified by describing the pharmacoki-
netics of amikacin in neonates. Consequently, this semi-physiological GFR model 
based on amikacin clearance was directly incorporated on cefazolin clearance. The 
remaining part was then considered as describing the clearance by active tubular 
secretion. To quantify these developmental changes in active tubular secretion, a sys-
tematic covariate analysis was performed. These results are discussed in the section 
“Summary, conclusions and perspectives” of this thesis. 
1.4. Renal and hepatic elimination of propylene glycol in 
preterm and term neonates
Besides the active substance(s), drug formulations often contain excipients. 
One of the frequently used excipients to increase the solubility and/or stability is 
propylene glycol. In general, excipients are considered to be safe, however toxic 
effects were reported in adults, children and neonates due to the administration of 
propylene glycol [44-48]. This may be explained by the limited knowledge on the phar-
macokinetics of propylene glycol. In adults, it is known that 45% of propylene glycol 
is eliminated through the renal route and 55% is metabolized in the liver by alcohol 
dehydrogenase to lactate and pyruvate [49, 50]. However, renal clearance of propylene 
glycol is expected to be lower in neonates compared to adults, due to immaturity of 
the renal function. Therefore, the aim of this section was to characterize renal and 
hepatic elimination of propylene glycol in preterm and term neonates. 
In a first analysis (chapter 7) the pharmacokinetics of propylene glycol were 
quantified based on 372 plasma samples of propylene glycol co-administered with in-
travenous paracetamol or phenobarbital, available in 62 preterm and term neonates. 
Based on a systematic covariate analysis different covariates were tested. The final 
model was subsequently used to simulate exposure to propylene glycol upon ad-
17
Scope and Outline
ministration of paracetamol or phenobarbital in neonates using the dosing regimens 
applied in the study. 
In chapter 8 renal and hepatic clearance of propylene glycol was character-
ized based on both plasma and urine samples of propylene glycol in 69 preterm and 
term neonates using a one compartment model parameterized in renal clearance, 
hepatic clearance and volume of distribution. Based on this model, the percentage of 
propylene glycol eliminated through the renal route and hepatic route was quantified 
in preterm and term neonates.
1.5. Developmental changes in GFR from neonates until 
adults
Glomerular filtration is supposed to reach adult levels between 6 months – 1 year 
of age when expressed per m2 body surface area. However an exact quantification 
of the maturation of GFR throughout the pediatric age range is missing. Therefore, 
the aim in this section (Section V – chapter 9) was to describe the developmental 
changes in GFR across the entire pediatric age range from preterm neonates to 
adults. To perform this analysis, a system-based pharmacology approach was used 
since the developmental changes in GFR from neonates until adults were character-
ized by describing the pharmacokinetics of three renally excreted drugs: gentami-
cin, tobramycin and vancomycin in one analysis whereby again the distinction was 
made between system-specific and drug-specific properties (see Section II). Using 
this approach the covariate model on clearance for the three drugs is not tested 
separately but the same covariate model on clearance was implemented for the three 
drugs as this part of the model is considered to contain system-specific information. 
Finally the model describing the developmental changes in GFR across the pediatric 
range was validated by performance of an NPDE analysis [41].
1.6. Conclusion and Perspectives
Section VI of this thesis provides a summary of the results and conclusions of the 
different chapters of this investigation. Furthermore the results are discussed as 
well as the applicability of the different covariate models to other drugs. Finally, an 
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The Role of Population PK-PD Modeling in Pediatric Clinical Research
Abstract
Children differ from adults in their response to drugs. While this may be the 
result of changes in dose-exposure (pharmacokinetics (PK)) and/or exposure- 
response (pharmacodynamics (PD)) relationships, the magnitude of these changes 
may not be solely reflected by differences in bodyweight. As a consequence, dosing 
recommendations empirically derived from adults dosing regimens using linear 
extrapolations based on bodyweight, can result in therapeutic failure, occurrence of 
adverse effect or even fatalities. In order to define rational, patient tailored dosing 
schemes, population PK-PD studies in children are needed. For the analysis of the 
data, population modeling using non-linear mixed effect modeling is the preferred 
tool since this approach allows for the analysis of sparse and unbalanced datasets. 
Additionally it permits the exploration of the influence of different covariates such 
as bodyweight, age and other covariates, to explain the variability in drug response. 
Finally, using this approach, these PK-PD studies can be designed in the most efficient 
manner in order to obtain the maximum information on the PK-PD parameters 
with the highest precision. Once a population PK-PD model is developed, internal 
and external validations should be performed. If the model performs well in these 
validation procedures, model simulations can be used to define a dosing regimen 
which in turn needs to be tested and challenged in a prospective clinical trial. This 
methodology will improve the efficacy/safety balance of dosing guidelines which will 
be of benefit to the individual child.
2.1. Introduction
Children differ from adults in their response to drugs. These differences may 
be caused by changes in the pharmacokinetics (PK) and/or pharmacodynamics (PD) 
between children and adults and may also vary between children of different ages. 
The PK of a drug includes processes of absorption, distribution, metabolism and 
elimination of a drug whereas the PD comprises the physiological and biological 
response to the administered drug and therefore may represent both efficacy and 
safety measures. While a child grows, enzyme pathways (involved in the PK), function 
and expression of receptors and proteins (involved in the PD) mature, which can be 
referred to as ‘developmental changes’ in childhood. The maturation rates of these 
developmental changes vary however between the pathways and receptors and often 
do not correlate solely with the increase in bodyweight of the child. The question is 
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therefore how to obtain data in children that allow for the study of these develop-
mental changes ultimately resulting in evidence based dosing regimens for drugs in 
children.
To date, only a small number of drugs used in children is licensed for use in this 
specific group. Up to 70% of the drugs in pediatric intensive care, and 90% of the 
drugs in neonatal intensive care, are prescribed in an off-label or unlicensed manner 
[1-4]. Pediatric dosing regimens are usually empirically derived from adult regimens 
using linear extrapolations based on bodyweight. Since these developmental changes 
are non-linear dynamic processes, this dosing paradigm may result in under or 
over-dosing particularly in specific age groups. This may cause therapeutic failure, 
occurrence of severe adverse effects or even fatalities such as fatalities occurring 
after long-term sedation with high doses of propofol [5, 6] and occurrence of the grey 
baby syndrome in neonates after treatment with chloramphenicol [7, 8]. As a result, 
dose adjustments in the younger age groups are often proposed. For vancomycin 
for example lower doses are administered in neonates younger than 1 week (20 mg/
kg/day) compared to 1-4 week-old neonates (30 mg/kg/day) and children between 1 
month and 18 years (40 mg/kg/day) [9]. 
Instead of the a priori use of bodyweight for dosing guidelines in children, detailed 
information on PK and potentially also the PD needs to be considered in order to 
define effective and safe dosing regimens throughout the pediatric age range. The 
lack of PK and PD information on drugs in children has lead to the European Regu-
lation which entered into force in 2007. This law imposes pharmaceutical companies 
to perform research in the whole pediatric age-range for all drugs that are developed 
for the European market, by requiring the submission of a pediatric investigational 
plan (PIP) in the early stages of the development of a new drug. In this PIP, a full 
description has to be given of the studies and of drug formulation in the pediatric 
population. In case little information is available about efficacy and safety of a drug, 
studies in children are only performed after more information is obtained in the 
adult population to increase the safety of the pediatric study [10-12]. The main targets 
of introducing the Pediatric Regulation were to facilitate development and availability 
of medicines in children between 0 and 17 years, to improve the availability of infor-
mation about medicines used in children, to ensure that the medicines are of high 
quality, can be administered in a safe and effective way and that pediatric studies are 
performed in an ethically correct way [10]. The reward for this effort is a six month 
supplementary production certificate for the pharmaceutical company.
Both for industry and for academic researchers, performing (PK-PD) studies in 
children in order to develop rational dosing schemes is very challenging because 
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of ethical and practical issues. Unlike studies in healthy adults, research in healthy 
children is considered to be unethical, so all pediatric studies are performed in the 
vulnerable group of children suffering from a disease. In all clinical trials, an informed 
consent has to be signed by the patient before he or she can be enrolled into a trial. 
In pediatric trials, this informed consent can not be obtained by the patient that 
participates in the trial, and is therefore replaced by the consent of the parents or 
guardians. In older age groups, in addition to this consent, an assent is used in which 
the aim of the study is explained in an age-appropriate language so that children can 
understand [1, 4, 13]. 
Apart from ethical issues, practical challenges also occur when performing studies 
in children. There are limitations to the number and volume of samples that can be 
obtained, resulting in infrequent sampling possibilities and the need for advanced drug 
assay techniques with improved sensitivity. Another complicating factor is the limited 
available number of subjects that suffers from the same disease. Finally, pharmaco-
dynamic endpoints that measure the efficacy of the drug, and which are validated for 
children may be lacking. All these factors call for highly advanced study designs and 
analysis techniques so that the burden for each child can be kept to a minimum while 
still addressing all the study objectives.
This paper aims to inform clinical pharmacologists, pediatricians and pharmacists 
about population PK-PD modeling in pediatric drug research. Advanced statistical 
tools are discussed that can be used to develop rational dosing schemes based on the 
PK and PD of a drug in children, despite practical and ethical restrictions. Using these 
tools, covariates can be identified in order to define appropriate doses and dosing 
intervals based on individual characteristics of each child with minimal burden to 
each patient. The paper also describes how to evaluate the predictive performance 
of the models by different validation methods including a prospective clinical trial. 
Ultimately, the efforts result in an individualized dosing regimen based on the PK-PD 
relation through the pediatric age-range.
2.2. PK-PD in children
Developmental changes in childhood can affect all PK processes from absorption 
until elimination as well as the pharmacodynamic effects. For example, in neonates 
intra-gastric pH is elevated (>4) which may increase the bioavailability of acid-labile 
compounds (penicillin G) and decrease the bioavailability of weak acids (phenobarbi-
tal) when given orally [14]. Additionally, gastric emptying in neonates is delayed, which 
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means that also the absorption of drugs e.g. paracetamol is slower in neonates [15, 16]. 
Other examples are changes in metabolizing enzyme capacity in children. Although 
most uridine 5’-diphosphate (UDP)-glucuronosyltransferases (UGTs) and P-450 cy-
tochromes (CYPs) are expressed during the first week of life, the activity at birth 
in comparison with adults is often low, e.g. UGT2B7 activity at birth is around 10% 
of the adult level and maturation rates of different enzyme systems are known to 
mature at different rates [14, 17-20].
In addition, renal function and liver flow are influenced by physiological changes 
depending on age, e.g. the glomerular filtration rate in mL/min/70kg in full term 
neonates is 35% of the adult value, while mL/min/70kg adult values are reached at 
approximately 1 year old [21]. When using units of mL/min/70kg however, it should 
be realized that actual values of GFR in children are still very low compared to adult 
values because of correction for differences in total body weight between adults and 
infants.
Furthermore the body composition of children changes continuously resulting in 
an age-dependent proportion of body water and fat, which influences the distribution 
of drugs. For example, the total amount of body water (80-90 % of the bodyweight) 
is higher in neonates compared to adults (55-60%). Hydrophilic drugs like aminogly-
cosides have a larger volume of distribution in neonates which can be explained by 
larger extra-cellular fluid (45% of the bodyweight) compared to adults (20%) [14, 22].
In order to characterize the specific influence of developmental changes in 
childhood on the PK of a drug, concentration-time profiles are necessary, which 
require measurements of drug concentrations. For ethical reasons, in pediatric 
studies, discomfort, like pain and anxiety associated with venipuncture, must be re-
stricted and practical issues limit the volume and amount of blood samples that 
can be obtained. Therefore, sensitive analysis techniques requiring only small blood 
samples should be used. While HPLC methods have reported to require only 50 µL 
of blood [23], more recently LC-MS methods can measure up to ten different drugs in 
volumes as low as 50-100 µL [24]. Additionally, also alternative matrices such as saliva 
should be explored as a non-invasive, more child-friendly alternative to measure a 
drug concentration. An example in this respect is a LC-MS/MS method which was 
developed and validated for the measurement of busulphan in saliva [24]. Also the use 
of a dried blood spot method e.g. for tacrolimus can facilitate the measurement of 
drugs in children [25]. Another method is capillary electrophoresis which requires only 
a low sample volume for the quantification of drugs in biological fluids [26].
Changes between children and adults may also result from differences in the 
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pharmacodynamics of a drug in children, e.g. by changes in the relative number and 
function of receptors. These age-related PD differences are until present rarely 
reported in literature, but one of the few examples is the increased sensitivity to 
d-tubocurarine, an antagonist of nicotinic neuromuscular acetylcholine receptors, in 
neonates and infants compared to children and adults [27]. Other examples are the 
observed lower minimum alveolar concentration (MAC) of isoflurane in preterm 
neonates compared to full-term neonates and older children [28, 29] and the different 
sensitivity to bronchodilators because of the lack of smooth muscles in the airways 
in neonates [30].
To study the PD of a drug in children, the use of a PD endpoint which is validated 
for use in children is a prerequisite. An illustrative example is the measurement of 
pain in young children. Since they are not able to report their pain using a visual 
analogue scale, an observational scale has been developed. This comfort behavioral 
(COMFORT-B) scale was developed and validated for use in children under the age 
of three years [31]. The scale assesses six behavioral items: alertness, calmness, muscle 
tone, body movement, facial tension, and crying (non-ventilated children) or respira-
tory response (ventilated children). All items range from 1 (no distress) to 5 (severe 
distress), resulting in a total score of varying from 6 to 30. This validated scale can 
then be used as a PD endpoint for the development of PD models for pain and/or 
sedation in children of different ages [32-34].
The influence of covariates such as the developmental changes, disease status and 
genetics on the PK and PD of drugs in children is depicted in Figure 1.
Figure 1: Schematic representation of the relationship between dose and concentration (pharmacokinetics, PK) and 
between concentration and a pharmacological (side) effect (pharmacodynamics, PD). Important covariates which may 
affect both the PK and/or PD are bodyweight, age, disease status (e.g. critically ill versus healthy children) and 
genetics.
PKDose Concentration




When both the PK and PD of a drug in children are characterized, the developed 
models can be used to derive rational dosing regimens with predictable efficacy and 
concentration profiles. An example of such a PK-PD model with a derived dosing 
regimen is an article published by Peeters et al. In this paper both the PK and the 
PD were characterized in children, the latter with the use of the COMFORT-B scale 
as pharmacodynamic endpoint [33]. Based on the model it was found that propofol 
clearance is two times higher in non-ventilated children compared to ventilated 
children and adults. For the PD, a model was derived in which an effect of propofol 
was characterized within a naturally occurring sleep pattern of children in the ICU. 
Both models (PK as well as PD) were used to simulate concentrations as well as the 
effects that could be expected using different dosing schemes (Figure 2). As a result, 
based on this PK-PD model, a propofol dose of 30mg/h was recommended for a 
child of 10 kg which will result in adequate COMFORT-B scales in the night following 
craniofacial surgery.
Figure 2: Simulation of propofol concentrations and response using COMFORT-B score versus time based on 
developed PK and PD models, after administration of different doses of propofol (0, 18, 30, and 36 mg/h) for a 10 
kg and a 5 kg non-ventilated infant in the first night at the Intensive Care following craniofacial surgery. Target 
COMFORT-B scores are between 12 and 14 preferably. Reproduced from [Peeters MY, Prins SA, Knibbe CA, DeJongh 
J, van Schaik RH, van Dijk M, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in 
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2.3. Methods to analyse data: standard two-stage or popula-
tion approach
When concentration-time and concentration-effect datasets obtained in children 
are considered for analysis, two different methods can be applied: the standard 
two-stage approach and the population approach using non-linear mixed effect 
models [35-38]. When using the standard two-stage approach or classical approach, in 
a first step parameters are estimated in each individual based on individual concen-
tration-time profiles (figure 3A). In a second step, these parameters are summarized 
by calculating the mean or median of the parameters and the variability between 
subjects (SE or IQR). A major drawback of this methodology is that this approach 
requires a relatively high number of samples in each individual patient (Figure 3A) 
while each patient has to contribute roughly the same number of samples. Moreover 
it is very difficult to distinguish between inter-individual (variability between subjects), 
intra-individual and residual variability (variability within one subject, measurement 
error, and model misspecification) and as a result inter-individual variability is often 
overestimated [39].
Since usually only a limited number of observations can be obtained in pediatric 
subjects, the population approach using non-linear mixed effect modeling to obtain 
PK and PD parameters, is the preferred approach [37]. The population approach differs 
from the standard two stage-approach in the fact that the analysis is based on simul-
taneous analysis of all data of the entire population while still taking into account 
that different observations come from different patients (Figure 3B). Additionally 
the population approach allows not only for the analysis of dense data but also for 
sparse (limited number of observations per individual) and unbalanced data (unequal 
distribution of observations in various parts of the concentration-time profile in the 
individuals) or a combination of both. Finally both the interindividual and intra-indi-
vidual variability are separately estimated in the dataset using this approach.
As a result of this methodology, when designing a pediatric study of which the 
data will be analyzed using the population approach, it is advisable to collect samples 
at different times (or time-windows) or to set alternating sampling schemes in 
subgroups of patients. This also means that (part of the) samples can be collected 
during routine clinical sampling. Consequently, the burden for the child that partici-
pates in the trial is reduced and the statistical power to develop a model describing 
the concentration-time or concentration-effect profile is not affected or improved.
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The term ‘mixed’ in non-linear mixed effects modeling stands for a mixture of 
fixed and random effects. For the fixed effects, a structural model describing the 
PK or PD is chosen (e.g. a two-compartment model for PK or an Emax model for 
PD). The random effects quantify the variability that is not explained by the fixed 
effects. These random effects include inter-subject and intra-subject and random 
variability  (Figure 4), which are both simultaneously and separately estimated. It is 
often assumed that the variability between subjects follows a normal distribution 
with a mean of zero and variance . Equation 1 is used to describe the relationship 
between individual and population parameter estimates.
 (Equation 1)
where  represents the parameter of the ith subject,  the population mean, 
and  the variability between subjects. The residual error is in generally described 
Figure 3: Concentration-time profiles of the same study using two different approaches. In figure 3A the standard 
two-stage approach is applied to a rich dataset. 3B shows the population approach with mixed effect modeling 
applied to the same dataset using only two datapoints for each individual so a sparse dataset is created. In 3A, in 
each of the six individuals 10 samples are available. The different symbols correspond to different individuals. Each 
black line corresponds to a separate fit to the 10 data points of each individual.
In 3B, which uses the mixed effect modeling approach, two samples of the 10 per subject in 2A are used. The 
different symbols correspond to the six different individuals. The black line illustrates the concentration time plot 
based on the population mean values of the PK parameters (PRED). The grey lines show the plots of the individual 
patients, which are based on the population mean values together with the measured concentrations of the specific 
individual (IPRED).
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using a proportional error (error is dependent on the concentration, which means 
a higher absolute error at higher concentrations (equation 2)) or additive error 
(constant for all observations (equation 3)) or a combination of both. This means for 
the th observed concentration of the th individual the relation ( ):
 (Equation 2)
 (Equation 3)
where  is predicted concentration and  is a random variable with mean zero 
and variance .
In general, model building requires three different steps. First a structural model 
(fixed effects) has to be designed, then a statistical sub-model (random effects) has to 
be developed and in the final step a covariate sub-model is identified. 
The structural model describes the overall trend in the data. The choice of struc-
tural model (e.g. one, two or three-compartment model for PK and an Emax model 
for PD) is to be based upon the best a priori information about the drug to be studied 
[40]. The structural model uses fixed effects parameters such as clearance and volume 
of distribution for PK or Emax and EC50 for PD. The population values for these pa-
rameters are called typical values (TV).
After selecting the structural model, the statistical sub-model which accounts 
for the inter-individual as well as the residual variability is chosen and tested. Infor-
mation on both inter- and intra- and residual variability is of clinical value, because 
it describes differences in clinical response between and within patients and may 
therefore provide guidance to rational dose adjustments. With the population 
approach, both these random effects are obtained, apart from estimates of both the 
population values (TV) and the individual values of PK and PD parameters (so called 
post hoc parameter estimates). 
In the final step the covariate sub-model is determined which expresses re-
lationships between covariates and parameters of the structural model (e.g. 
influence of bodyweight on volume of distribution or clearance). Covariates can 
be individual-specific (age, bodyweight, genetic profile, etc) or time-varying (renal 
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function, hemodynamic parameters, body temperature etc). The covariate analysis 
will be explained more in details in the following section. 
As these three models are interrelated, the choice of the structural (and sta-
tistical) model may affect the choice of the covariate model and vice versa. The 
process of finding a model that adequately describes the data is thus an elaborate 
task, where model checking/refining is performed in several steps. To assess model 
fit in relation to the observed concentrations or effect measures, scatter plots or the 
so called goodness-of-fit plots are created (see Validation of the PK-PD models). Free 
software packages (Xpose, PSN etc.) are available to generate these plots.
The most commonly used software package for model building, which is also 
supported by the European Medicines Agency (EMEA) is the nonlinear mixed-ef-
fect modeling program NONMEM (GloboMax/ ICON, Ellicott City, MD) [4, 41-43]. 
NONMEM estimates parameters (e.g. clearance, volume of distribution or EC50) via 
a maximum likelihood approach. This means that with the given data, the estimations 
of the parameters are the estimations which occur with the highest probability. Al-
ternative software packages that can be used are for example Monolix, WinNonMix, 
USC*PAC which uses nonparametric maximum likelihood methods [44] or ADAPT 
using maximum a posteriori (MAP) methods [45].
Figure 4: In 4A, the inter-individual variability is shown between three individuals who received the same dose. 4B 
presents the intra- or residual variability by showing the concentration-time profile after repeated administration. 
Both these random variables are assumed to be normally distributed with a mean of zero and a variance of 2 or 
2 respectively.
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2.4. Covariate analysis 
To determine the optimal dose based on the individual characteristics of a patient, 
a covariate analysis has to be performed [40, 46, 47]. The aim of the covariate analysis is 
to identify specific predictors (covariates) of PK and PD variability and can typically 
be studied in population models. Covariate analysis involves the modeling of the 
distribution of the individual parameter estimates as a function of covariates which 
can be of demographic (e.g. age, bodyweight, gender), patho-physiological (e.g. renal 
or hepatic function), and genetic/environmental origin and/or be the result of the 
concomitant use of other drugs, which may influence the PK and/or PD. The identifi-
cation of predictive covariates for variability provides the scientific basis for rational 
and individualized, patient tailored dosing schemes. 
The influence of developmental changes in childhood can be explored primarily 
by using size and/or age as covariates. Size (bodyweight) can be incorporated into 
the model using two different approaches. The first approach or ‘allometric size 
approach’ includes size a priori by using a bodyweight based exponential equation 
with a fixed exponent of 0.75 for clearance and 1 for volume of distribution [48-52]. 
Once size is incorporated in the model using this fixed manner, the influence of 
age is investigated, being the difference between actual value of the PK parameter 
and the 0.75 allometric equation. When incorporating age as a covariate, different 
age descriptors may be used like postmenstrual age (PMA), gestational age (GA) or 
postnatal age (PNA) [53]. The choice for any of these age descriptors is based on the 
results of the systematic covariate analysis as described below [50, 54]. In the second 
approach or ‘systematic covariate analysis’, bodyweight is regarded as a covariate as 
any other which means that the descriptive properties on the PK parameters are 
evaluated in a systematic covariate analysis as described below [55-57]. 
In a systematic analysis, when studying the influence of covariates, scatter plots 
and summary plots of individual parameter estimates and/or weighted residuals 
versus covariates are used to screen for appropriate covariates to include in the 
covariate sub-model. Additionally these plots are used to explore the nature of the 
influence of the covariate (linear, exponential, allometric, subpopulations etc). Likely 
candidate covariates are then added to the model (forward inclusion). The influence 
of each covariate on the parameters is examined separately and compared to the 
simple model (no covariates). To assess whether the model with covariate statistical-
ly improved the fit to the data, the difference between their objective function value, 
referred to as log-likelihood ratio, is calculated. This ratio is assumed to be Chi-
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square distributed, which means that a reduction in objective function of 3.84 is con-
sidered to be significant (P<0.05) [43, 58]. Beside the reduction in objective function, 
goodness-of-fit plots of the simple model and covariate model are explored for diag-
nostic purposes. Furthermore, the confidence interval of the parameter estimates, 
the correlation matrix (indicates the relationship between two structural parame-
ters) and visual improvement of the individual plots are used to evaluate the model. 
Finally, a superior model is expected to reduce the inter-subject variance and/or 
the residual error terms. This procedure of covariate modeling implies that each 
covariate is only implemented if this can be fully justified by the data and the results 
of the statistic evaluations.
When two or more covariates are found to significantly improve the model the 
covariate that reduced the objective function most is included in the model after 
which the other covariates are tested again for their significance. After all covariates 
that significantly improved the objective function are added to the simple model, a 
backward deletion is performed, which means that each covariate is removed from 
the full model, one at a time (the one which causes the smallest increase in objective 
function first). Retaining or removing the covariate is statistically tested by the use of 
the objective function (Chi-square test) until each covariate has been tested. 
In datasets containing sparse data, there may not be enough information to accu-
rately estimate inter- and intra-individual variability. This causes the values of these 
parameters to shrink to 0, resulting in individual parameter estimates that are closer 
to the population parameter estimates than they really are. This phenomenon is 
called shrinkage [59]. Shrinkage may cause individual predictions, individual parameter 
estimates and diagnostics based on them to be less reliable. It can also hide, falsely 
introduce or distort the shape of covariate relationships.
Shrinkage is the result of properties of the data and is therefore difficult to avoid. 
One can only be aware of the presence of shrinkage, realize the influence it may have 
on the covariate analysis and use diagnostics other than those based on individual 
predictions or individual weighted residuals in the model building and model evalua-
tion procedures. 
2.5. Validation of PK-PD models
The objective of a PK or PK-PD modeling exercise is usually not just to describe 
the dataset of the sample of individuals that were studied. Generally, models are used 
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to simulate which concentrations and/or effects and their variability can be expected 
when different doses are given to future patients. These simulations may therefore 
lead to optimized dosing recommendations or to optimization of new studies for the 
entire population where the sample of individuals belongs to. It is often said that ‘all 
models are wrong, but some are useful’ [60]. In order to define whether a model is 
useful and valid for clinical and trial simulations, thorough evaluation and validation 
of the model is necessary. Although validations of PK models are only performed in 
17% of the published pediatric studies [4] and in 28% of the adults studies [61], proper 
model validations are an essential step in model building. For this purpose, different 
evaluation and validation methods are available. As described before [62], a proper 
validation and evaluation procedure includes an internal model evaluation followed 
by an external evaluation and a prospective clinical study. 
The first evaluation method is the basic internal model validation used to assess 
whether the model is able to describe the learning dataset (dataset used to develop the 
model) accurately and without bias. This evaluation should actually be considered the 
final stage of the model building procedure. Subsequently, in the external evaluation 
it is assessed whether the model is able to describe one or more external datasets 
(datasets other than the one used to develop the model) adequately. Alternatively 
if a dataset is sufficiently large the original dataset may be split in two so that the 
model is developed using one part (about two thirds) of the dataset and evaluated 
externally using the other part (one third) of the dataset. In pediatric studies, it is 
then especially important to stratify the data correctly and ascertain that all age 
groups are represented in equal proportions in both datasets. 
Various techniques are available for the validation and evaluation of population PK 
and PK-PD models (both for internal and external validation procedures).
• Basic goodness-of-fit plots ((1) individual predicted versus observed concen-
trations, 2) population predicted versus observed, 3) (conditional) weighted 
residuals versus time and 4) (conditional) weighted residuals versus dependent 
variable plots).  and  are calculated as the following:




• Where  is the vector of measurements,  is the expectation of the data 
and  is the covariance matrix of the data [63].
• These plots are used in model building, but can also be used to ascertain 
that there is no trend or bias in the model predictions of the final model. 
Furthermore, these plots can also be used for both the internal and external 
evaluation of the model. 
• In a bootstrap analysis new datasets are generated by resampling from the 
original dataset and is therefore an internal validation of the model. The new 
datasets are subsequently refitted to the original model, yielding mean values 
and standard errors for every model parameter.
• A bootstrap analysis provides information on the stability of the model and 
its dependence on specific individuals in the learning dataset. With the freely 
available PSN or Wings for NONMEM software packages an automated 
bootstrap analysis can be performed. 
• In a visual predictive check (VPC) [64] a PK or PD profile is simulated a 100 to 
1000 times and lines for the median values and their 90% prediction interval 
are plotted in a graph. The observed values in the internal or external dataset 
are subsequently plotted on top of this. It can then be visually checked 
whether 90% of the observations are within the indicated prediction interval 
and whether there is no bias in the observations compared to prediction 
interval. In figure 5, two examples of a VPC are given, showing when a model 
does not work and when a model does work on the same data.
• The VPC is a simulation-based diagnostic that can be used when the PK or 
PD profiles for all individuals in the dataset are similar and it allows for easy 
interpretation of the result. For this diagnostic tool, there are not statistical 
tests and all evaluations are based on visual evaluations. When the individual 
profiles are expected to deviate largely from one another because there is 
for instance a large variability in the time and amount of dose administrated, 
or when there are many covariates, the use of this diagnostic becomes more 
difficult. 
• Another simulation-based diagnostic which can be used for both internal and 
external validations is the normalized prediction distribution error (NPDE) 
[65]. An example of an NPDE published before is shown in figure 6 [55]. This 
method yields information on how accurate the model predicts the median 
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value of the observations and the variability within them. The interpretation 
of this diagnostic is less straightforward than for the VPC, but the advantage 
of this method is that it can be used when the variability in dosing regimen 
(both in time, amounts and rates) is high or when there is a large number of 
covariates in the model. This can for instance be the case for data obtained 
during routine pediatric clinical practice. Software (e.g. NPDE add-on package 
for R) [66] to perform this analysis is freely available. For the NPDE, beside 
visual evaluation of the plots, statistical tests are available. These statisti-
cal tests are however reported to be highly sensitive and powerful, so that 
decisions for the model should primarily be based on visual assessments. An 
example is the statistically significant deviation of zero of the mean value 
because of the large number of data, while the actual deviation is small (e.g. 
0.074) and not of clinical relevance.
If the model performed well in both the evaluation procedures, the dosing 
algorithm that results from the PK-PD model needs to be tested and challenged in a 
prospective (clinical) trial. If the predictive performance of the model is corroborated 
by the trial it can be used with confidence in clinical practice.
Figure 5: Two examples of a visual predictive check (VPC) are illustrated based on the same dataset (warfarin 
concentrations and prothrombin complex activity (PCA)) using two different models. In 5A the VPC of the effect 
compartment model is shown, while in 5B the VPC of the turnover model is demonstrated. The median (black thick 
line) and the 90% intervals (black thin lines) together with the observed data (PCA) (dots) are shown. Based on 
both graphics, the turn over model is the most appropriate model since 90% of the observations are lying within 
the prediction interval. Furthermore, unlike the effect compartment model, no bias is seen in the observations.
Reproduced from [Holford N, 2005. The visual predictive check - Superiority to Standard Diagnostic (Rorschach) 
Plots. PAGE 14, Abstr 738. (http://www.page-meeting.org/?abstract=738)].
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2.6. Optimal design of pediatric studies
When new population PK-PD studies are performed, it is important to design 
these studies in the most efficient manner possible to obtain maximum information 
about the PK and PD parameters so that they can be determined with the highest 
precision [51, 67]. When designing PK-PD studies in pediatrics certain factors need to 
be taken into account e.g. age-range of the pediatric group, therapeutic index, possi-
bility to collect blood samples, availability of validated PD endpoints for children, and 
the availability of sensitive analytical methods.
When optimizing a PK or PK-PD study design, using literature data from adults or 
children of different age-ranges or possible in vitro or pre-clinical data, a concentra-
tion-time or effect-time profile for a study can be simulated. This can help to identify 
possible shortcomings in the design or to perform a power-analysis. Alternatively 
software packages are available (WINPOPT [68], PopED [67] and PFIM [69]) that can help 
to identify the optimal number and time points of observations in a study based on 
the prior information on a drug [70]. To determine the appropriate sample size certain 
Figure 6: Example of a normalized prediction distribution error (NPDE) analysis, which show the NPDE distributions 
for morphine. The normal distribution is presented by the solid line. The values for the mean and standard devia-
tion of the observed NPDE distribution are given below the histogram, with * indicating a significant difference 
of a mean of 0 and a variance of 1 at the p<0.05 level, as determined by the Wilcoxon signed rank test and 
Fisher test for variance. Additionally the distribution of NPDE vs time after the first dose and NPDE vs the log of 
the concentrations are also shown. The dotted lines represent the 90% distribution of the NPDE. Reproduced from 
[Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, et al. Morphine glucuronidation in 
preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet2009;48(6):371-85] with permission 
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factors, which are summarized in Table 1, need to taken into account. Each of these 
factors can influence the required number of patients and/or samples in a positive 
or negative way. In a study of Peeters et al. [32] only 24 patients (aged between 3 and 
24 months) were required to determine both the PK and PD since rich sampling was 
performed (median of 11 samples per child) and no covariates were found in the rela-
tively homogenous population. This in contrast to a study performed by Knibbe et al. 
[55] in which 250 children were included. This higher number was required because in 
addition to the large dispersion in age from (preterm) neonates up to toddlers of 3 
years of age, only 1 to 4 samples were available for each subject. Moreover infusion 
rates and additional bolus doses varied for each child during the study to obtain the 
desired analgesic effect. In another example [71], only 6 patients (aged between 1 and 
5 years) were required in which 7 samples per patient were collected. This lower 
number of patients (N=6) compared to the study of Peeters et al. (n=24) can be 
explained because there often exist a lower variability in PK than in PD which results 
in a lower required number of patients (Table 1).
Table 1: Factors influencing the required number of patients and/or samples per patient.
Factor Number of patients/samples
Study of PK only relatively small number of patients/samples
Study of PK-PD relationship relatively high number of patients/samples
Even distribution of covariates (age, bodyweight)  number of patients/samples
 Number of changes in dose /- number of patients/samples (depending on other aspects 
of the study design)
 Number of samples/child  number of patients
Use of optimal sampling strategies  number of patients/samples
Different sampling windows(e.g. two or three 
sampling schemes)
 number of patients/sample
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2.7. Conclusions and perspectives
In view of the European Regulation which came into force in 2007, it seems now 
time to use the progress that has been made in the field of integrated PK-PD modeling 
[72] to develop rational and individualized dosing schemes for children. Because of the 
possibility to analyse sparse and unbalanced datasets thereby minimizing the burden 
for each child, population PK-PD modeling and simulation using non-linear mixed 
effect modeling has become the preferred tool to develop effective and safe dosing 
regimens for children. Specifically in pediatrics where the developmental changes 
have to be taken into account, which may influence the PK and/or the PD of the 
drugs, this advanced statistical tool is of critical value. 
Before dosing regimens can be tested in clinical practice, proper validations 
of the models should be performed, for which recently adequate tools have been 
developed. Beside internal and external validations, prospective clinical trials, which 
allow for the evaluation of the model based dosing regimens, are needed, not only 
to adjust the proposed dosing regimen but also to convince pediatricians to use the 
information that has been generated using these modeling exercises. 
Furthermore, one of the future goals may be to explore possibilities for 
cross-validation of the models, in which the reported influences of developmen-
tal changes on a certain PK or PD parameter of one drug are evaluated for use in 
another drug that go through the same metabolic route or share the same mechanism 
of action. In this respect, physiologically-based pharmacokinetic (PBPK) models are 
needed. PBPK models consider the physiological and biochemical processes by using 
in vitro data to describe the PK of drugs [73, 74]. The combination of these two ap-
proaches may use the information that is already available in a more optimal way in 
defining effective and safe dosing regimens for every individual patient.
In conclusion, analyses of pediatric data using population PK-PD modeling and 
covariate analysis will result in individualized dosing regimens for children of different 
age, bodyweight and genetic background. Thus population PK-PD modeling consti-
tutes an innovative approach to the study of drug effects in this very special patient 
population, which is otherwise difficult to study.
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Predicting glomerular filtration rate using clearance of amikacin in neonates
Abstract
Background and Objectives
During the newborn period and early infancy, renal function matures resulting in 
changes in glomerular filtration rate (GFR). This study was performed to quantify 
developmental changes in GFR in (pre)term neonates by use of amikacin clearance as 
proof of concept. The model was used to derive a rational dosing regimen in com-
parison to currently used dosing regimens for amikacin.
Methods
Population pharmacokinetic modeling was performed in NONMEM 6.2. using 
data of 874 neonates obtained from two previously published datasets (gestational 
age 24-43 weeks; postnatal age 1-30 days; birth weight 385-4650 g). The influence 
of different age and weight related and other covariates was investigated. The model 
was validated both internally and externally.
Results
Postmenstrual age was identified as the most significant covariate on clearance. 
However the combination of birth weight and postnatal age proved to be superior 
over postmenstrual age alone. Birth weight was best described using an allome-
tric function with an exponent of 1.34. Postnatal age was identified using a linear 
function with a slope of 0.2 while co-administration of ibuprofen proved to be a third 
covariate. Current weight was the most important covariate for volume of distribu-
tion using an allometric function. The external evaluation supported the prediction 
of the final pharmacokinetic model. This analysis illustrated clearly that the currently 
used dosing regimens for amikacin in reference handbooks may possibly increase the 
risk of toxicities and should be revised. Consequently a new model-based dosing 
regimen based on current bodyweight and postnatal age was derived.
Conclusions
Amikacin clearance, reflecting GFR in neonates, can be predicted by birth weight 
representing the antenatal state of maturation of the kidney, postnatal age repre-
senting postnatal maturation and co-administration of ibuprofen. Finally the model 
reflects maturation of GFR allowing for adjustments of dosing regimens of other 




During the newborn period and early infancy renal function matures, resulting 
in differences in glomerular filtration rate (GFR) at different stages of development. 
Although GFR is well defined in adults and many efforts were undertaken in the past 
to describe the maturation of GFR in the pediatric age range [1-6], the description of 
GFR is still limited in pediatrics, particularly in neonates. Nephrogenesis starts in 
the embryo at week 5-6 of gestation and is completed at week 36 [7-9]. Birth causes 
hemodynamic changes leading to an increase in renal blood flow and a decrease in 
renal vascular resistance resulting in rapidly rising GFR during the first weeks of life [4, 
7-9] approaching adult GFR levels at approximately 6-12 months of age. To define safe 
and effective dosing regimens for renally excreted drugs throughout the pediatric age 
range GFR, particularly in the first year of life, needs to be quantified. 
Different methods have been described to calculate GFR in neonates based on 
either determination of clearance of endogenous (creatinine [10, 11]) or exogenous 
compounds (inulin [11-14], radio-isotopes [11]). However several limitations are linked 
to each of these methods making routine application cumbersome in pediatric and 
certainly in neonatal clinical practice [10, 12, 15-17]. The most pragmatic method, which 
has been proposed before [18, 19] is to assess GFR in the pediatric age range by deter-
mination of the clearance of a drug that is exclusively eliminated by GFR. 
Therefore the aim of this study was to describe the pharmacokinetics of amikacin in 
preterm and term neonates with specific emphasis on clearance, since this parameter 
reflects GFR. A full covariate analysis was performed in which the influence of all 
bodyweight and age related, and other covariates on amikacin clearance were tested. 
The results based on the present amikacin datasets may ultimately serve to predict 
the maturation of both GFR and clearance of other renally excreted compounds in 
preterm and term neonates. 
3.2. Methods
3.2.1. Patients
Model building was based on data from 874 neonates, obtained after combining 
two published datasets [1, 2]. Both studies were conducted at the University Hospital 
Leuven Belgium. More details on the studies can be found in the original articles [1, 
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2]. Patients were enrolled in any of the two studies when at least two samples (peak 
and trough) were available for each patient. In the first study, 205 preterm neonates 
were considered. Forty-three patients were excluded since they received acetylsali-
cylic acid while other patients received ibuprofen (n=71), or no nonsteroidal anti-in-
flammatory drugs (n=91). In the second study, data from 715 patients were collected 
of which 71 patients received ibuprofen while the other patients (n=668) did not 
receive any nonsteroidal anti-inflammatory drugs. Three patients were considered 
as outliers due to administrative errors and were excluded from the second dataset. 
Data on prenatal use of betamethasone were also collected. More details on patient 
characteristics are shown in table I.
3.2.2. Drug administration, bloodsampling and assay
Before 2002, an amikacin dose of 20mg/kg/36hours was administered to neonates 
with a postmenstrual age below 30 weeks and 20mg/kg/24hours to neonates with a 
postmenstrual age of ≥30 weeks. After 2002, dosing was based on Langhendries et 
al.[20]. 
Amikacin (Amukin®; Bristol Myers Squibb, Braine-l‘Alleud, Belgium) was admin-
istered by an intravenous infusion over 20 minutes. Blood samples were collected 
just before (trough) and 1 hour after initiation of administration (peak) of the second 
dose. In some of the individuals, more than two samples were available. Amikacin 
concentrations were measured with fluorescence polarization immunoassay using an 
Abbott TDx kit (Abbott Laboratories, Diagnostics Division, Abbott Park, IL, USA). 
The lower limit of quantification was 0.8 mg/L. The coefficient of variation (CV) was 
<3.5% (assessed at 5,15 and 30 mg/L).
3.2.3. Pharmacokinetic analysis and model evaluation
The pharmacokinetic analysis was performed using the non-linear mixed effects 
modeling software NONMEM version 6.2. (Globomax LLC, Hanover, MD, USA). 
Tools like S-Plus, PsN, XPose and R were used to visualize and evaluate the models. 
Model building was performed in four different steps: (i) selection of structural 
model, whereby a one- as well as a two-compartment model was tested, (ii) choice 
of statistical sub-model, (iii) covariate analysis, (iv) model evaluation. To discriminate 
between different pediatric (covariate) models the framework proposed by Krekels 
et al. [21] to systematically evaluate the descriptive and predictive performance of 
pediatric models was used as a guide. This framework was used because evaluation 
tools that are routinely used in the adult population may not suffice in the pediatric 
population due to the scarcity of the data, the increased variability in dosing and 
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sampling schemes or the heterogeneity in the population. Therefore advanced 
and additional diagnostics next to standard tools may be required in the pediatric 
population compared to the adult population. This includes the following standard 
tools: discrimination between models by comparison of the objective function (OFV) 
and total number of parameters. A decrease in OFV of more than 7.8 points was 
considered as statistically significant (p<0.005 based on X2 distribution). Furthermore, 
the goodness-of-fit plots (both observed versus individual and population predicted 
concentrations, time as well as population predictions versus conditional weighted 
residuals) were evaluated with specific emphasis on observed versus population 
predicted concentrations [21]. Moreover improvement of individual plots, confidence 
intervals of the parameter estimates and correlation matrix were assessed. Over-
parameterization (ill-conditioning) was tested by calculating the condition number 
by dividing the largest eigen value to the smallest eigen value [22]. Finally in pediatric 
datasets there is often not enough information to accurately estimate the inter- and 
intra-individual variability. Therefore shrinkage was  considered [23]. Other pediatric 
specific evaluation tools are mentioned in the section Covariate analysis and  Internal 
evaluation procedure.
3.2.4. Covariate analysis
Covariates were plotted independently against the individual post hoc parameter 
estimates and the weighted residuals to visualize potential relationships. The 
following covariates were evaluated for inclusion: gestational age, postnatal age, 
postmenstrual age (sum of gestational and postnatal age), birth weight (weight at day 









Number of patients 162 712 80 159
Gestational age (weeks) 28 (24-30) 33 (24-43) 26 (24-41) 31 (25-42)
Postnatal age (days) 2 (1-3) 2 (1-30) 16 (3-30) 1 (1-3)
Birth weight (g) 1052 (475-1910) 1990 (385-4650) 880 (440-4430) 1740 (526-5420)
Current bodyweight (g) 1052 (475-1910) 1990 (385-4780) 1060 (450-4430) 1665 (526-5420)
Co-administration of ibuprofen 71 (43%) 47 (6%) 0 0
Birth weight = weight at day of birth, current bodyweight = weight at day of blood sampling
Table I: Clinical characteristics of the patients in both model building datasets and external datasets, presented as 
median (range).
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ibuprofen, prenatal exposure to betamethasone and creatinine concentrations. Infor-
mation on co-administration of dopamine, ventilation and positive blood culture was 
not available for all patients. Consequently they could not be evaluated as possible 
covariates. However in the past it was shown that the impact of these covariates was 
not significant [1, 6, 24].
Potential covariates were separately implemented into the model using a linear or 
allometric equation (equation 1).
 (Equation 1)
In this equation Pi represents the individual parameter estimate of the ith subject, 
Pp equals the population parameter estimate, Cov is the covariate and k is the 
exponent which was fixed to 1 for a linear function or estimated for an allometric 
function. The significance of a covariate was statistically tested by use of the objective 
function. A p value <0.005 was applied to evaluate the covariates in the forward 
inclusion (decrease of OFV of at least 7.8 points) while a more stringent p value of 
<0.001 was used in the backward deletion (decrease of OFV of at least 10.83 points). 
When two or more covariates were found to significantly improve the model, the 
covariate causing the largest reduction in OFV was left in the model. Additional 
covariates had to reduce this OFV further to be retained in the model. In order 
to select the final covariate model, as suggested by Krekels et al. [21], individual and 
population parameter estimates were plotted against the most predictive covariate 
to evaluate whether the individual predicted parameters were equally distributed 
around the population predicted parameters. The choice of the covariate model was 
further evaluated as discussed in the previous paragraph whereby the results of the 
internal evaluation were also considered.
3.2.5. Internal evaluation procedure
The final pharmacokinetic model was validated using two methods [21]: (i) the 
bootstrap resampling method, and (ii) the normalized prediction distribution error 
(NPDE) method. The bootstrap analysis to evaluate the stability was performed in 
S-plus, version 6.2.1 (Insightful software, Seattle, WA) with NM.SP.interface version 
05.03.01 (© by LAP&P Consultants BV, Leiden, The Netherlands). The model building 
datasets were resampled 1000 times to produce a new dataset of the same size con-
taining a different combination of individuals. The parameter estimates were sum-
marized in terms of mean values and standard errors and were compared with the 
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estimates obtained from the model building datasets.
The accuracy of the model was evaluated with the NPDE method [25, 26] in which 
the observed and simulated concentrations are compared using the NPDE software 
package in R. In this study each observation was simulated 1000 times after which the 
software assembled the predictions in a cumulative distribution and determined the 
value of the cumulative distribution at the observed concentration. The normalized 
prediction distribution errors were then obtained after applying the inverse function 
of the normal cumulative density function [25, 26]. The NPDE as simulation-based diag-
nostic is preferred over the visual predictive check  (VPC) since it easier to interpret 
when data are obtained during routine clinical practice causing a high variability in 
both dosing and sampling schemes. Consequently a NPDE is often preferred over a 
VPC in the analysis of pediatric datasets. The results of NPDE method are visualized 
in different graphs: (1) quantile-quantile plot (2) histogram showing the distribu-
tion of the normalized prediction distribution errors which are expected to follow 
a normal distribution, (3) scatterplot NPDE versus time and (4) scatterplot NPDE 
versus predicted concentrations. 
3.2.6. External evaluation procedure
External evaluation was performed by using two published external datasets [6, 27]. 
In total 517 concentrations were available obtained from 80 neonates in the first [6] 
and 159 neonates in the second external dataset [27]. In external dataset 1, peak (taken 
60 minutes after start of infusion) and trough concentrations (measured at 24 hours) 
were available. In external dataset 2, only 1 ample was available, which was collected 
between the first and second dose. More details on the studies (including information 
on co-medication and prenatal drug treatment) can be found in the original articles 
[6, 27]. In neither one of these two external datasets, ibuprofen was administered. 
Patient characteristics of the external datasets are given in table I. 
The final pharmacokinetic model (with all parameters fixed to final values with 
maxeval=0 and without covariance step) was used to simulate concentrations for 
each data point of the two external datasets. Additionally, the final pharmacokinetic 
model was used to compute the NPDE [25, 26] for each of the external datasets. Each 
concentration was simulated 1000 times. 
Finally parameters of the final model were re-estimated on the basis of the 
two model building datasets and external dataset 1. In a second step both external 
datasets combined with both model building datasets were analyzed. 
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3.2.7. Simulations of currently used dosing regimens
The parameter estimates from the final pharmacokinetic model were used to 
simulate concentration time profiles upon different dosing regimens currently used 
or suggested in reference textbooks [6, 20, 28-30]. Simulations were performed in three 
patients (gestational age 24, 32, 40 weeks) selected from the two model building 
datasets. The three patients were selected to cover the entire study population in 
terms of bodyweight and gestational age. For the first preterm patient (gestational 
age 24 weeks) the lowest birth weight was chosen. In the second preterm (gestation-
al age 32 weeks) and third term patient (gestational age 40 weeks) a median birth 
weight of 1730 g and 3520 g, was chosen respectively. In the simulations, five con-
secutive doses were administered starting from day at birth. The simulations were 
performed excluding the interindividual and residual variability. Based on the results 
a new dosing schedule was designed, aiming to achieve Cmax values in the range of 
24-35 mg/L [6] and trough values below or between 1.5-3 mg/L [31]. Since the dose 
was given over 20 minutes in the model building datasets while in most reference 
textbooks (Neofax® [28], Red Book® [29], BNFc [30], Sherwin et al. [6]) an infusion time 
of 30 minutes is applied, both infusion rates were used to simulate the concentra-
tion-time profiles of the model-based dosing regimen.
3.3. Results
3.3.1. Patients and data
The pharmacokinetic analysis was based on 2186 observations from 874 neonates 
obtained from two studies performed by Allegaert et al. [1, 2]. The external evaluation 
was executed using two previously published datasets [6, 27] containing data of 80 and 
159 neonates respectively. A summary of all patient characteristics is presented in 
table I.
3.3.2. Pharmacokinetic model building
A two compartment model parameterized in terms of clearance (CL), inter-com-
partmental clearance (Q), volume of distribution of central compartment (V1) and 
peripheral compartment (V2) was preferred over a one compartment model since 
it was able to describe the model building datasets more accurately. The objective 
function of the final two compartment model (OFV=7738) was significantly lower 
(p<0.001) compared to the corresponding one compartment model (OFV=7946). 
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Furthermore the goodness-of-fit plots improved. In particular samples taken later 
than 48 hours after dosing were more accurately described using the two compart-
ment model. However, when estimating Q and V2 independently of CL and V1, no 
covariance step could be given, probably due to over parameterization of the model. 
As a result the model was simplified by estimating Q and V2 as fraction of CL and 
V1, respectively, resulting in no increase in OFV and even better diagnostics plots. 
Because of failure of the bootstrap, V2 was equalized to V1 in the final model which 
only resulted in an increase in OFV of 7 points and similar diagnostic plots. The 
residual variability was best described using a combined additive and proportional 
error model. 













1 and external 
dataset 2
Value (CV%) Value (CV%) Value (CV%) Value (CV%) Value (CV%)
Fixed Effects
CL (L/h) 0.0743 (3.11)
CL(L/h/kg BWb) 0.0493 (2.21) 0.0495 (2.68) 0.0496 (2.3) 0.0485 (2.06)
Q (fraction of CL) 0.681 (6.3) 0.415 (12.3) 0.446 (13.94) 0.422 (12.3) 0.36 (10.9)
CL*((BWb/median) ) - 1.34 (2.04) 1.34 (2.22) 1.34 (2.02) 1.33 (1.84)
CL*(1+ *(PNA/median)) - 0.213 (9.81) 0.217 (10.33) 0.211 (9.1) 0.202 (10.6)
CL* (IBU) - 0.838 (3.88) 0.836 (4.13) 0.838 (3.96) 0.851 (3.43)
V1=V2 (L/kg cBW) 0.716 (2.19) 0.833 (1.34) 0.827 (1.47) 0.836 (1.34) 0.845 (1.18) 
V1* ((cBW/median) ) - 0.919 (2.46) 0.915 (2.52) 0.909 (2.22) 0.91 (2.14)
Interindividual variability
2 (CL) 0.677 (6.51) 0.0899 (14.9) 0.0917 (15.36) 0.097 (13.9) 0.0822 (13.3)
Residual Error
2 (proportional) 0.184 (6.25) 0.0614 (8.19) 0.0580 (8.47) 0.0614 (8.26) 0.0592 (8.07)
2 (additive) 1.15 (13.6) 0.267 (27.2) 0.489 (36.73) 0.3 (25.9) 0.297 (23.7)
CL = Clearance, Q = Intercompartmental clearance, V1 = volume of distribution of central compartment, V2 = 
Volume of distribution of peripheral compartment, BWb = bodyweight at birth, cBW = current bodyweight, PNA 
= postnatal age, (IBU)=1 : no co-administration of ibuprofen, (IBU)=0.838 : co-administration of ibuprofen
Table II: Population parameter estimates of the final pharmacokinetic model based on two model building datasets, 
the values obtained after bootstrap of the final pharmacokinetic model and the model parameter estimates after 
combining the model building datasets together with the external datasets.
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3.3.3. Systematic covariate analysis
The systematic covariate analysis identified current bodyweight as most important 
covariate implemented on volume of distribution using an allometric function (table 
II) causing a drop in the OFV of 1488 points. For clearance postmenstrual age 
was identified as most important covariate causing a drop in OFV of 1160 points. 
However, birth weight and postnatal age together proved to be superior ( OFV 1598 
points) to postmenstrual age alone. The model using postmenstrual age as covariate 
on clearance was not able to describe the data as well as the final model with birth 
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Figure 1: Observed versus individual predicted concentrations and observed versus population predicted concen-
trations of (a-b) the model building datasets [1,2], (d-e) external dataset 1 [6] and (g-h) external dataset 2 [27]. The 
histograms show the distribution of the NPDE method of (c) the model building datasets, (f) external dataset 1 and 
(i) external dataset 2. The solid line represents a normal distribution.
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Simple Model Final Model
Figure 2: Interindividual variability for clearance (Eta on CL) versus birth weight, postnatal age (PNA) and co-
administration of ibuprofen for the simple (left) and the final model (right).
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weight and postnatal age unless additionally the covariates birth weight and/or 
postnatal age also were introduced. Consequently birth weight was implemented as 
first covariate on clearance using an allometric function with an estimated exponent 
of 1.34 ( OFV 940 points). A further decrease in OFV of 659 points was achieved 
by implementing postnatal age linearly on clearance. The model further improved by 
introducing co-administration of ibuprofen ( OFV 26 points) as third covariate on 
clearance. A correlation between creatinine concentrations and clearance, as seen in 
adults, was not identified in this population.
3.3.4. Final pharmacokinetic model and internal evaluation
Table II gives an overview of the parameter estimates of the simple and final phar-
macokinetic model together with the values obtained from the bootstrap analysis. 
In figure 1a-b, observed versus individual and population predicted concentrations 
are given for the final pharmacokinetic model, while in figure 1c the histogram of the 
NPDE is shown. The histogram follows the normal distribution expected by the solid 
line indicating the accuracy of the final pharmacokinetic model. No trend was seen in 
the NPDE versus time or versus predicted concentrations (data not shown). In figure 
2 interindividual variability in clearance is plotted against birth weight, postnatal 
age and co-administration of ibuprofen for the simple and the final pharmacokinetic 
model to illustrate that by introducing these three covariates into the model, a sig-
nificant part of the interindividual variability (68%) is explained. This is also reflected 
by the estimate of interindividual variability in clearance which was reduced from 
0.677 to 0.0899 when the three covariates were introduced (table II). Plotting the 
population and individual predicted values for clearance versus birth weight (data 
not shown) as proposed by Krekels et al. [21] illustrated that the individual predicted 
values are equally scattered around the population predicted values. No ill-condi-
tioning was detected since the condition number (value of 43) for the final pharma-
cokinetic model was far below the critical value of 1000.
The model-based predicted clearance values of the final pharmacokinetic model 
versus birth weight for PNA 0, 14, 28, with and without co-administration of ibuprofen 
are illustrated in figure 3. The figure shows horizontally the influence of birth weight 
representing the antenatal maturation and vertically postnatal age representing 
postnatal maturation.
3.3.5. External evaluation of the final model
The predictive performance of the final pharmacokinetic model was evaluated 
using two previously published external datasets [6, 27] (table I). In figure 1 observed 
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< 28 - -
20
20 42
28-30 - - 20 36
31-33 - - 18.5 30
34-37 - - 17 30
> 37 - - 15.5 24
Sherwin et al.[17]
< 29 - -
30
15 36
29-36 - - 14 24
> 36 - - 15 24
Neofax® (2009)
[32]




8-28 - 15 36
> 28 - 15 24
30-34 0-7 - 18 36
> 7 - 15 24
> 34 - - 15 24
RedBook® 
(2009) [38]





> 2000 7.5-10 12
>7
1200-2000 7.5-10 8-12
> 2000 10 8
BNFc (2009) [39] - - - 30 15 24
* 6 hour prolongation of dosing interval when ibuprofen is co-administered
** Neonates suffering from asphyxia, having a patent ductus arteriosus or co-administration of indomethacin
Table III: Amikacin dosing recommendations in preterm and term neonates according to 5 dosing regimens currently 
used or suggested in reference text books.
versus individual (d,g) and population predicted concentrations (f,i) are given for both 
the external datasets. Additionally, the histograms of the NPDE are shown in figure 
1f and 1i respectively. While the final pharmacokinetic model is able to predict the 
data of external dataset 1 with adequate precision and without bias, a slight bias is 
seen for external dataset 2 in which sampling was not performed at peak and trough 
timepoints but in between these two moments.  This small bias is observed in figure 
1h showing observed versus predicted concentrations as well as in figure 1i in which 
the normal distribution is shifted from the solid line. Furthermore a trend was seen 
in the NPDE versus time and the npde versus predicted concentrations (data not 
shown).
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- 800-1200 16 42
- 1200 - 2000 15 36
- 2000 - 2800 13 30




- 800 - 1200 20 36
- 1200 - 2000 19 30
- 2000 - 2800 18 24
- ≥ 2800 17 20
*10 hours prolongation of dosing interval when ibuprofen is co-administered
Table IV: A model-based dosing regimen for preterm and term neonates based on target Cmax concentrations of 
24-35 mg/L and trough concentrations below 2-5 mg/L.
However combined analysis of the two model building datasets and the external 
dataset 1 as well as the model building datasets and both external datasets, revealed 
that fairly similar parameter values were obtained (table II), indicating the stability of 
the final pharmacokinetic model.
3.3.6. Simulations of currently used dosing regimens
Concentration-time profiles for amikacin for three different individuals (gestational 
age 24, 32 and 40 weeks and birth weight 480, 1730 and 3520g, respectively) following 
five different dosing regimens currently used or proposed in reference textbooks 
(table III) were predicted on the basis of the final pharmacokinetic model (figure 4). 
Peak concentrations below the target range of 24-35 mg/L [6] and concentrations 
above the aimed trough concentration range of 1.5-3 mg/L [31] are represented by a 
black dot while predicted peak and trough concentrations within the target range 
are indicated by open circles. The dosing guidelines suggested by the Red Book® 
and the British National Formulary for children (BNFc) are potentially inducing 
toxicity in preterm and even term neonates since target trough values are not 
reached which may  be associated with a higher risk for nefro- or ototoxicity [32, 33] 
due to aminoglycoside accumulation. Although the dosing guidelines according to 
Langhendries et al. [20], Sherwin et al. [6] and Neofax® approach the target trough 
concentrations more closely, adjustments are needed for all of them since target 
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trough concentrations below 1.5-3 mg/L are only reached in patient 2 by Neofax®. 
Target peak and trough values are only reached in all three patients using the model-
based new dosing regimen (table IV) which is based on current bodyweight (covariate 
for volume of distribution, determining the peak concentration), postnatal age and 
co-administration of ibuprofen (covariates for clearance determining the dosing 
interval).
3.4. Discussion
During infancy renal function matures resulting in changes in GFR, which is most 
pronounced in neonates. Since amikacin is almost entirely eliminated by GFR, we 
aimed to quantify developmental changes in GFR in (pre)term neonates by describing 
the maturation of amikacin clearance. 
The pharmacokinetic model developed in this study was based on 2186 trough 
and peak concentrations from 874 (pre)term neonates obtained from two datasets 
[1, 2] covering an extensive variation in gestational age, postnatal age and birth weight. 
An internal and external evaluation was performed to demonstrate descriptive and 
predictive properties. Birth weight, representing maturation of GFR until birth 
[34], proved to be the most important covariate for clearance. Birth weight, which 
Figure 3: Model-based predicted amikacin clearance values versus birth weight for postnatal age (PNA) of 0, 14 or 
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ranged between 385g and 4650g, was found to influence clearance on the basis of 
an allometric function as shown in figure 3. Maturation after birth was quantified 
using postnatal age (range 1-30 days) as covariate for clearance (figure 3). In previous 
studies [1, 2, 4, 6, 35-38], which were often based on a more restricted number and range 
in patients and data, these two processes were merged together into one covariate, 
postmenstrual age, which is a combination of gestational and postnatal age. The 
model with postmenstrual age was inferior compared to the final pharmacokinetic 
model with both birth weight and postnatal age unless birth weight and postnatal age 
were added as second and third covariate to postmenstrual age. We consider our 
approach using birth weight and postnatal age superior because the combination of 
postmenstrual age, birth weight and postnatal age repeatedly uses the same informa-
tion. More specifically, birth weight and postnatal age as morphometric surrogates 
for organ function are distinctly different and independent covariates since birth 
weight reflects the antenatal maturation and postnatal age is representing postnatal 
maturation. The limited predictive value of postmenstrual age in this analysis may be 
explained by the large variation in gestational and postnatal age, as postmenstrual age 
does not distinguish between pre- and postnatal maturation. Meanwhile birth weight 
also proved to be a superior covariate compared to gestational age. For the same 
gestational age, a large range in birth weight was observed in our datasets, showing 
that birth weight represents more accurately the antenatal maturation thereby 
reflecting (dys)maturity  or (dys)function of the neonate. The specific influence of 
birth weight, postnatal age and co-administration of ibuprofen is given in figure 3. 
This figure illustrates clearly how clearance of amikacin increases with birth weight 
(antenatal maturation) and postnatal age (postnatal maturation). Large differences in 
clearance values (4.4 fold) are observed when comparing an individual with a birth 
weight of 1 kg (0.026 L/h) and 3 kg (0.112 L/h) at day 1. This difference in clearance 
is still present at day 28 between an individual of 1 kg (0.092 L/h) and 3 kg (0.404 
L/h) indicating that catch-up growth of prematurely born neonates (e.g. normalizing 
in height, weight and clearance values) does not appear in the first month. Further-
more it also illustrates the reduction in GFR following administration of ibuprofen 
[1, 39-42] causing a decrease in amikacin clearance of 16.2%. This decrease in clearance 
by ibuprofen was seen before and is caused by inhibition of the cyclo-oxygenase 
cascade inducing a downregulation in the formation of prostaglandins. This results in 
a reduction of the vasodilative effects which normally help to support the glomerular 
filtration rate and glomerular perfusion leading to a decrease in clearance.
In some previous trials, GFR was determined by measuring the clearance of inulin, 
which is considered as the gold standard[13]. In most of these publications gestational 
age was found as most important covariate for clearance in (pre)term neonates [43-45], 
followed by an increase in GFR due to postnatal age [44, 45]. However these findings are 
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based on a smaller number of patients and more narrow age range compared to our 
analysis in which birth weight and postnatal age were identified as most important 
covariates. Although the use of amikacin as a marker for GFR may also have some 
restrictions - amikacin itself may influence the renal function after repetitive dosing 
as well as the fact that amikacin is often given to treat neonatal sepsis, a disease state 
that also may influence renal function - our findings are based on a very large dataset 
of preterm as well as term neonates with a postnatal age up to 30 days. Further-
more as discussed previously birth weight was found to represent more accurately 
the antenatal maturation of the kidney in our analysis compared to gestational age. 
Moreover practical and ethical constraints make a prospective evaluation of matura-
tion of GFR by measuring clearance of inulin not possible in this age group.
Model-based concentration-time profiles were simulated for three different 
patients using 5 different dosing guidelines (table III, table IV) (figure 4). According 
to our simulations the dosing guidelines suggested by Langhendries et al. [20], Sherwin 
et al. [6] and Neofax® approach the target values closely even though target trough 
values between 1.5-3 mg/L [31] are not reached, except in patient 2 by Neofax® 
(figure 4). A possible explanation might be that target trough values between 2-5 
mg/L [20, 28] instead of 1.5-3 mg/L [31] were aimed for in the past. Regarding the dosing 
guidelines suggested by Langhendries et al. [20] target trough values may also not 
be reached since this dosing regimen was only validated for neonates directly after 
birth, implying that postnatal age was not taken into account. However, all dosing 
regimens for amikacin currently used or suggested in reference handbooks in both 
preterm and term neonates up to 30 days possibly increase the risk of toxicities and 
therefore need to be updated. Especially the dosing regimens proposed in the Red 
Book® and BNFc may potentially induce nefro- and ototoxicity in preterm and even 
term neonates since target trough values are not reached [32, 33]. Moreover potential 
risk of oto- and nefrotoxicity is not only related to higher trough concentrations but 
is also linked to treatment duration. Therefore future studies should be considered 
on treatment duration to even further reduce amikacin toxicity. Finally, exposure 
to aminoglycosides in neonates with mutations in the MT-RNR1 gene that are as-
sociated with aminoglycoside-induced hearing loss [46] should be avoided. A prenatal 
screening in which mothers are tested for these variants would prevent the exposure 
of aminoglycosides to babies at risk.
Based on the final pharmacokinetic model a new dosing regimen was developed 
by adjusting the dose to current bodyweight (covariate for volume of distribu-
tion, determining the peak concentration), postnatal age and co-administration of 
ibuprofen (covariates of clearance, determining the dosing interval). When ibuprofen 
is co-administered it is suggested to extend the dosing interval to 10 hours since 
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trough concentrations between 1.5-3 mg/L are not yet reached upon a prolongation 
by 6 hours. For the model-based dosing regimen concentration-time profiles were 
simulated using an infusion time of 20 and 30 minutes. Both infusion times resulted 
in the same trough concentrations and only slightly higher peak concentrations when 
the dose was administered over 20 minutes which are of no clinical relevance. This 
limited influence of infusion rate was expected since the final pharmacokinetic model 
based on data using an infusion time of 20 minutes was able to describe accurately 
the data of external dataset 1 in which an infusion time of 30 min was applied. 
Even though the final model described the data of all age and weight ranges most 
adequately a slight bias was observed in the plot 1b. When re-evaluating retrospec-
tively the medical records it seemed that these individuals were suspect for perinatal 
asphyxia. Although Langhendries et al. [20] proposed before that the time interval 
for amikacin dosing needs to be adapted following perinatal asphyxia, we were not 
able to identify in our datasets which patients were suffering from asphyxia since 
no robust indicators have been identified in practice. Therefore we could not study 
asphyxia as a covariate. In order to better determine the impact of perinatal asphyxia 
in future models, we suggest to prospectively report potential indicators (Apgar 
score, lactate, Thompson score) [47].
Although the stability of the final pharmacokinetic model was indicated by the 
bootstrap and the NPDE as well as the ability to predict external dataset 1 accurate-
ly, the predictive performance was slightly biased for external dataset 2. This could 
not be explained by differences in age or bodyweight or any other covariate between 
external dataset 2 and the other datasets. The only observed discrepancy was the 
time at which samples were taken. Unlike the model building datasets and external 
dataset 1, no peak and trough but only midterm samples, taken between 3.5 - 33 
hours, were available in external dataset 2. While this result indicates that the final 
pharmacokinetic model is not entirely able to describe the midterm samples which 
are concentrations measured in a different phase of the distribution, the results of 
external dataset 1 show that the model very well predicts peak and trough concen-
trations which are used as surrogate markers for respectively efficacy and safety of 
amikacin. In this respect it can be emphasized that in clinical practice only trough 
samples are of interest in terms of aminoglycoside accumulation monitoring meaning 
that midterm samples should be avoided. 
The clinical response was not investigated in the new dosing regimen and may be 
considered as one of the limitations of this study. However amikacin was given in this 
population when an infection was suspected. Another remark can be made on the 
adequate use of antibiotics given in association with the aminoglycosides. Aminogly-
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Figure 4: Model-based predicted concentration-time profiles for three individuals using five different dosing guide-
lines (Langhendries et al. [20], Sherwin et al. [6], Neofax® [28], Red Book® [29] and British National Formulary for 
children (BNFc) [30]) (table III) and according to the model-based new dosing regimen (table IV). GA = gestational 
age, BWb = birth weight. The dotted lines indicate the target peak (24-35 mg/L) and trough (1.5-3 mg/L) 
amikacin concentrations aimed for. Peak concentrations below and trough concentration above the target range are 
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cosides are often administered in association with beta-lactam antibiotics. Although 
it is well known that aminoglycosides exhibit a postantibiotic effect, the acceptable 
duration between two administrations in terms of this postantibiotic effect remains 
still unclear. Future studies are needed to develop rational dosing schemes for the 
antibiotics given in association with amikacin based on the new dosing regimen.
Finally creatinine concentrations could not be identified as a significant covariate 
in this study. To a certain extent, this was anticipated since creatinemia in the first 3 
days of postnatal life reflects maternal renal function. In addition, creatinemia trends 
throughout neonatal life display an initial progressive increase with peak concen-
tration in the second part of the first week of life due to passive back leaking of 
creatinine through the renal tubular cells, with a subsequent decrease throughout 
neonatal life [15, 16].
3.5. Conclusions
Amikacin clearance in neonates can be predicted by combination of the morpho-
metric surrogates for organ function: birth weight representing the antenatal state of 
maturation of the kidney, postnatal age representing postnatal maturation and co-ad-
ministration of ibuprofen. Postmenstrual age proved to be less predictive compared 
to the contribution of birth weight and postnatal age together. This study shows 
notably that the dosing regimens for amikacin suggested in reference handbooks for 
both preterm and term neonates up to 30 days need to be updated. Finally the model 
reflects maturation of GFR allowing for adjustments of dosing regimens of other 
renally cleared drugs.
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Abstract
Introduction
The dosing regimens for amikacin in neonates in reference handbooks may poten-
tially lead to lack of efficacy and/or toxic effects. Therefore, a novel dosing regimen 
with bodyweight, postnatal age and co-administration of ibuprofen as covariates was 
proposed based on a recently derived population pharmacokinetic model. The aim 
of the current study was to prospectively evaluate the accuracy and precision of this 
novel model-based dosing regimen for amikacin in preterm and term neonates aged 
between 1-30 days. 
Methods
The model-based dosing algorithm for amikacin was prospectively evaluated in 579 
(pre)term neonates (median birth bodyweight 2285g (range 420-4850g), postnatal 
age 2 days (range 1-30 days), gestational age 34 (range 24-41 weeks)). Observed 
peak and trough concentrations (n=1195), obtained upon application of the novel 
dosing algorithm in these 579 individuals, were compared with the concentrations 
predicted by the model. Additionally, a NPDE (normalized prediction distribution 
error) was performed for all observed concentrations of the prospective dataset. 
Finally, Monte Carlo simulations were performed to evaluate amikacin exposure in 
(pre)term neonates of different bodyweight and age. 
Results
Across the entire neonatal population, observed amikacin concentrations were 
accurately predicted by the final pharmacokinetic model without bias. Moreover the 
accuracy of the model was confirmed by the NPDE.  Based on the Monte Carlo 
simulations, it was shown that peak concentrations above 24 mg/L were reached in 
almost all patients with different bodyweight, postnatal age and use of ibuprofen. 
Depending on bodyweight and age, trough concentrations below 3 mg/L were found 
for 78-100% of the individuals when ibuprofen was co-administered and for 45-96% 
of the individuals when ibuprofen was not co-administered.
Conclusion
 A novel model-based dosing algorithm for amikacin leads to optimized peak and 
trough concentrations in preterm and term neonates with varying birth bodyweight, 
78
Chapter 4
current bodyweight, postnatal age and ibuprofen co-administration. The model-based 
approach for dosing drugs in the highly variable population of neonates, as applied 
here for amikacin, substantially contributes to the individualization of dosing drugs 
in neonates.
4.1. Introduction 
Even to date, drugs in children are often used in an off-label or unlicensed manner 
[1, 2]. Moreover, despite profound differences between children and adults, most 
dosing regimens are derived from adult dosing regimens using linear extrapolations 
based on bodyweight, which may lead to under- or overdosing [3, 4]. This, in turn, 
may result in therapeutic failure or occurrence of adverse or even toxic effects. In 
order to establish  rational and evidence-based dosing regimens, detailed information 
is needed on the variation in pharmacokinetics (PK) and pharmacodynamics (PD) 
of drugs in children [5]. However, the execution of PK-PD studies in children faces 
significant challenges resulting from ethical considerations and practical issues such 
as the limited number and volume of blood samples. These limitations can be partly 
overcome by the application of population PK and/or PD analysis techniques using 
non-linear mixed effect modeling [3, 4, 6]. The advantage of the population approach is 
that pharmacokinetic and pharmacodynamic parameters can be derived from dense 
data but also from sparse and unbalanced data, which is often the case when analyzing 
data from routine pediatric or neonatal clinical practice. Furthermore, by using this 
approach both the inter- and intra-individual variability can be estimated separately. 
Finally, specific predictors of variability also called covariates, can be identified which 
subsequently can be used as the basis to develop new evidence-based and individu-
alized dosing regimens [4]. When applying this approach it is crucial to establish in a 
prospective clinical trial whether the proposed dosing regimen indeed leads to the 
expected concentrations and/or effects [5]. 
Although amikacin is commonly used in pediatric clinical practice, it has been 
shown (figure 1) that the currently used dosing regimens for amikacin in reference 
handbooks may potentially lead  to lack of efficacy and/or toxic effects and need to 
be updated [7]. Therefore on the basis of a population pharmacokinetic model for 
amikacin which was recently developed, a novel model-based dosing regimen was 
developed in which the dose is individualized on the basis of current bodyweight 
(a covariate found for volume of distribution), birth bodyweight, postnatal age and 
co-administration of ibuprofen (covariates for clearance) [7]. As model-based dosing 
regimens in which identified covariates are used as a basis for dosing may result 
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in more effective and safe use of drugs in the pediatric population, the aim of the 
current study was to prospectively evaluate this novel model-based dosing regimen 
for amikacin in preterm and term neonates aged between 1-30 days, on the basis of 
a comparison of the observed versus the model-based predicted concentrations, an 
NPDE analysis and Monte Carlo simulations.
4.2. Methods
4.2.1. Patients
All neonates admitted to the Neonatal Intensive care unit of the University 
Hospitals Leuven from whom routine amikacin therapeutic drug monitoring (TDM) 
samples were available between July 2011 and December 2012 were considered for 
inclusion in this study. During this period a simplified version of the model-based 
dosing regimen [7], was applied (Table I). Patients were excluded from this analysis 
if initiation of amikacin treatment was based on a previously used dosing regimen, 
when data were missing or if patients had a postnatal age above 30 days. 
4.2.2. Drug administration and TDM sampling
Amikacin (Amukin, Bristol Myers Squibb, Braine-L’Alleud, Belgium) was 
administered as an intravenous infusion over 20 minutes. As part of routine clinical 
care, blood samples for amikacin TDM were collected just before (trough sample) 
and 1 hour after administration of the second dose (peak sample). 
4.2.3. Amikacin assay
Up to May 31th 2012, amikacin concentrations were measured with a fluorescence 
polarization immunoassay using an Abbott TDx kit (Abbott Laboratories, Diagnos-
tics Division, Abbott Park, IL 60064 USA). The lower limit of quantification (LLOQ) 
was 0.8 mg/L. According to the insert, the coefficient of variation was < 5% (assessed 
at 5, 15 and 30 mg/L). From May 31th 2012, amikacin quantification occurred with an 
immunoassay based on a kinetic interaction of microparticles in solution (KIMS) on 
Roche/Hitachi Cobas c systems (Roche Diagnostics GmbH, Mannheim, Germany). 
Also in this assay, the LLOQ was 0.8 mg/L.  According to the insert, the coefficient 
of variation was < 4%. To avoid censoring of data below the LLOQ, these concentra-




To evaluate the predictive performance of the recently developed pharmacokinetic 
model [7], a pharmacokinetic analysis was performed using NONMEM VI in which 
model-based individual and population predicted concentrations were simulated 
for each observation in the prospective dataset. These simulated individual and 
population predicted concentrations were obtained by use of the recently developed 
pharmacokinetic model [7] in which all parameters were fixed to the final values 
with MAXEVAL = 0 and without covariance step. Subsequently the individual and 
population predicted concentrations predicted by the population pharmacokinetic 
model were visually compared to the observed, measured concentrations. 
Additionally, to evaluate the accuracy, the recently developed pharmacokinetic 
model [7] was used to compute an NPDE (normalized prediction distribution error 
method) [9, 10] for each of the observations of the prospective dataset. A histogram 
of the NPDE distribution and scatterplots showing the NPDE versus time and versus 
predicted concentration were used as evaluation tools [9, 10]. Finally the parameters of 
the recently developed pharmacokinetic model [7] were re-estimated on the basis of 
the data of the prospective dataset. 
4.2.5. Monte Carlo simulations
Monte Carlo simulations were performed to evaluate whether target peak (above 
24 mg/L) [11] and trough concentrations (below 3.0 mg/L) [12] of amikacin in preterm and 
term neonates were attained following the simplified model-based dosing regimen 
(Table I), the original model-based dosing regimen (Table I) [7], the dosing regimen 
Simplified model-based dosing regimen Original model-based dosing regimen [7]
Current bodyweight (g) PNA <14 days PNA ≥ 14 days PNA <14 days PNA ≥ 14 days
0-800 16 mg/kg/48h (Gr. 1) 20 mg/kg/42h (Gr. 2) 16 mg/kg/48h 20 mg/kg/42h 
800-1200 16 mg/kg/42h (Gr. 3) 20 mg/kg/36h (Gr. 4) 16 mg/kg/42h 20 mg/kg/36h 
1200-2000 15 mg/kg/36h (Gr. 5) 18 mg/kg/30h (Gr. 6) 15 mg/kg/36h 19 mg/kg/30h
2000-2800 15 mg/kg/30h (Gr. 7) 18 mg/kg/24h (Gr. 8) 13 mg/kg/30h 18 mg/kg/24h
≥ 2800 15 mg/kg/24h (Gr. 9) 18 mg/kg/20h (Gr. 10) 12 mg/kg/24h 17 mg/kg/20h
The dosing interval was prolonged 10 hours, when ibuprofen was co-administered or when asphyxia was diagnosed/
considered by the treating physician. Duration of the intravenous infusion was 20 minutes. PNA = postnatal age. 
Gr = dosing group.
Table I: Simplified model-based dosing regimen used in the current study and original model-based dosing regimen 
[7] of amikacin for preterm and term neonates. The differences between both dosing regimens are highlighted in a 
grey field.
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proposed by Neofax® [13] and the dosing regimen proposed by the British National 
Formulary for Children (BNFc) [14]. For the peak concentrations, concentrations 
below 24 mg/L, between 24 – 35 mg/L [11] and above 35 mg/L were evaluated. For 
the trough concentrations, concentrations between 1.5 - 3.0 mg/L were evaluated 
because this was the primary target of the model based dosing regimen [7]. In addition, 
the percentage of trough concentrations below 1.5, between 3.0 – 5.0 and above 5.0 
mg/L was evaluated, the latter because this concentration is associated with toxicity. 
The results of the Monte Carlo simulations were compared among the different 
neonatal dosing groups as defined in Table I. 
For the Monte Carlo simulations, the covariates identified in this recently 
developed final pharmacokinetic model [7] - birth bodyweight and PNA (covariates 
found on clearance) and current bodyweight (covariate found on volume of distri-
bution) - were sampled from the prospective dataset taking into account their cor-
relation. The Monte Carlo simulations were performed twice in 5000 individuals 
following the model-based dosing regimen, one in which ibuprofen was not co-ad-
ministered and one in which ibuprofen was co-administered because co-administra-
tion of ibuprofen was found to result in a 16% reduction in neonatal clearance [7]. For 
the simulations, 5 consecutive doses of amikacin were administered over 20 or 30 
minutes depending on the dosing regimen (Table I).
4.3. Results
4.3.1. Patients
During July 2011 and December 2012 a total of 701 preterm and term neonates 
were evaluable for the pharmacokinetic analysis of this prospective evaluation of the 
model-based dosing regimen. In total a 122 patients were excluded from this analysis: 
32 because the dosing regimen was based on a previous dosing regimen, 76 neonates 
because there were missing data and 14 patients because of a postnatal age above 
30 days. A summary of the patient characteristics (N=579) evaluated in this study 
are presented in Table II together with the patient characteristics of the recently 
developed model for amikacin [7]. 
4.3.2. Pharmacokinetic analysis
Figure 2 shows the individual and population predicted concentrations versus con-
centrations observed in this prospective study for the different dosing groups based 
on current bodyweight and postnatal age as described in Table I. Both panels indicate 
82
Chapter 4
Figure 1: Model-based predicted concentration-time profiles for three typical neonates (480g, 1730g and 3520g) at 
postnatal age of 1 day on the basis of five different dosing guidelines (Langhendries et al., Sherwin et al., Neofax®, 
Red Book® and the British National Formulary for Children (BNFc)) and according to the new model-based dosing 
regimen.
The dotted lines indicate the target peak (24-35 mg/L) and trough (1.5-3 mg/L) amikacin concentrations aimed for.  
Peak concentrations below and trough concentration above the target range are indicated by a black dot.
Reproduced from [De Cock RF, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in 
neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012 Feb 1;51 (2): 105-17] with permission from 
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a lack of bias and an adequate prediction of the observed concentrations across the 
different bodyweight and age groups. Moreover, the distribution of the data points 
around the line of unity of the observed versus predicted plot indicates that the 
interindividual variability is both acceptable and similar across the entire neonatal 
population. This is also reflected in figure 3 in which the interindividual variability on 
clearance is plotted against birth bodyweight, postnatal age and co-administration 
of ibuprofen. Figure 3 illustrates that the final pharmacokinetic model of amikacin 
is able to describe the prospective dataset accurately across the different covari-
ates as no trend is seen in the interindividual variability on clearance versus these 
covariates. This result was obtained such despite the fact that there were small dif-
ferences between the dataset that was used to build the model [7] compared to the 
current prospective dataset (Table II). Table III gives an overview of the parameter 
estimates of the recently published final pharmacokinetic model [7] together with 
the parameter estimates obtained on the basis of the current prospective dataset 
in 579 individuals. Based on the values in Table III, it can be seen that fairly similar 
parameter values are obtained when evaluating the prospective dataset compared to 
the previously obtained parameters, which indicates the stability of the model. The 
population value for clearance and volume of distribution was slightly higher in the 
current prospective dataset (0.066 L/H and 1.03 L) compared to the values of the 
recently developed amikacin model (0.049 L/H and 0.833 L). This can be explained by 
the fact that in the current prospective dataset, slightly more mature neonates are 
included as reflected by the small differences seen in gestational age, postmenstrual 
age, birth bodyweight and current bodyweight (Table II). Figure 4 shows the results 
of the NPDE analysis. The histogram follows the normal distribution indicated by the 
black solid line. Additionally, no trend is seen in the NPDE versus time and the NPDE 
versus predicted concentrations indicating the accuracy of the model.
Characteristics Recently developed amikacin model [7]
N= 874
Current prospective amikacin analysis
N=579
Gestational age (weeks) 32 (24-43) 34 (24-41)
Postmenstrual age (weeks) 33 (24-43) 34 (24-45)
Postnatal age (days) 2 (1-30) 2 (1-30)
Birth bodyweight (g) 1750 (385-4650) 2285 (420-4850)
Current bodyweight (g) 1760 (385-4760) 2100 (420-5040)






Table II: Clinical characteristics of the patients included in the recently published analysis on amikacin [7] and in the 
current prospective analysis (median, range, or absolute number and incidence).
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4.3.3. Monte Carlo simulations
Monte Carlo simulations were performed to illustrate the exposure to amikacin 
in two times 5000 preterm and term neonates (with and without ibuprofen 
administration) following the simplified model-based dosing regimen, the original 
model-based dosing regimen [7], the dosing regimen proposed by Neofax®[13] and 
the British National Formulary for Children [14]. In Table IV the percentages of the 
individuals with trough concentrations after 5 doses below 1.5 mg/L, between 1.5-3.0 
mg/L, between 3.0-5.0 mg/L and above 5.0 mg/L and peak concentrations after 5 
doses below 24 mg/L, between 24-35 mg/L and above 35 mg/L following the Monte 
Carlo simulations in 5000 individuals according to the different dosing regimens 
Parameter Recently developed amikacin model [7]
n=879 patients




CLp in CL = CLp x (bBW/median)m x
(1+ n x (PNA/median)) x o (ibuprofen)
0.049 (2.21) 0.066 (3.2)
m 1.34 (2.04) 1.30 (2.95)
n 0.213 (9.81) 0.302 (9.34)
o 0.838 (3.88) 0.846 (6.55)
Vp in V1 = Vp x (cBW/median)p 0.833 (1.34) 1.03 (1.47)
p 0.919 (2.46) 0.863 (4.03)
Q = r x CL 0.415 (12.3) 0.480 (13.5)
V2=V1 V2=V1 V2=V1
Interindividual Variability
2 (CL) 0.0899 (14.9) 0.0921 (19.3)
Residual Variability
2 (proportional) 0.0614 (8.2) 0.0448 (22.3)
2 (additive) 0.267 (27.2) 0.315 (16.3)
CLp = population value for clearance (L/h), Vp = population value for volume of distribution of the central com-
partment (L), bBW = bodyweight at birth (g), cBW = current bodyweight (g), PNA = postnatal age (days), Q = 
intercompartmental clearance (L/h), V2 = Volume of distribution of the peripheral compartment (L), median values 
for the recently developed model for amikacin: bBW = 1750g, PNA = 2 days, cBW=1760g; median values for the 
current prospective study: bBW = 2285g, PNA = 2 days, cBW = 2100g
Table III: Final parameter estimates and coefficients of variation (CV%) of the pharmacokinetic model that was 
recently developed on the basis of the original dataset (n=874) [7] and on the basis of the current prospective 
dataset (n=579)
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are given when ibuprofen is not co-administered. In Table V, these percentages are 
shown when ibuprofen is co-administered. Both tables are graphically presented in 
figure 5 and figure 6 in which ibuprofen is not co-administered and co-administered, 
respectively. In both figures the upper panels (A) represent the trough concentrations 
while the lower panels (B) represent the peak concentrations. Based on these tables 
and figures, it can be seen that for the model based dosing regimens (with and without 
ibuprofen) the percentages for trough concentrations between 1.5 and 3.0 mg/L are 
relatively constant across the ten different age and weight groups. This confirms the 
predictions that were performed in the previous analysis [7] as the model based dosing 
guideline was designed to aim for trough concentrations between 1.5 and 3.0 mg/L 
across the entire neonatal age range. Overall, the figures and tables show that trough 
concentrations below 3.0 mg/L [12] are reached in most individuals of the different 
dosing groups upon the simplified model-based (78-100% and 45-96%) and original 
model-based dosing regimen (86-100% and 62-92%) whereas these percentages were 
much lower upon Neofax® (25-96% and 40-100%) and BNFc (2-100% and 3-100%), 
when ibuprofen is co-administered or not, respectively. From these results, it seems 
that particularly the dosing guidelines suggested by BNFc may potentially induce 
toxicity since target trough values below 5 mg/L are not reached in many individuals 
and specifically in neonates with a postnatal age < 14 days. More specifically, trough 
concentrations above 5 mg/L which are associated with oto- and nephrotoxicity, 
were observed in 0-20%, 0-9%, 0-43% and 0-93% of the individuals of the different 
dosing groups as defined in Table I, for the simplified dosing regimen, original dosing 
regimen [7], Neofax and BNFc, respectively (Table IV and V). Considering the peak 
concentrations, it can be seen that for the simplified model-based dosing regimen 
peak concentrations above 24mg/L are reached in almost all individuals while 
for the original model-based dosing regimen [7], Neofax® and BNFc target peak 
concentrations are not reached in all individuals of one or more dosing subgroups. 
Finally, it can be seen that higher peak concentrations are reached in the different 
dosing groups upon the dosing regimens of Neofax® or the BNFc compared to the 
model-based dosing regimens [7].
4.4. Discussion
Recently a population pharmacokinetic model was developed for amikacin in 
874 preterm and term neonates [7]. Based on the final model which was both in-
ternally and externally validated, a model-based dosing regimen was developed for 
amikacin in preterm and term neonates aged between 1-30 days [7]. The main aim of 
this dosing regimen was to obtain trough concentrations of 1.5-3.0 mg/L and peak 
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Figure 2: Observed versus model-based individual and population predicted concentrations for the different dosing 
groups based on current bodyweight and postnatal age (Table I) for the current prospective dataset. 
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concentrations above 24 mg/L across the entire neonatal population for which ten 
dosing groups were defined [7] (Table I). To reach this aim, the model-based dosing 
regimen is based on current bodyweight, a covariate found on volume of distribution 
which determines the peak concentrations, postnatal age and co-administration of 
ibuprofen, covariates found on clearance which determine the maintenance dose 
and the dosing interval, respectively (Table I). In order to evaluate whether the 
model-based dosing guideline for amikacin indeed leads to the expected concentra-
tions, a prospective clinical trial is imperative [4, 5]. In the current prospective clinical 
study we first evaluated the predictive value of the previously derived model [7] for 
observed concentrations in a newly collected dataset consisting of 579 preterm and 
term neonates (Table II) in which neonates were dosed on previously derived covari-
ates (Table I). Furthermore, we evaluated the target attainment of the trough con-
centrations between 1.5 and 3.0 mg/L [12] and peak concentrations between 24 and 
35 mg/L [11] across the entire preterm and term neonatal age range as targets of the 
model-based dosing algorithm in the original study [7].  For this purpose, Monte Carlo 
simulations were performed to simulate peak and through concentrations following 
the model-based dosing guideline and currently used guidelines to evaluate their per-
formance across the different age groups that can be identified in neonates.  
Based on the results presented in this analysis, it can be concluded that the final 
pharmacokinetic model is able to predict the observed concentrations in the current 
study without bias across the entire neonatal range (Figure 2). Moreover, in figure 
3, it is shown that the covariates birth bodyweight, postnatal age and co-administra-
tion of ibuprofen are correctly implemented on clearance as no trend is seen when 
plotting the interindividual variability on clearance versus the different covariates. 
This means that the conclusion that 10 different neonatal dosing groups (Table I) 
are needed to cover the large differences seen in clearance values between preterm 
and term neonates is justified. Finally when evaluating figure 2 and figure 3, it can 
be concluded that only random variability is remained in the model while variability 
allocated to covariates is explained. This latter is of course of major importance 
when developing and evaluating new model-based dosing regimens on the basis of 
these covariates, which we have done in the current analysis.
Another important aim of the current prospective analysis was to evaluate 
whether the aimed target peak (24-35 mg/L) [11] and trough concentrations (1.5-3 
mg/L) [12], as defined in the recently published study [7], were reached in preterm 
and term neonates. When evaluating the results of the Monte Carlo simulations 
(Table IV and V and Figure 5 and 6), peak and trough concentrations were found 
in the target range in most individuals of the different dosing groups in case of the 
model-based dosing regimens. Moreover, the number of individuals with trough con-
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Figure 3: Interindividual variability (eta) on clearance (CL) versus birth bodyweight (a), postnatal age (b) en 
co-administration of ibuprofen (c) for the current prospective dataset using the recently developed pharmacokinetic 
model [7]. 
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Figure 4: Results of the NPDE analysis performed for the prospective dataset using the recently developed 
pharmacokinetic model [7]. Left panel: Histograms of the NPDE distribution with the solid line representing a 
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centrations above 5 mg/L, which are generally related to occurence of oto- and/or 
nephrotoxicity, are notably lower in the model-based dosing regimens compared to 
the dosing regimen proposed by Neofax® and BNFc, in particular when ibuprofen is 
given (Table IV and V). However, 11% and 20% of the individuals of group 7 (current 
weight 2000-2800g, PNA<14 days) and group 9 (current weight >2800g, PNA<14 
days) of the simplified model-based dosing regimen, respectively, had trough con-
centrations above 5 mg/L when ibuprofen was not co-administered. In addition, as 
shown in tables IV and V, a higher percentage of individuals with trough concentra-
tions above 3 mg/L (38% and 55%) compared to the original model-based dosing 
regimen (28% and 38%) can be expected upon this simplification of the model-based 
algorithm. Although less neonates in group 7 and group 9 are observed with trough 
concentrations above 3 mg/L upon the original model-based dosing regimen [7], the 
original model-based dosing regimen does not offer an alternative since a notable 
number of patients (between 8-33%) does not reach peak concentrations above >24 
mg/l needed for efficacy. This deviation may be partly explained by the fact that in 
the original study, less data of neonates were available in group 7 and 9 compared 
to the current prospective study. Consequently this indicates the importance of a 
prospective validation as more information can be obtained in certain age and weight 
groups. As a result, new Monte Carlo simulations need to be performed in both 
these groups to evaluate whether lower trough concentrations are obtained when 
the dosing interval is prolonged.
The Monte Carlo simulations emphasize that the dosing regimen proposed by 
Neofax® and BNFc for amikacin in preterm and term neonates may potentially lead 
to toxicity. This applies in particular to the dosing regimen of BNFc, which does not 
make any distinction between weight or age groups, but proposes a similar dose and 
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Table IV: The percentage of the individuals of the subgroups 1-10 as defined in Table I with trough concentrations 
after 5 amikacin doses below 1.5 mg/L, between 1.5-3 mg/L, between 3-5 mg/L and above 5 mg/L and peak 
concentrations (grey background) after 5 doses below 24 mg/L, between 24-35 mg/L and above 35 mg/L following 
the Monte Carlo simulations in 5000 individuals according to the different dosing regimens (simplified model-based 




Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10
Simplified model-based dosing regimen
< 1.5 34% 55% 30% 65% 27% 58% 17% 53% 8% 58%
1.5-3 45% 30% 45% 30% 45% 38% 45% 36% 37% 36%
3-5 16% 15% 21% 5% 23% 4% 27% 11% 35% 6%
> 5 5% 0% 4% 0% 5% 0% 11% 0% 20% 0%
< 24 0% 0% 0% 0% 0% 0% 0% 3% 0% 0%
24-35 95% 50% 94% 71% 97% 83% 90% 97% 81% 94%
>35 5% 50% 6% 29% 3% 17% 10% 0% 19% 6%
Original model-based dosing regimen [7]
< 1.5 33% 55% 29% 43% 25% 56% 25% 60% 16% 61%
1.5-3 41% 30% 48% 36% 47% 36% 47% 32% 46% 25%
3-5 21% 15% 18% 14% 22% 8% 23% 5% 29% 11%
> 5 5% 0% 5% 7% 6% 0% 5% 3% 9% 3%
< 24 0% 0% 0% 0% 0% 0% 9% 3% 24% 9%
24-35 96% 50% 93% 64% 97% 70% 91% 89% 76% 84%
>35 4% 50% 7% 36% 3% 30% 0% 8% 0% 7%
Neofax® [13]
< 1.5 12% 50% 14% 71% 19% 64% 14% 56% 20% 84%
1.5-3 28% 35% 34% 19% 41% 33% 37% 33% 41% 16%
3-5 36% 15% 25% 10% 24% 3% 30% 11% 24% 0%
> 5 24% 0% 27% 0% 16% 0% 19% 0% 15% 0%
< 24 0% 0% 0% 10% 0% 0% 0% 14% 0% 30%
24-35 31% 100% 44% 90% 50% 100% 49% 86% 52% 70%
>35 69% 0% 56% 0% 50% 0% 51% 0% 48% 0%
BNFc [14]
< 1.5 0% 0% 0% 31% 1% 50% 3% 79% 9% 76%
1.5-3 3% 50% 5% 38% 12% 40% 24% 18% 34% 24%
3-5 13% 25% 19% 31% 32% 10% 39% 3% 37% 0%
>5 84% 25% 76% 0% 55% 0% 34% 0% 20% 0%
< 24 0% 0% 0% 0% 0% 0% 0% 28% 0% 26%
24-35 43% 100% 48% 100% 63% 100% 73% 72% 78% 74%
>35 57% 0% 52% 0% 37% 0% 27% 0% 22% 0%
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Table V: The percentage of the individuals of the subgroups 1-10 as defined in Table I with trough concentrations 
after 5 amikacin doses below 1.5 mg/L, between 1.5-3 mg/L, between 3-5 mg/L and above 5 mg/L and peak 
concentrations (grey background) after 5 doses below 24 mg/L, between 24-35 mg/L and above 35 mg/L following 
the Monte Carlo simulations in 5000 individuals according to the different dosing regimens (simplified model-




Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10
Simplified model-based dosing regimen
< 1.5 45% 60% 46% 72% 50% 72% 42% 81% 33% 82%
1.5-3 39% 40% 43% 21% 40% 28% 43% 14% 45% 14%
3-5 13% 0% 8% 7% 9% 0% 12% 5% 18% 4%
> 5 3% 0% 3% 0% 1% 0% 3% 0% 4% 0%
< 24 0% 0% 0% 0% 0% 0% 0% 0% 0% 2%
24-35 97% 50% 95% 50% 99% 85% 96% 92% 93% 80%
>35 3% 50% 5% 50% 1% 15% 4% 8% 7% 18%
Original model-based dosing regimen [7]
< 1.5 48% 55% 50% 88% 47% 48% 48% 84% 49% 81%
1.5-3 38% 45% 38% 12% 42% 40% 42% 14% 41% 19%
3-5 11% 0% 11% 0% 9% 12% 9% 2% 9% 0%
> 5 3% 0% 1% 0% 2% 0% 1% 0% 1% 0%
< 24 0% 0% 0% 0% 0% 0% 8% 0% 33% 8%
24-35 99% 50% 97% 52% 98% 44% 92% 89% 67% 90%
>35 1% 50% 3% 48% 2% 56% 0% 11% 0% 2%
Neofax® [13]
< 1.5 7% 35% 7% 52% 13% 37% 7% 44% 10% 63%
1.5-3 18% 40% 22% 38% 30% 48% 26% 33% 40% 33%
3-5 35% 25% 28% 5% 28% 15% 34% 20% 23% 4%
> 5 40% 0% 43% 5% 29% 0% 33% 3% 27% 0%
< 24 0% 0% 0% 10% 0% 0% 0% 5% 0% 12%
24-35 16% 100% 26% 90% 32% 100% 32% 95% 37% 88%
>35 84% 0% 74% 0% 68% 0% 68% 0% 63% 0%
BNFc [14]
< 1.5 0% 0% 0% 0% 0% 23% 1% 62% 4% 69%
1.5-3 0% 15% 2% 54% 4% 50% 11% 31% 21% 31%
3-5 7% 40% 9% 38% 20% 23% 32% 7% 37% 0%
>5 93% 45% 89% 8% 76% 4% 56% 0% 38% 0%
< 24 0% 0% 0% 0% 0% 0% 0% 10% 0% 7%
24-35 28% 85% 28% 100% 40% 100% 51% 90% 58% 93.%
>35 72% 15% 72% 0% 60% 0% 49% 0% 42% 0%
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dosing interval for all neonates, independent of age or weight. As a result, neonates 
with a PNA<14 days are particularly at risk for toxic effects as the concentrations 
remain above the target trough concentrations, when ibuprofen is not given. When 
ibuprofen is given, even more individuals are at risk. Therefore on the basis of the 
results of this study, it can be concluded that the currently used dosing regimens 
in reference handbooks need to be updated, certainly when ibuprofen is co-
administered. Moreover it should also be considered to lower the dose in neonates 
with a PNA<14 days, certainly in the lower weight groups (800-2000g). Considering 
the administration of ibuprofen, it should however be noted that in the Monte Carlo 
simulations ibuprofen is given to all weight groups, while in the recently developed 
amikacin model [7], ibuprofen was only given to preterm neonates in case of open 
ductus. Since ibuprofen can also be given to these neonates as anti-inflammatory 
drug, we chose to perform the Monte Carlo simulations also in term neonates when 
ibuprofen is co-administered to illustrate amikacin exposure. However this means 
that caution is needed when interpreting the results.
In this analysis we show that amikacin dosing in neonates can be optimized on the 
basis of a previously developed model resulting in a dosing algorithm that is evaluated 
in a prospective clinical study. However, when for each drug such an approach 
should be followed much time and resources would be needed. Therefore, advanced 
approaches to use information from one drug for another drug are needed [17]. 
Recently, it was shown by two different groups that the pharmacokinetic covariate 
model of amikacin contains system-specific information on the developmental 
changes in glomerular filtration in preterm and term neonates [15]. Consequently the 
covariate model on amikacin clearance with birth bodyweight, postnatal age and co-
administration of ibuprofen as most important covariates could be used to predict the 
dosage regimens of other renally excreted drugs (netilmicin, tobramycin, gentamicin 
and vancomycin) in neonates [15, 16]. This semi-physiological approach may be used 
to optimize sparse data analysis and may facilitate development of pharmacokinetic 
models and evidence-based dosing regimens in the pediatric population [17]. As a 
result, in future analyses it should be evaluated whether the different dosing groups 
used in this prospective analysis, which are based on the recently developed model 
for amikacin [7], can be applied to the other renally excreted drugs. In this context, 
it should also be noted that the dosing regimen for amikacin in neonates according 
to BNFc [14], as illustrated in this analysis, is rather simple while the dosing regimen 
according to BNFc for gentamicin is much more complicated. Based on the fact 
that covariate models are considered to contain system-specific information, this 
is rather remarkable. Therefore, as stated above, the dosing regimens of other 
renally excreted drugs such as gentamicin, tobramycin, vancomycin and netilmicin in 
neonates may need to be revised accordingly.
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Figure 5: Bar graphs to illustrate the percentages of individuals of the different dosing groups as defined in Table 
I with A/ trough concentrations after 5 doses below 1.5 mg/L (light grey), between 1.5-3 mg/L (white), between 
3-5 mg/L (dark grey) and above 5 mg/L (black) and B/ peak concentrations after 4 doses below 24 mg/L (light 
grey), between 24-35 mg/L (white) and above 35 mg/L (dark grey) following the Monte Carlo simulations in 5000 
individuals according to the different dosing regimen (1= simplified model-based dosing regimen, 2 = original 
model-based dosing regimen [7], 3 = Neofax® [13], 4 = BNFc [14]) when ibuprofen was not co-administered.
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Figure 6: Bar graphs to illustrate the percentages of individuals of the different dosing groups as defined in Table 
I with A/ trough concentrations after 5 doses below 1.5 mg/L (light grey), between 1.5-3 mg/L (white), between 
3-5 mg/L (dark grey) and above 5 mg/L (black) and B/ peak concentrations after 4 doses below 24 mg/L (light 
grey), between 24-35 mg/L (white) and above 35 mg/L (dark grey) following the Monte Carlo simulations in 5000 
individuals according to the different dosing regimen (1= simplified model-based dosing regimen, 2 = original 
model-based dosing regimen [7], 3 = Neofax® [13], 4 = BNFc [14]) when ibuprofen was co-administered.
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Finally it can be concluded that evidence-based dosing regimens are often lacking 
in the pediatric population due to practical and ethical constraints. Based on the 
analysis in this study, it can be determined that population pharmacokinetic modeling 
facilitates the development of drug dosing regimens in children. First of all, the use 
of this methodology makes it possible to derive pharmacokinetic and/or pharmaco-
dynamic parameters from sparse and unbalanced data. Secondly covariates which 
explain the interindividual variability can be identified and serve as a guide for in-
dividualized dosing. Moreover the pharmacokinetic model used in this study was 
extensively validated before testing it in a prospective study. Based on this prospec-
tive study, it can be concluded that the model-based dosing regimen for amikacin 
with current bodyweight, postnatal age and co-administration of ibuprofen as co-
variates, results in target peak and trough concentrations in a very high percentage 
of individuals. Particularly the consistency of the predictions across the different 
weight categories are emphasized (figure 5 and 6) as across the different subgroups 
similar percentages in the target trough concentration range were found (Table IV 
and V). These predictions are in large contrast with predictions that were obtained 
upon currently used guidelines such as from Neofax® or BNFc for which the dosing 
regimens need to be reevaluated, particularly in neonates <14 days and the lower 
weight groups (800-2000g) or when ibuprofen is given. Consequently model-based 
dosing regimens in which developmental changes are taken into account may result 
in more effective and safe use of drugs in the pediatric population. 
4.5. Conclusions
A novel model-based dosing algorithm for amikacin yields plasma concentrations 
that are close to the targeted concentrations in preterm and term neonates with 
varying birth bodyweight, current bodyweight, postnatal age and ibuprofen co-
administration. The model-based approach for dosing drugs in the highly variable 
population of neonates, as applied here for amikacin, substantially contributes to the 




This study was performed within the framework of Top Institute Pharma project 
number D2-104. The clinical research of K. Allegaert is supported by the Fund for 
Scientific Research, Flanders (Belgium) (clinical fellowship 1800214 N) and has been 
supported by an IWT-SBO project (130033). The authors also would like to thank 
LAP&P Consultants for their technical support with NONMEM.
References
1. Cuzzolin L, Atzei A, Fanos V (2006) Off-label and unlicensed prescribing for newborns 
and children in different settings: a review of the literature and a consideration about drug 
safety. Expert Opin Drug Saf 5 (5): 703-718 
2. t Jong GW, Vulto AG, de Hoog M, et al (2001) A survey of the use of off-label and unli-
censed drugs in a Dutch children's hospital. Pediatrics 108 (5): 1089-1093 
3. Knibbe CA, Danhof M (2011) Individualized dosing regimens in children based on popula-
tion PKPD modelling: are we ready for it? Int J Pharm 415 (1-2): 9-14 
4. De Cock RF, Piana C, Krekels EH, et al (2011) The role of population PK-PD modelling in 
paediatric clinical research. Eur J Clin Pharmacol 67 Suppl 1: 5-16 
5. Ince I, de Wildt SN, Tibboel D, et al (2009) Tailor-made drug treatment for children: cre-
ation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov 
Today 14 (5-6): 316-320 
6. Bellanti F, Della Pasqua O (2011) Modelling and simulation as research tools in paediatric 
drug development. Eur J Clin Pharmacol 67 Suppl 1: 75-86 
7. De Cock RF, Allegaert K, Schreuder MF, et al (2012) Maturation of the glomerular filtration 
rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 51 (2): 105-117 
8. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J 
Pharmacokinet Pharmacodyn 28 (5): 481-504 
9. Brendel K, Comets E, Laffont C, et al (2006) Metrics for external model evaluation with an 
application to the population pharmacokinetics of gliclazide. Pharm Res 23 (9): 2036-2049 
10. Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution er-
rors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput 
Methods Programs Biomed 90 (2): 154-166 
11. Sherwin CM, Svahn S, Van der Linden A, et al (2009) Individualised dosing of amikacin 
in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 65 (7): 
705-713 
97
Validation of a novel model-based dosing regimen for amikacin in neonates
12. De Hoog M, van den Anker J (2010) Aminoglycosides and glycopeptides. In: Yaffe S.J., 
Aranda J. V.,editors. Neonatal and Pediatric Pharmacology: Therapeutic Principles in prac-
tice.  Fourth ed. Philadelphia (PA). Lippincott Williams & Wilkins. pp412-435.
13. Young TE, Magnum B (2010) Neofax. Thomson Reuters, Montvale, NJ, USA.
14. British National Formulary for children. (2009) BMJ group, Tavistock Square, London, UK.
15. De Cock RF, Allegaert K, Sherwin CM, et al (2013) A Neonatal Amikacin Covariate Model 
Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtra-
tion in Neonates. Pharm Res Sep 25, Epub ahead of print 
16. Zhao W, Biran V, Jacqz-Aigrain E (2013) Amikacin maturation model as a marker of renal 
maturation to predict glomerular filtration rate and vancomycin clearance in neonates. 
Clin Pharmacokinet 52 (12): 1127-1134 
17. Knibbe CA, Krekels EH, Danhof M (2011) Advances in paediatric pharmacokinetics. Ex-
pert Opin Drug Metab Toxicol 7 (1): 1-8

Chapter 5
A Neonatal Amikacin Covariate Model Can 
Be Used to Predict Ontogeny of Other Drugs 
Eliminated through 
Glomerular Filtration in Neonates
Roosmarijn F.W. De Cock, Karel Allegaert, Catherine M.T. Sherwin, Elisabet 
I. Nielsen, Matthijs de Hoog, Johannes N. van den Anker, Meindert Danhof, 
Catherijne A.J. Knibbe




Prediction of GFR mediated drug clearance in neonates
Abstract
Purpose
Recently, a covariate model characterizing developmental changes in clearance of 
amikacin in neonates has been developed using birth bodyweight and postnatal age. 
The aim of this study was to evaluate whether this covariate model can be used to 
predict maturation in clearance of other renally excreted drugs. 
Methods
Five different neonatal datasets were available on netilmicin, vancomycin, to-
bramycin and gentamicin. The extensively validated covariate model for amikacin 
clearance was used to predict clearance of these drugs. In addition, independent 
reference models were developed based on a systematic covariate analysis. 
Results
The descriptive and predictive properties of the models developed using the 
amikacin covariate model were good, and fairly similar to the independent reference 
models (goodness-of-fit plots, NPDE). Moreover, similar clearance values were 
obtained for both approaches. Finally, the same covariates as in the covariate model 
of amikacin, i.e. birth bodyweight and postnatal age, were identified on clearance in 
the independent reference models. 
Conclusions
This study shows that pediatric covariate models may contain physiological infor-
mation since information derived from one drug can be used to describe other drugs. 
This semi-physiological approach may be used to optimize sparse data analysis and to 




Although regulations like the Pediatric Rule (FDA) and the Pediatric Regulation 
(EMA), encourage pharmaceutical companies to perform research in the pediatric 
age range when new drugs are developed, to date, drugs in pediatrics are often 
administered in an off-label or unlicensed manner [1-3]. Because of practical, ethical 
and economical reasons, it remains very challenging to perform pharmacokinetic 
and pharmacodynamic studies in the pediatric population with the ultimate aim to 
develop rational dosing regimens [4, 5]. One of the preferred approaches to facilitate 
the knowledge on the pharmacokinetics and pharmacodynamics in pediatrics is by 
applying population pharmacokinetic/pharmacodynamic (PK/PD) modeling [4, 6-8]. This 
approach is based on a simultaneous analysis of all data of the entire population 
while still taking into account that different observations are derived from different 
patients. Consequently, this population approach allows for the analysis of sparse 
and unbalanced data, which often applies to pediatric clinical studies. Moreover, the 
application of the population approach may lead, besides a reduction in invasiveness 
and burden for the patients, to considerably reduced costs.
However, to avoid that for each new or existing drug a systematic and time-con-
suming pharmacokinetic and/or pharmacodynamic analysis needs to be conducted 
[9, 10], new approaches are required. One approach, which is gaining more attention 
in industry, academia and regulatory agencies, is to develop evidence-based dosing 
regimens in children by PK/PD modeling and simulation in which extrapolations are 
performed between populations that vary in age [10-12] (bridging). Another recently 
proposed approach is the use of information obtained from one drug for extrapola-
tion to other drugs that are eliminated through the same route [13]. This implicates 
that pediatric covariate models also contain biological system-specific information 
reflecting underlying physiological changes that can be used between drugs [13-15].
In a previous analysis, the developmental changes in amikacin clearance were 
characterized in more than 800 (pre)term neonates with varying gestational ages, 
birth bodyweights and postnatal ages, on the basis of birth bodyweight and postnatal 
age as covariates representing antenatal and postnatal maturation of the kidney, 
respectively [16]. The aim of this study was to evaluate whether this internally and 
externally validated covariate model of amikacin in (pre)term neonates contains 
system-specific information on the developmental changes in glomerular filtration 
and that therefore the covariate model can be extrapolated to other drugs eliminated 
through glomerular filtration. In this study the amikacin covariate model was primarily 
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extrapolated to netilmicin, tobramycin, vancomycin and gentamicin, drugs which 
were used as paradigm compounds as they are all almost entirely eliminated through 
GFR and with similar physicochemical properties compared to amikacin. 
5.2. Methods
5.2.1. Patients and data
For this analysis, data of renally excreted antibiotics in neonates were obtained 
from 5 different (in part) previously published studies [17-21]. Since the amikacin 
covariate model [16] which was based on data from 874 neonates varying in postnatal 
age between 1-30 days, was used to describe the data of the other renally excreted 
drugs, only neonates with a postnatal age until 30 days were included from these 
datasets. Besides trough and peak samples taken before and at 1 hour after initiation 
of the dose, respectively, samples at varying time points were available in all datasets 
[17, 19-21], except for the tobramycin dataset [18]. An overview of the patient character-
istics of the different datasets is given in table I. The different datasets are discussed 
briefly here, while more details on the studies can be found in the original articles 
[17-21].
Amikacin [16]
A dataset of amikacin containing 2186 concentrations from 874 (pre)term 
neonates (birth bodyweight (bBW) 385-4650g, postnatal age (PNA) 1-30 days) was 
used to obtain the amikacin covariate model. Patients were enrolled in the study 
when at least one peak and trough concentration was available for each patient. 
Netilmicin [17]
This dataset contained 267 netilmicin concentrations, collected in 88 (pre)term 
neonates (bBW 470-3000g, PNA 3-30 days). Concentrations were taken at the ad-
ministration of the third dose or after a change in dose or dosing interval. 
Tobramycin [18]
Four-hundred and seventy (pre)term neonates (bBW 485-5245g, PNA 1-4 days) 
were included in this dataset of which only paired peak and trough concentrations 





This dataset contained 689 vancomycin concentrations collected in 273 preterm 
neonates (bBW 385-2550g, PNA 1-28 days). Concentrations were taken around the 
second or third dose infusion of vancomycin.
Gentamicin [20, 21]
For this drug two different datasets were available.
The first dataset (Gentamicin A), was obtained after combining previously 
published data [20] with more recently obtained data, resulting in a total of 1531 con-
centrations from 673 (pre)term neonates (bBW 440-5240g, PNA 1-30 days).
In the second dataset (Gentamicin B) [21], 796 gentamicin concentrations were 
available of 59 (pre)term neonates (bBW 520-4950g, PNA 1-30). In this study several 
concentrations taken at different time points (e.g. 15 min or 4-8h after the end of the 
infusion), besides peak and trough, were available. 
5.2.2. Pharmacokinetic Modeling
Model development
Non-linear mixed effect modeling was used to analyze the pharmacokinetic 
data. The first-order conditional estimation method with interaction option was 
used in NONMEM 6.2. (ICON Development solutions, Hanover, MD, USA). The 
following tools were used to visualize and evaluate the model:  S-Plus version 6.2.1 
(Insightful software, Seattle, WA) with NM.SP.interface version 05.03.01 (© by 
LAP&P Consultants BV, Leiden, The Netherlands), PsN and R (version 2.10.1). To 
test the hypothesis of between-drug extrapolation of covariate models, two different 
population pharmacokinetic models were developed for each dataset [14]: 1) Models 
using the amikacin covariate model [16] and 2) Independent reference models based on 
a systematic covariate analysis. More information on both approaches can be found 
below under Covariate model.  Model development was performed in four different 
steps: (i) choice of the structural model, (ii) choice of the statistical sub-model, (iii) 
choice of the covariate model, (iv) model evaluation. Discrimination between models 
was based on different diagnostic tools [22]. A difference in objective function value 
(OFV) of 3.9 points or more was considered as statistically significant (p<0.05 based 
on X2 distribution). Finally, the goodness-of-fit plots, the total number of parameters, 
visual improvement of individual plots, correlation matrix, confidence intervals of 
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parameter estimates, ill-conditioning [23] and shrinkage [24] were assessed. The ill-
conditioning was assessed by taking the ratio of the largest and smallest eigenvalue of 
the covariance matrix of the estimate from the NONMEM output.
Structural model
For the structural model, both one-, two and three-compartment models were 
tested. A two compartment model parameterized in terms of clearance (CL), in-
ter-compartmental clearance (Q), volume of distribution of the central compart-
ment (V1) and the peripheral compartment (V2) was found to best describe the 
different datasets for both the models using the amikacin covariate models as the 
reference models. Only for the reference model of tobramycin, a two compart-
ment model could not be supported as only peak and trough samples were available. 
Therefore, a one compartment model was preferred for the tobramycin reference 
model. For some of the models no covariance step could be given or the bootstrap 
failed meaning that some of the models were possibly overparameterized. As a result 
these models were simplified by equalizing V2 to V1 or Q to CL or by estimating Q 
as a fraction of clearance. These assumptions did not influence the estimate of the 
parameters of primary focus (CL and V1) with changes in parameter estimates being 
less than 5%.
Table I: Overview of the patient characteristics of the model developed for amikacin applied in the models using the 
amikacin covariate model and of the different datasets used in the current analysis as basis for the models using 
the amikacin covariate model and the independent reference models. Values are expressed as median (range).
Amikacin 
dataset [16]
Datasets used in this analysis
Dataset Amikacin[16] Netilmicin[17] Tobramycin[18] Vancomycin[19] Gentamicin A[20] Gentamicin B[21]
Number of patients 874 88 470 273 673 59
Gestational age 
(weeks)
32 (24-43) 28 (23-41) 32 (24-43) 29 (23-34) 34 (23-43) 29 (23-42)
Postmenstrual age 
(weeks)
33 (24-43) 30 (23-44) 32 (24-43) 30 (24-38) 36 (23-44) 30 (23-42)
Postnatal age (days) 2 (1-30) 15 (3-30) 2 (1-4) 14 (1-28) 3 (1-30) 6 (1-30)




























The interindividual variability was tested assuming a log-normal distribution in an 
individual i (post hoc value) and is given by the following equation:
 (Equation 1)
in which TV is the typical value of the parameter and i is assumed to be a random 
variable with mean value zero and variance 2. For the intra-individual variability and 
residual error (statistical submodel), proportional, additive and combination error 
models were tested. In this analysis, the interindividual variability was only estimated 
on clearance since the interindividual variability on the other parameters (V1, V2 and 
Q) could not be estimated and was therefore fixed to zero for all models. For the 
intra-individual variability and residual error a proportional error model (equation 2) 
was chosen for all the models:
 (Equation 2)
where Yij is the jth observation in the ith individual, Cpred,ij is the predicted con-
centration and ij is a random variable from a normal distribution with a mean of zero 
and estimated variance of 2. 
Covariate model
For each dataset two population pharmacokinetic models were developed as 
proposed in the analysis of Krekels et al. [14]
1/ Models using the amikacin covariate model [16]: In these models, the internally 
and externally validated covariate model for amikacin [16] (figure 1), was directly 
incorporated into the pharmacokinetic model that was developed for each dataset. 
This implicates that birth bodyweight was implemented as a covariate on clearance 
using a power function with an exponent of 1.34 as well as postnatal age using a 
linear function with a slope of 0.213. In the original covariate model of amikacin, 
co-administration of ibuprofen was identified as a third covariate on clearance, 
causing a 16.2% decrease in clearance of amikacin. This decrease in clearance was 
also implemented in the current analysis when ibuprofen or indomethacin was co-
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administered. Although the decrease in glomerular filtration was reported to be 
more pronounced after the administration of indomethacin compared to ibuprofen 
[25], in this analysis the 16.2% decrease in clearance seen for ibuprofen was also 
applied for indomethacin.
Current bodyweight was implemented on volume of distribution using a power 
function with 0.919 as exponent. While the pediatric covariate model is considered 
to describe the developmental changes in clearance and volume of distribution, the 
population values of these parameters were still estimated by NONMEM since they 
are considered drug specific properties [14] (equation 3):
 
(Equation 3)
where CLi represents the clearance in the ith individual, CLp represents the 
population value of clearance and is estimated separately for each drug since it is 
considered to be a drug specific property, and the amikacin covariate model with 
birth bodyweight (bBW), postnatal age (PNA) and co-administration of ibuprofen is 
considered to describe the developmental changes in clearance through glomerular 
filtration.
2/ Independent reference models [14]: For these models a systematic covariate 
analysis [22] was performed in which the following covariates were tested for 
significance: birth bodyweight (weight at day of birth), current bodyweight (weight 
at day of blood sampling), gestational age, postmenstrual age, postnatal age, serum 
creatinine, co-administration of ibuprofen or indomethacin. Covariates were tested 
using a linear or power function. For serum creatinine, linear or power functions 
were tested in the denominator since a negative relationship was seen between 
serum creatinine concentrations and clearance. Previously, it has been shown that 
serum creatinine values in the first days of life are derived from the mother reflecting 
maternal renal function instead of neonatal renal function [26, 27]. Additionally, a 
progressive increase in serum creatinine concentrations has been reported with 
maximum serum creatinine concentrations at day 3-4 after birth followed by a 
subsequent decrease. This trend may be caused by differences in duration and extent 
of passive tubular back leak [28]. As a consequence, serum creatinine values in the first 
five days of life were not taken into account in this analysis. 
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The significance of a covariate was statistically evaluated by the use of the objective 
function value. In the forward inclusion a p value <0.005 was considered as statis-
tically significant while a more stringent p value <0.001 was used in the backward 
deletion. When two or more covariates were found to significantly improve the 
model, the covariate that reduces the objective function value the most was retained 
into the model and served as a basis for subsequent inclusion of additional covariates. 
In addition, the individual and population predicted parameters were plotted against 
the most predictive covariate to evaluate whether the individual predicted parame-
ters were equally distributed around the population predicted parameters [22]. Finally 
the covariate model was evaluated as mentioned previously under Model develop-
ment, whereby the results of the Model validation were also considered.
5.2.3. Model validation
The models using the amikacin covariate model as well as the independent 
reference models were internally validated using two different methods [22]. 
Figure 1: Covariate model of amikacin[16] which was applied to the other renally excreted drugs. The figure illus-
trates the model-based predicted amikacin clearance (CL) values versus birth bodyweight (bBW) for postnatal age 
of 0, 14 and 28 days with (grey) and without (black) co-administration of ibuprofen. Birth bodyweight reflects the 
antenatal maturation of the kidney, postnatal age is reflecting the postnatal maturation. Reproduced from [De Cock 
RF, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amika-
cin clearance. Clin Pharmacokinet 2012 Feb 1;51 (2): 105-17] with permission from Adis (© Springer International 
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To evaluate parameter precision and stability a non stratified bootstrap analysis 
was performed in which 1000 replicate datasets of the same size as the original 
data analysis but with a different combination of individuals were generated. The 
parameter estimates obtained with the bootstrap were compared to the parameter 
estimates of the final models. 
To evaluate the predictive properties of the models using the amikacin covariate 
model and reference models, the normalized prediction distribution error method 
(NPDE) was used, which is a Monte-Carlo simulation-based diagnostic in which 
the random effects were included [29, 30] The dataset was simulated 1000 times in 
NONMEM, each observed concentration was subsequently compared to the 
simulated reference distribution using the NPDE add-on package in R. A histogram 
of the NPDE distribution in the total dataset and plots of NPDE versus individual 
predicted concentrations and versus time were used to evaluate the final model.
5.2.4. Comparison of the models using the amikacin covariate model and indepen-
dent reference models
The descriptive and predictive performance of the models using the amikacin 
covariate model and the independent reference models was compared by different 
diagnostic tools [14, 22]. The goodness-of-fit plots were compared to visually evaluate 
the descriptive performance. Secondly, individual and population clearance values 
obtained in the models using the amikacin covariate model were compared with the 
values obtained in the independent reference models [14]. To evaluate the difference in 
clearance values more closely between both models, the population clearance values 
were plotted for both approaches versus birth bodyweight for PNA 1, 14 and 28 
days. Furthermore, the individual and population predicted parameters were plotted 
against the most predictive covariate for both approaches to evaluate whether the 
individual predicted parameters were equally distributed around the population 
parameters [22]. Additionally, the objective function values were evaluated as the 
models developed using both approaches are based on the same datasets. Finally, 
the results of the model validation (bootstrap analysis) as well as ill-conditioning 
and shrinkage were assessed. The predictive performance of the models using the 




Table II: Final parameter estimates and their corresponding coefficients of variation (CV%) of the model developed 
for amikacin applied in the models using the amikacin covariate model and of the models derived in the current 
study using the amikacin covariate model for netilmicin, tobramycin, vancomycin, gentamicin dataset A and genta-
micin dataset B.
Parameter Amikacin[16] Netilmicin[17] Tobramycin[18] Vancomycin[19] Gentamicin A[20] Gentamicin B[21]
Objective function 
value
7738.145 278.771 970.81 2763.631 1824.456 570.064
Fixed effects
CLp in CL = CLp x 
(bBW/median)m x
(1+ n x (PNA/me-
dian)) x o (ibuprofen)
0.049 
(2.21)
0.051 (5.22) 0.062 (2.06) 0.053 (2.74) 0.049 (1.47) 0.047 (3.12)








- 0.838 0.838 0.838 0.838










0.919 0.919 0.919 0.919 0.919
Q = r x CL
0.415 
(12.3)
- - 0.904 (10.4) - 1.47 (14.3)
Q=CL - Q=CL Q=CL - Q=CL -














- - - - -
CLp = population value for clearance, Vp = population value for volume of distribution of the central compartment, bBW = 
bodyweight at birth, cBW = current bodyweight, PNA = postnatal age, Q = intercompartmental clearance, V2 = Volume of 
distribution of the peripheral compartment
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5.3. Results
5.3.1. Pharmacokinetic Modeling
1/ Models using the amikacin covariate model [16]: 
In these models, the previously published amikacin covariate model (Figure 1) 
was directly incorporated in the pharmacokinetic models of the different drugs. The 
parameter estimates obtained for the models using the amikacin covariate model are 
shown in table II together with the parameter estimates obtained in the final model 
for amikacin [16]. As illustrated in figure 2 (top panels), the models using the amikacin 
covariate model described the observed concentrations without bias. The individu-
al post hoc clearances and population predicted clearances versus the most predic-
tive covariate (birth bodyweight) are given in figure 3, showing that the population 
predicted clearance values are describing the individual post hoc clearances without 
bias.  Furthermore, the results of the NPDE analysis in figure 4 show that the models 
can predict the median concentrations in the different datasets accurately. Finally, no 
trend was seen in the plots of the NPDE versus time and predicted concentrations 
(figure 4). 
2/ Independent reference models:
In the independent reference models of netilmicin, vancomycin and gentamicin 
datasets A and B, birth bodyweight and postnatal age were identified as the most 
important covariates to describe clearance. Current bodyweight was found as 
most important covariate to describe volume of distribution. Birth bodyweight and 
current bodyweight were implemented on clearance and volume of distribution 
of the central compartment, respectively, using a power function. Postnatal age 
was implemented using a power function (netilmicin, gentamicin A and gentamicin 
B datasets) or linear function (vancomycin dataset) depending on the dataset. For 
tobramycin, birth bodyweight was implemented on both clearance and volume of 
distribution using a power function. Based on the statistical criteria, postnatal age 
was not identified as a covariate on clearance. This may be explained by the fact 
that data of tobramycin were only available for the first four days after birth. In 
figure 2 (bottom panels) the observed versus population predicted concentrations 
are illustrated for the independent reference models. In table III, the different 
parameter estimates are given for the reference models of the 5 different neonatal 
datasets. In the various independent reference models, serum creatinine was not 
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and population predicted clearance values versus birth bodyweight, it was seen that 
the individual post hoc clearances were randomly scattered around the population 
predicted clearances (figures not shown). Finally the results of the NPDE analyzes 
showed that the independent reference models were able to adequately predict the 
median concentrations of the different datasets (figures not shown). 
5.3.2. Comparison of the models using the amikacin covariate model and indepen-
dent reference models
In figure 2, observed versus population predicted concentrations are shown for 
the models using the amikacin covariate model as well as the independent reference 
models. Visual examination of the plots shows that both the models using the 
amikacin covariate model as well as the independent reference models are able to 
predict the observed concentrations and that the difference in performance of the 
two approaches is negligible. In figure 5 the individual and population clearance values 
for the models using the amikacin covariate model are plotted versus those of the 
independent reference models of the different datasets. While both approaches 
estimate similar individual and population clearance values for netilmicin, tobramycin, 
gentamicin A and gentamicin B, a slight difference in population clearance values is seen 
for vancomycin, a drug with slightly different physicochemical and pharmacokinetic 
drug properties compared to amikacin and the other drugs. In figure 6, the population 
clearance values obtained using both approaches are plotted versus birth bodyweight 
for PNA 1, 14 and 28 days. To obtain the clearance values for the models using the 
amikacin covariate model, the full study range of the amikacin dataset was used 
while for the independent reference models, the study range available for that 
particular dataset was applied, explaining the differences seen in the length of both 
lines illustrating the population clearance values using both approaches. Based on 
this figure, it was concluded that at day of birth (day 1) and 14 days similar clearance 
values are obtained for both approaches for all drugs, while at day 28, a slight 
difference is seen for vancomycin and gentamicin B. For tobramycin it should be 
noted that no population clearance values are illustrated following the independent 
reference model for day 14 and 28 since this model is based on the original dataset 
which only included data during the first four days after birth. When plotting the 
individual and population predicted parameters against the most predictive covariate 
for both approaches, it was observed that the individual predicted parameters were 
equally distributed around the population parameters. Finally, when considering 
the differences in objective function values between the models using the amikacin 
covariate model and the reference models (table II and table III), it was seen that 
the reference models of netilmicin, vancomycin, and gentamicin A and B had a lower 
objective function value (  objective function value: netilmicin 5 points, vancomycin 
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23 points, gentamicin A 67 points, gentamicin B 59 points) as compared to the 
models using the amikacin covariate model. For tobramycin, the objective function 
value of the reference model was 43 points higher compared to the model using the 
amikacin covariate model, which can be explained by the use of a one compartment 
reference model versus a two compartment model using the amikacin covariate 
model. Furthermore, table II and table III show that the coefficients of variation of 
both fixed and random effects are well below 50% indicating that both approaches 
are able to estimate the parameters with high precision. Moreover, no ill-conditioning 
was detected in the models using both approaches since the condition number of the 
final pharmacokinetic models (range 2.23-64.44) was far below the critical value of 
1000. Finally, -shrinkage expressed as a percentage was identified to be below 20% 
for all final pharmacokinetic models using both approaches.
Results of the bootstrap analysis showed that the median estimated values based 
on re-sampled data were close (<20%) to the estimated values of the final models 
using the amikacin covariate model and independent reference models. This suggests 
that the final models using the amikacin covariate model and the independent 
reference models are stable and that the estimated parameter values are precise.
Considering the predictive performance, both the models using the amikacin 
covariate model as well as the independent reference models perform similar 
since both approaches can accurately predict the overall median concentrations. 
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Gentamicin B [21]Gentamicin A [20]
Netilmicin [17] Vancomycin [19]Tobramycin [18]
Figure 3: Individual post hoc (black) and population predicted (grey) clearance values (l/h) versus the most 
predictive covariate, birth bodyweight (g), for the models using the amikacin covariate model. 
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Figure 4: Results of the NPDE analysis for the models using the amikacin covariate model of a) netilmicin, b) tobra-
mycin, c) vancomycin, d) gentamicin A and e) gentamicin B. Left panel: Histograms of the NPDE distribution with 
the solid line representing a normal distribution as a reference, Middle panel: NPDE versus time (hours); Right 





















































































































































































































Time (hours) Observed Concentrations (mg/L)
E Gentamicin B [21]
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In addition, there was no bias in the normalized prediction distribution errors over 
time, nor over the predicted concentration range.
Table III: Final parameter estimates and their corresponding coefficients of variation (CV%) of the independent 
reference models derived in the current study for netilmicin, tobramycin, vancomycin, gentamicin dataset A and 
gentamicin dataset B.
Parameter Netilmicin[17] Tobramycin[18] Vancomycin[19] Gentamicin A[20] Gentamicin B[21]
Objective function value 273.659 1013.684 2740.457 1757.241 511.263
Fixed effects
CLp in CL = CLp x (bBW/median)m 
x (1+ n x (PNA/median)) 
- 0.067 (1.43) 0.038 (9.24) - -
m - 1.31 (2.43) 1.1 (5.72) - -
n - - 0.955 (19.7) - -
CLp in CL = CLp x (bBW/median)o 
x (PNA/median)p
0.063 (5.92) - - 0.097 (1.5) 0.046 (4.04)
o 1.44 (7.57) - - 1.36 (2.12) 1.41 (4.42)
p 0.481 (18.5) - - 0.458 (8.78) 0.371  (8.36)
Vp in V1 = Vp x (cBW/median)q 0.65 (7.14) 0.926 (1.45) 0.618 (2.85) 1.07 (2.3) 0.508 (1.74))
q 1 (13.4) 0.859 (3.41) 0.952 (8.21) 0.807 (5.29) 0.848 (3.27))
Q = r x CL - - - - 0.688 (12.1)
Q = CL Q=CL - Q=CL Q=CL -
V2 = s - - - - 0.846 (25.9)
V2 = V1 V2=V1 - V2=V1 V2=V1 -
Interindividual Variability
2 (CL) 0.188 (32.1) 0.065(10.4) 0.103 (12.5) 0.102 (13.4) 0.0357 (22.1)
Residual Variability
2 (proportional) 0.114 (17.9) 0.0439 (9.16) 0.0938 (7.64) 0.0776 (9.27) 0.0465 (8.65)
CLp = population value for clearance, Vp = population value for volume of distribution of the central compart-
ment, bBW = bodyweight at birth, cBW = current bodyweight, PNA = postnatal age, Q = intercompartmental 
clearance, V2 = Volume of distribution of the peripheral compartment
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5.4. Discussion
To facilitate the development and availability of drugs in children and to avoid 
the development and validation of PK/PD models for each new or existing drug, 
new approaches are needed. Therefore the aim of the current study was to evaluate 
whether the internally and externally validated covariate model of amikacin in (pre)
term neonates [16] can be extrapolated to other drugs eliminated through glomerular 
filtration  in neonates. This implicates that pediatric covariate models also contain 
biological system-specific information reflecting underlying physiological changes [13-15]. 
To test this hypothesis the covariate model of amikacin was directly incorporated 
in the pharmacokinetic model for netilmicin, vancomycin, tobramycin, gentamicin A 
and gentamicin B, drugs that, like amikacin are almost entirely eliminated through 
glomerular filtration. Using this approach a distinction is being made between drug-
specific and system-specific information as explained in the methods section in which 
the pediatric covariate model is considered system-specific while the population 
values are considered to be drug-specific. Subsequently the descriptive and predictive 
performance of models using the amikacin covariate model was compared to the 
independent reference models in which the covariate model was identified using a 
systematic covariate analysis [14, 22]. 
To extrapolate information from one drug to another a few requirements need to 
be met [14]. First of all it is a prerequisite that the covariate models, which are assumed 
to contain system-specific information, are extensively validated. In this analysis the 
covariate model, developed to describe the pharmacokinetics of amikacin, was based 
on the analysis of 2186 amikacin samples in 874 (pre)term neonates. The covariate 
model was both internally and externally validated [16]. Furthermore, it is important 
that the covariate models which are extrapolated to other drugs, are based on a con-
siderable number of samples from a large patient cohort with varying characteristics 
such as gestational age, birth bodyweight and postnatal age. In addition, it should 
be emphasized that the covariate models can only be extrapolated to populations 
with clinical characteristics that are within the studied range of the applied covariate 
model. In this analysis the amikacin covariate model developed for (pre)term 
neonates between 1 and 30 days was extrapolated to five other datasets in which 
the clinical characteristics are similar compared to the amikacin dataset considering 
bodyweight and age range (table I). Finally, a similar disease status was seen between 
the patients used for development of amikacin covariate model and the patients 
collected for the analysis of the unstudied drugs since all patients were admitted to 
the neonatal intensive care unit. When all the mentioned requirements are fulfilled, 
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model development of the unstudied drugs (netilmicin, vancomycin, tobramycin and 
gentamicin) may be based on an even more limited number of data which is by all 
means a major advantage in the design and sampling strategy of (pediatric) clinical 
trials since the number of patients and the burden for patients participating in the 
trial can be reduced. However a limited amount of data still needs to be available 
to estimate the population parameter values for each drug as these are considered 
to be drug-specific parameters (see methods section - covariate model). When all 
the above mentioned requirements are fulfilled, an advantage of utmost importance 
is seen in the time required to develop and validate models using a covariate model 
which already has been extensively validated (weeks) compared to reference models 
(months).
The descriptive and predictive performance of the models using the amikacin 
covariate model was confirmed by figure 2, 3 and 4. This suggests that the covariate 
model of amikacin may contain system-specific information on the developmental 
changes in glomerular filtration. In an analysis of Krekels et al. [14], the same concept 
was applicable since it was illustrated that the covariate model for the glucuronida-
tion of morphine in (pre)term neonates to children up to 3 years of age was able 
to describe the developmental changes in the glucuronidation of zidovudine in term 
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Figure 5: Individual and population predicted clearances for the models using the amikacin covariate model versus 
the independent reference models for netilmicin, vancomycin, tobramycin, gentamicin dataset A and gentamicin 
dataset B.
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neonates and infants. Although similar individual and population clearance values 
are predicted by both approaches as seen in figure 5, a slight difference is seen in 
population clearance values of vancomycin and gentamicin B between the reference 
model and the model using the amikacin covariate model for the higher population 
values for clearance. This is also reflected in figure 6 in which this slight difference 
was seen between the clearance values for vancomycin and gentamicin B following 
both approaches at day 28. It is however unknown which of the two approaches 
best reflects the true clearance of these drugs. For gentamicin B, it should be noted 
that this difference seen in the higher clearance values of both approaches is only 
based on a limited number of data. Considering vancomycin, it is possible that the 
population clearance values predicted by the reference model are slightly different 

























Figure 6: Population clearance values for the models using the amikacin covariate model (black) and the indepen-
dent reference models (dotted line) versus birth bodyweight for PNA 1 (above), 14 (middle) and 28 days (below) 
for netilmicin, vancomycin, tobramycin, gentamicin A and gentamicin B. For the clearance values obtained with the 
amikacin covariate model, the full study range of the amikacin dataset is used while for the independent reference 
models, the study range available for that particular dataset is used causing the differences seen in the length of 
both lines illustrating the population clearance values using both approaches. Moreover for tobramycin, no clearance 




because this model is only based on vancomycin data from preterm neonates (Table 
I). This limitation in information is less important in the model using the amikacin 
covariate model in which missing information is supplemented by information gained 
from the amikacin covariate model. The slight difference in population clearance 
values between the two approaches can also indicate that although vancomycin is 
mainly eliminated by glomerular filtration, the elimination of vancomycin may be 
modified by the presence of tubular processes (secretion or reabsorption) [31], which 
is not captured by the amikacin model. Finally, the difference may also be due to the 
different physicochemical properties of vancomycin compared to the other drugs, 
because in contrast to netilmicin, tobramycin and gentamicin, drugs that belong to 
the same class as amikacin, namely the aminoglycosides, vancomycin is a tricyclic 
glycopeptide. Besides the large difference in molecular mass of vancomycin (1449.3 
g/mol) compared to amikacin (585.603 g/mol), netilmicin (475.58 g/mol), tobramy-
cin (467.515 g/mol) and gentamicin (477.596 g/mol), the difference between the two 
drugs classes is also reflected in the protein binding. For the aminoglycosides the 
protein binding is below 10% in adults while this is much higher (approximately 55%) 
for the glycopeptide vancomycin. For antibiotics with a higher protein binding a lower 
renal clearance is often seen since only free drug is eliminated through the renal 
function [32]. 
In this analysis, the amikacin covariate model was in a first step extrapolated 
to drugs which are also almost entirely eliminated through GFR and with similar 
physicochemical properties compared to amikacin. However the majority of the 
drugs is eliminated by different elimination routes (hepatic and renal elimination). 
Therefore in a future analysis, the extension of the amikacin covariate model will 
be evaluated as well as the exact influence of differences in physicochemical and 
pharmacokinetic drug properties on the extrapolation of the amikacin covariate 
model to other drugs which are eliminated by different routes. To analyze this, a 
future analysis needs to be performed as done by Krekels et al. [15]. In that analysis 
the exact influence of differences in physiochemical properties on the extrapolation 
potential of the glucuronidation function was examined by using a physiological based 
(PBPK) modeling approach. Finally it will also be evaluated whether it is possible to 
characterize developmental changes in tubular processes in preterm and term based 
on the amikacin covariate model describing the developmental changes in GFR. A 
combination of all these different strategies (extrapolation to other drugs, adult data 
or non-clinical data) [33-35] will result in an approach focusing on the underlying system 
instead of focusing on the drugs and may facilitate development of pharmacokinetic 
models and evidence-based dosing regimens in the pediatric population.
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5.5. Conclusions
In this study it was demonstrated that the descriptive and predictive performance 
of the models using the amikacin covariate model was similar to the independent 
reference models. This indicates that the use of system-specific information from 
one drug to other drugs may lead to optimization of sparse data analysis in children 
and that the covariate model, which in this case is describing the developmental 
changes in GFR, can be used to evaluate and optimize study and sampling design. As 
a consequence, the covariate model may play an important role to determine first-
in-child dosing strategies and evidence-based dosing regimens of new and existing 
drugs. 
Supplement Table I: Bootstrap results and their corresponding coefficients of variation (CV%) of the models derived 
in the current study using the amikacin covariate model for netilmicin, tobramycin, vancomycin, gentamicin dataset 
A and gentamicin dataset B.
Parameter Netilmicin[17] Tobramycin[18] Vancomycin[19] Gentamicin A[20] Gentamicin B[21]
Fixed effects
CLp in CL = CLp x (bBW/me-
dian)m x (1+ n x (PNA/median)) 
x o (ibuprofen)
0.051 (5.08) 0.062 (3.36) 0.053 (2.81) 0.049 (1.52) 0.047 (3.15)
m 1.34 1.34 1.34 1.34 1.34
n 0.213 0.213 0.213 0.213 0.213
o - 0.838 0.838 0.838 0.838
Vp in V1 = Vp x (cBW/median)p 1.01 (7.18) 1.04 (8.07) 0.914 (2.74) 0.763 (1.9) 0.731 (3.37)
p 0.919 0.919 0.919 0.919 0.919
Q = r x CL - - 0.907 (10.5) - 1.47 (13.85)
Q=CL Q=CL Q=CL - Q=CL -
V2=V1 V2=V1 V2=V1 V2=V1 V2=V1 V2=V1
Interindividual Variability
2 (CL) 0.188 (35.2) 0.15 (11.3) 0.11 (12.6) 0.106 (13.6) 0.0530 (21.7)
Residual Variability
2 (proportional) 0.116 (18.0) 0.045 (17.6) 0.095 (7.94) 0.081 (9.39) 0.0477 (12.1)
CLp = population value for clearance, Vp = population value for volume of distribution of the central compart-
ment, bBW = bodyweight at birth, cBW = current bodyweight, PNA = postnatal age, Q = intercompartmental 
clearance, V2 = Volume of distribution of the peripheral compartment
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Parameter Netilmicin[17] Tobramycin[18] Vancomycin[19] Gentamicin A[20] Gentamicin B[21]
Fixed effects
CLp in CL = CLp x (bBW/
median)m x (1+ n x (PNA/
median)) 
- 0.066 (1.60) 0.034 (10.38) - -
m - 1.31 (3.18) 1.07 (18.57) - -
n - - 1.09 (25.13) - -
CLp in CL = CLp x (bBW/
median)o x (PNA/median)p
0.062 (6.79) - - 0.096 (1.5) 0.046 (4.37)
o 1.43 (8.34) - - 1.36 (2.14) 1.40 (4.97)
p 0.410 (50.18) - - 0.460 (10.67) 0.372  (9.05)
Vp in V1 = Vp x (cBW/
median)q
0.66 (6.78) 0.929 (2.22) 0.613 (2.96) 1.07 (2.30) 0.504 (2.14))
q 0.97 (14.75) 0.839 (16.21) 1.00 (7.75) 0.808 (5.17) 0.851 (3.54))
Q = r x CL - - - - 0.733 (17.25)
Q = CL Q=CL - Q=CL Q=CL -
V2 = s - - - - 0.851 (25.99)
V2 = V1 V2=V1 - V2=V1 V2=V1 -
Interindividual Variability
2 (CL) 0.196 (34.4) 0.063(12.85) 0.18 (21.13) 0.101 (13.63) 0.035 (22.1)
Residual Variability
2 (proportional) 0.114 (18.76) 0.0458 (25.54) 0.0975 (7.97) 0.078 (9.38) 0.0453 (8.46)
CLp = population value for clearance, Vp = population value for volume of distribution of the central compart-
ment, bBW = bodyweight at birth, cBW = current bodyweight, PNA = postnatal age, Q = intercompartmental 
clearance, V2 = Volume of distribution of the peripheral compartment
Supplement table II: Bootstrap results and their corresponding coefficients of variation (CV%)  of the independent 
reference models derived in the current study for netilmicin, tobramycin, vancomycin, gentamicin dataset A and 
gentamicin dataset B.
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Cefazolin pharmacokinetics and dosing in neonates
Abstract 
Objectives
Cefazolin is frequently administered for antimicrobial prophylaxis and treatment 
of infections. In neonates, pharmacokinetic observations are limited and dosing 
regimens variable. The aim of this study was to describe the pharmacokinetics 
of cefazolin in neonates based on total and unbound concentrations to optimize 
cefazolin dosing.
Methods 
Thirty-six neonates [median birth bodyweight (bBW) 2720 (range 540-4200)g, 
current bodyweight (cBW) 2755 (830-4200)g, postnatal age (PNA) 9 (1-30) days] 
receiving intravenous cefazolin (50mg/kg/8h) were included. Based on 119 total 
and unbound plasma concentrations, a population pharmacokinetic analysis with a 
covariate analysis was performed. Monte Carlo simulations were performed aiming 
for unbound concentrations above a minimal inhibitory concentration of 8 mg/L 
(>60% of time) in all patients.
Results 
A one-compartment pharmacokinetic model was developed in which total and 
unbound concentrations were linked by a maximal binding capacity Bmax of 136 mg/L 
and a dissociation constant for cefazolin protein binding KD of 46.5 mg/L. Current 
bodyweight was identified as covariate for volume of distribution (Vd), bBW and PNA 
for clearance (Cl) and albumin plasma concentration for Bmax, explaining 50%, 58% 
and 41% of interindividual variability in Vd, Cl and Bmax, respectively. Based on Monte 
Carlo simulations, a bodyweight and PNA adapted dosing regimen was proposed 
resulting in similar exposure across different weight and age groups. 
Conclusions
A neonatal pharmacokinetic model taking into account total and unbound 
cefazolin concentrations with saturable plasma protein binding was identified. As 
current bodyweight and PNA were the most important covariates, these may be 




Based on a European survey, 15% of antimicrobial use for surgical prophylaxis 
in children is covered by first generation cephalosporins [1]. In a United States point 
prevalence survey in pediatric (PICU) and neonatal intensive care unit (NICU) 
patients, cefazolin was used in respectively 17.6% and 1.2% of patients on the day of 
survey [2]. Indications for cefazolin administration in neonates are mainly prophylactic 
(72%), to a lesser extent therapeutic (17%) (e.g. coagulase-negative staphylococcal 
sepsis) [3] or empiric (11%) [2]. While the pharmacokinetics (PK) of cefazolin have 
been described in adults, information on cefazolin PK in early life is limited [4-6]. 
Cefazolin is highly bound to human serum albumin and this binding displays saturation 
[7-9]. Only the unbound cefazolin distributes to the extravascular compartments and 
undergoes renal elimination. Neonates have a proportionally large total body water 
volume, immature renal function and low albumin level [10-12]. This population specific 
physiology likely affects cefazolin disposition.
Efficacy of cefazolin relates to the time unbound cefazolin concentrations exceed 
the minimal inhibitory concentration (MIC) for a given pathogen (T>MIC) 
[13]. In 
neonates, often regarded as vulnerable and even immunocompromised patients, 
effective cefazolin therapy requires at least 60% of T>MIC  
[14]. 
Up to now, neonatal cefazolin clearance values described in literature are based 
on total cefazolin concentrations only, necessitating a cefazolin PK analysis integrating 
both total and unbound drug concentrations in neonates. Moreover, currently used 
cefazolin dosing regimens for neonates are variable (Table S1) [15-21].
Therefore, the aim of this study was to describe the pharmacokinetics of cefazolin 
in preterm and term neonates on the basis of both total and unbound cefazolin con-
centrations. Based on the final pharmacokinetic model, Monte Carlo simulations 
were performed to illustrate exposure to cefazolin in (pre)term neonates following 
currently used dosing regimens. Subsequently, a model-based dosing regimen was 
developed for preterm and term neonates.
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6.2. Methods
6.2.1. Ethics, study population and drug dosing
The patients included in this study are based on a previously published cohort 
of 39 neonates and young infants, all admitted to the Neonatal Intensive Care Unit 
of the University Hospitals Leuven Belgium [8]. The study was approved by the 
ethical board of the hospital, registered at ClinicalTrials.gov (NCT01295606) and 
parental written informed consent was obtained. Inclusion was feasible if cefazolin 
(Cefazolin Sandoz®, Sandoz, Vilvoorde, Belgium) was administered intravenously as 
routine surgical prophylaxis. At induction of surgery, a cefazolin 50 mg/kg dose was 
administered over 30 minutes. According to the local standard of care (depending 
on foreign body implantation or contamination risk of the procedure), additional 50 
mg/kg cefazolin dose(s) could be administered every 8 hours up to a maximum of 
48 hours. As in the present analysis only neonates with postnatal age (PNA) 1-30 
days were included, three patients (PNA 48, 51 and 108 days) were excluded from 
the original dataset [8]. Clinical characteristics were extracted from the medical 
files. Albuminaemia (g/L), indirect serum bilirubin concentrations (mg/dL) and serum 
creatinine (mg/dL) registered in a time interval of 24 h before or after the first 
cefazolin administration were collected. Plasma free fatty acids concentrations were 
determined in samples at the end of the study. Clinical characteristics of the study 
population are presented in Table 1.
6.2.2. Blood sampling
Blood samples were collected in lithium-heparin tubes at fixed time points, i.e. 
at 0.5, 2, 4 and 8 h after the first cefazolin administration and subsequently at 8 h 
intervals prior to each scheduled cefazolin administration, to determine total and 
unbound cefazolin concentrations. However, the number of samples collected from 
each patient was limited since the predefined total volume of blood available for 
sampling per patient was maximized to 1 mL/kg bodyweight. Blood samples (0.6 
mL/sample) were immediately centrifuged (5 minutes, 4500 rpm at 4 °C) and the 
resulting 0.3 mL plasma was stored at -20°C in two aliquots of 0.15 mL. 
6.2.3. Drug assay 
Total and unbound cefazolin concentrations were determined by High Performance 
Liquid Chromatography after solid-phase column extraction. The initial method was 
developed in our laboratory [22] and adapted for measurement of cefazolin in small 
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volume plasma samples [8]. The lower limit of quantification for cefazolin was 0.1 µg/
mL, with a coefficient of variation lower than 20%. Intra-assay precision and accuracy 
averaged 3.9 and 5.5% respectively. Inter-assay precision and accuracy averaged 5.7 
and 6.8%, respectively, which is in line with FDA analytical recommendations [23, 24].
6.2.4. Biochemical assays
Albumin, indirect bilirubin and creatinine (enzymatic) were quantified on Roche 
Modular P (Roche Diagnostics, Basel, Switzerland). Free fatty acids were determined 
with a kit from DiaSys (DiaSys, Diagnostic Systems, Holzheim, Germany).
6.2.5. Population pharmacokinetic analysis
Model development
The population pharmacokinetic analysis was performed using the non-linear 
mixed effect modeling software NONMEM version 6.2 (Globomax LLC, Hanover, 
MD, USA) using the first-order conditional estimation method with the interaction 
option (FOCE-I). Tools like S-Plus version 6.2.1 (Insightful software, Seattle, WA) 
with NM.SP.interface version 05.03.01 (© by LAP&P Consultants BV, Leiden, The 
Patient characteristics Median (range)
Number of patients 36
Number of samples 119
Birth bodyweight (g) 2720 (540-4200)
Current bodyweight (g) 2755 (830-4200)
Postnatal age (PNA, days) 9 (1-30)
Gestational age (weeks) 37 (24-40)
Postmenstrual age (PMA, weeks) 38 (25-41)
Albumin (g/L) 34.5 (28.2-43.7)
Creatinine (mg/dL) 0.46 (0.26-1.03)
Free fatty acids (mmol/L) 0.08 (0-0.84)
Indirect bilirubin (mg/dL) 2.91 (0.1-11.13)
Gender (male/female) 22 / 14 
Table 1: Clinical characteristics of the patients included in the study. Data are presented as median (range) or 
incidence.
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Netherlands), PsN and R (version 2.10.1) were used to visualize and evaluate the 
model. 
The model building process was performed in a stepwise manner: (i) choice of the 
structural model, (ii) choice of the statistical sub-model, (iii) choice of the covariate 
model, (iv) model evaluation. Different diagnostic tools were used to discriminate 
between the different models [25]. A decrease in objective function (OFV) of 3.9 
points or more was considered statistically significant (p<0.05 based on X2 distri-
bution, for nested models). Furthermore, the goodness-of-fit plots were evaluated. 
Finally the total number of parameters, visual improvement of individual plots, cor-
relation matrix, confidence intervals of parameter estimates, ill-conditioning [26] and 
shrinkage [27] were assessed.
Structural and statistical sub-model
A one and two compartment pharmacokinetic model was fitted to both total and 
unbound cefazolin concentrations using NONMEM VI, subroutine ADVAN6, TOL=3. 
Unbound cefazolin concentrations were related to total cefazolin concentrations by 
the following equation, taking into account non-linear protein binding [28].
 
(Equation 1)
In this equation Cunbound represents the unbound cefazolin concentrations, Ctotal 
the total cefazolin concentrations, Bmax the maximum protein binding and KD the 
dissociation constant.
For the statistical sub-model, the inter-individual variability was assumed to follow 
a log-normal distribution. For the intra-individual variability and residual error, a pro-
portional, additive and a combined error model were tested.
Covariate analysis
The following covariates were evaluated in the covariate analysis: birth body-
weight (bodyweight at day of birth, bBW, gram), current bodyweight (bodyweight at 
day of blood sampling, cBW, gram), postnatal age (PNA, days), gestational age (GA, 
weeks), postmenstrual age (PMA, weeks, combination of GA and PNA in weeks), al-
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buminaemia (g/l), creatininaemia (mg/dL), free fatty acids (mmol/L), indirect bilirubin 
(mg/dL) and gender. Potential covariates were separately implemented into the model 
using a linear or power equation (equation 2): 
 (Equation 2)
In this equation Pi represents the individual parameter estimate of the ith subject, 
Pp equals the population parameter estimate, Cov is the covariate and k is the 
exponent which was fixed to 1 for a linear function or was estimated for a power 
function. Covariates were considered statistically significant if the objective function 
decreased 7.8 points (p-value <0.005) or more. The covariate causing the largest 
reduction in objective function was chosen as a basis to sequentially explore the 
influence of additional covariates. The choice of the covariate models was further 
evaluated as discussed under Model development, whereby the results of the Model 
validation were also considered.
Model validation
The stability of the final pharmacokinetic model was evaluated by a bootstrap 
analysis, in which the model building dataset was resampled 1000 times, in S-plus, 
version 6.2.1. (Insightful software, Seattle, WA) with NM.SP.interface version 
05.03.01 (© by LAP&P Consultants BV, Leiden, The Netherlands). To evaluate the 
accuracy of the model the normalized prediction distribution error (NPDE) method 
was performed. To perform this analysis the dataset was simulated 1000 times after 
which each observed concentration was compare to the simulated concentrations 
using the NPDE package in R [29, 30].
6.2.6. Monte Carlo simulations
To evaluate T>MIC, the Clinical and Laboratory Standards Institute (CLSI) 2012 
[31] MIC interpretative criteria for susceptibility to cefazolin corresponding with the 
5 bacterial species isolated most frequently from neonatal blood cultures from our 
department were used. Therefore, all positive blood culture results (n=137) from our 
unit, for the period January - October 2012, were retrospectively collected. Identi-
fication of bacterial isolates was done by use of MALDI Biotyper (Bruker Daltonics, 
Bremen, Germany). Staphylococcus species contributed for 94.4% of the top 5 isolates. 
Consequently, the CLSI MIC interpretative criterion for susceptibility to cefazolin of 
Staphylococcus species (8 mg/L) was used as target MIC (Table 2) [31].
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As effective cefazolin therapy is reported to require at least 60% of T>MIC 
[15], the 
probability of attaining unbound cefazolin concentrations during 60% of the dosing 
interval [14] above 8 mg/L was evaluated on the basis of Monte Carlo simulations using 
the final pharmacokinetic model. These Monte Carlo simulations were performed 
in 1000 individuals to evaluate the exposure to cefazolin in (pre)term neonates 
following the currently used dosing regimen in this study and the dosing regimen 
proposed by the Dutch Children’s Formulary [15]. The covariates identified in the final 
pharmacokinetic model were sampled from the original dataset taking into account 
their correlation. Albumin was randomly generated according to the observed distri-
bution in these 36 neonates. For the simulations, cefazolin doses were administered 
over 30 minutes every 8 hours until 48 hours after the first dose. To evaluate the 
results of the Monte Carlo simulations, 4 different groups (Group 1: PNA ≤ 7 days, 
cBW ≤ 2000g, Group 2: PNA ≤ 7 days, cBW > 2000g, Group 3: PNA > 7 days, cBW ≤ 
2000g, Group 4: PNA > 7 days, cBW > 2000g) were created. Based on these results, 
a new model-based dosing regimen was proposed.
Table 2: The 5 bacterial species isolated most frequently from neonatal blood cultures (n=137) in the Leuven 
neonatal intensive care unit for the period January 2012 until October 2012. Corresponding CLSI MIC values are 
reported.
Isolate Contribution to 




CLSI MIC values (mg/L)
Susceptible Intermediate Resistant
1) S. epidermidis 51.82 65.74
≤ 8 16 ≥ 32
2) S. hominis 9.49 12.04
3) S. aureus 6.57 8.33
4) S. capitis 6.57 8.33
5) E. coli 4.38 5.56 ≤ 2 4 ≥ 8






The pharmacokinetic analysis was based on 119 plasma concentrations of cefazolin 
obtained in 36 (pre)term neonates with PNA 1-30 days. Median total and unbound 
cefazolin plasma concentrations, were respectively 101.09 (range 17.44-404.22) mg/L 
and 41.15 (range 5.34-261.38) mg/L. Median unbound fraction was 0.40 (range 0.14-
0.73). Clinical characteristics are presented in Table 1. 
6.3.2. Population pharmacokinetic analysis
Structural and statistical sub-model
A one compartment model was selected as structural model because a two 
compartment model was not superior over a one compartment model. The final 









Figure 1: Schematic representation of the pharmacokinetic model using both total and unbound concentrations 
of cefazolin. K
D 
= Dissociation constant, B
max 
= Maximum protein binding, FU = unbound fraction of cefazolin, 
CL
unbound
 = Clearance of unbound cefazolin. 
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cefazolin concentrations, was parameterized in terms of clearance, volume of 
distribution (Vd), maximum protein binding Bmax and the dissociation constant KD 
(Figure 1). By the determination of Bmax and KD, unbound cefazolin concentrations 
could be calculated from total concentrations (equation 1). Initially, a separate 
proportional error was estimated for total and unbound cefazolin concentrations. 
Since these errors were not significantly different (p>0.05), the model was simplified 
by estimating one proportional error for both total and unbound concentrations.
Table 3: Model-based population pharmacokinetic parameter estimates and the values obtained after the bootstrap 
analysis.






Value (CV%) Value (CV%) Value (CV%)
Fixed effects
CL (L/h) = CLp 0.229 (11.7) - -
CLp in CL = CLp x (bBW/median)m 
x (1+(PNA/median) x n)
- 0.185 (12.8) 0.187 (13.3)
m - 1.37 (16.4) 1.41 (17.3)
n - 0.496 (38.5) 0.524 (44.5)
V (L) = Vp 0.812 (3.0) - -
Vp in V = Vp x (cBW/median) - 0.863 (3.55) 0.860 (3.63)
B
max
 (mg/L) = B
max









- 136 (12.6) 141 (14.5)
Kd (mg/L) =Kdp 53.2 (22.9) 46.5 (20.9) 49.5 (24.1)
Interindividual variability ( 2)
2 CL 0.535 (33.6) 0.163 (35.1) 0.149 (38.0)
2 V 0.14 (29.1) 0.0259 (38.6) 0.0258 (43.2)
2 Bmax 0.102 (41.0) 0.0367 (54.0) 0.0368 (56.7)
Residual variability ( 2)
2 (proportional) 0.0332 (22.1) 0.0351 (21.5) 0.0342 (22.5)
CL= clearance, CLp = population value for clearance for an individual with birth bodyweight of 2720g and postna-
tal age of 9 days, V = Volume of distribution, Vp = population value for volume of distribution for an individual 
with a current bodyweight of 2755g, B
max
 = maximum protein binding, B
max
p = population value for maximum 
protein concentration for an individual with an albumin concentration of 34.5 g/L, Kd = Dissociation constant of 
the drug, Kdp = population value of dissociation constant of the drug, bBW = birth bodyweight, cBW = current 




Current bodyweight was found as most important covariate on Vd. Initially, 
current bodyweight was implemented on Vd using a power function with an 
estimated exponent of 0.94. However since the 95% confidence interval of this 
parameter included 1, a linear relationship between current bodyweight and Vd was 
used (p>0.05). Implementation of current bodyweight on Vd caused a significant 
drop in objective function (OFV) of 46 points (p<0.005). Although for clearance, 
PMA was identified as most important covariate, a combination of the covariates 
birth bodyweight and PNA was preferred over PMA alone. First of all, both analyses 
resulted in a comparable improvement of the model (i.e. same reduction in objective 
function ( OFV 32 points, P< 0.005). Secondly, the combination of birth bodyweight 
and PNA allows to make a distinction between the antenatal (birth bodyweight) 
and postnatal (PNA) maturation component of cefazolin clearance. Birth bodyweight 
was implemented on clearance using a power function with an estimated exponent 
of 1.37, while PNA was implemented using a linear function with an estimated slope 
of 0.496 (Table 3). The model was further improved ( OFV 12 points, P< 0.005) by 
introducing albumin on Bmax using a linear function (Table 3). 
The parameter estimates of the simple and the final pharmacokinetic model and 
the values obtained from the bootstrap analysis are provided in Table 3. In Figure 2, 
the observed versus predicted concentrations are plotted for the total and unbound 
concentrations showing that the model adequately describes the data. In Figure S1, 
the inter-individual variability in clearance, Vd and Bmax is plotted against the relevant 
covariates for the simple and the final pharmacokinetic model. A significant part of 
the interindividual variability is explained (Figure S1). This is also reflected by the 
decrease in the estimates of the interindividual variability when comparing the simple 
and the final pharmacokinetic model which results in a decrease of 50% of the inter-
individual variability on Vd, 58% on clearance and 41% on Bmax (Table 3). In Figure 3 
the observed and population predicted bound and unbound cefazolin concentrations 
are plotted from which Bmax and the value for the unbound concentration for which 
the binding was half-maximal (KD) can be derived. Variation in population predicted 
bound and unbound cefazolin concentrations are explained by differences in current 
bodyweight, birth bodyweight and PNA of the subjects (Figure 3). 
The number of binding sites on the albumin molecule was derived from Bmax, which 
was corrected for molecular weight of albumin (67000 g/mol) and cefazolin (454.5 g/
mol) (Equation 3), and the median albumin concentration (34.5 g/L) (Equation 4) and 
proved 0.6. 
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The results of the bootstrap analysis (Table 3) show that the median estimated 
values based on the resampled dataset are within 10% of the values obtained in the 
final model. The NPDE histograms are following the normal distribution, indicating 
the accuracy of the final pharmacokinetic model (Figure 2). Furthermore no trend 
was seen between the NPDE versus time or versus predicted concentrations (figures 
not shown). The number of ill-conditioning (74.6) was far below the critical number 
of 1000 indicating that the final pharmacokinetic model was not overparameter-
ized. Finally, -shrinkage expressed as a percentage was identified to be 9.8% for 
clearance, 21.2% for Vd and 30% for Bmax.
6.3.3. Monte Carlo simulations
Concentration-time profiles following the currently used dosing regimen, the 
dosing regimen proposed by the Dutch Children’s Formulary and the new model 
based-dosing regimen (Table 4) were predicted based on Monte Carlo simulations 
using the final pharmacokinetic model (Figure 4). In Figure S2, box plots illustrate the 
median and interquartile ranges (5% and 95%) of the individual predicted concentra-
tions at 60% of the dosing interval after the first dose and after the fourth or sixth 
dose. This illustrates that less than 10% of the individual predicted concentrations at 
60% of the dosing interval are below a MIC of 8 mg/L. Relatively high cefazolin peak 
concentrations are reached, particularly in neonates in group 1, 2 and 3 following 
the dosing regimen used in the current study and in group 3 following the dosing 
regimen proposed by the Dutch Children’s Formulary (Figure 4, S2). Therefore, a 
new dosing regimen was advised based on the dosing regimen proposed by the Dutch 
Children’s Formulary but including a lower dose for group 3 (Table 4). Using this 
dosing regimen, 0%, 1.2%, 0.7% and 1.0% of the individuals of group 1, 2, 3 and 4, 





Neonatal cefazolin PK data are outdated since they are mainly based on total drug 
concentrations collected in a limited number of subjects. We aimed to characterize 
cefazolin pharmacokinetics and its covariates based on both total and unbound drug 
concentrations. In our study, the median cefazolin clearance value (coefficient of 
variation, %) for a neonate with a birth bodyweight of 2720 g and PNA 9 days was 
0.185 (12.8) L/h (i.e. 0.068 L/kg/h). This is slightly higher than the earlier reported 
values of 0.53-1.10 mL/kg/min (i.e. 0.032-0.066 L/kg/h) in 11 neonates receiving 30 
mg/kg cefazolin intravenously. Since only the unbound cefazolin is pharmacologically 
active and total drug concentrations only partially reflect unbound concentrations 
(Figure 3), we would like to emphasize that unbound concentrations need to be 
measured instead of using estimated unbound concentrations based on a fixed protein 
binding percentage. Especially in highly protein bound drugs this is of relevance. 
Figure 2: Observed versus individual predicted concentrations (a,d) and population predicted concentrations (b,e) 
for total (upper panels) and unbound (lower panels) cefazolin concentrations. The histograms show the distribution 
of the normalized prediction distribution error (NPDE) methods for total (c) and unbound (f) cefazolin concentra-
tions.
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Cefazolin pharmacokinetics and dosing in neonates
Postnatal age and birth bodyweight were the most important covariates of 
neonatal cefazolin clearance. This is in line with expectations, taking into account the 
elimination of cefazolin by renal route. Renal clearance displays maturation during 
early life and covariates birth bodyweight and PNA can hereby respectively reflect 
the prenatal and postnatal maturation [32]. Furthermore, age and bodyweight were 
earlier documented as clearance predictors of other beta-lactams in neonates [33-36]. 
We can only hypothesize on factors affecting the remaining unexplained cefazolin 
clearance variability within the neonatal population. Possibly, maturation of the renal 
tubular activity is a contributing factor. Also for other beta-lactams (e.g. amoxicillin, 
flucloxacillin) the presence of other elimination pathways, in addition to glomerular 
filtration rate (GFR), such as tubular secretion or non-renal clearance routes was 
suggested earlier [33, 37]. Since only the unbound drug can be eliminated and since 
compound specific clearance depends on compound specific protein binding, we 
hereby want to stress that the mean (± standard deviation) protein binding of flu-
cloxacillin (74.5±3.1%) and in particular amoxicillin (11.7±2.7%) is lower compared to 
cefazolin [34, 38] Therefore, results of amoxicillin and flucloxacillin may not be directly 
applied to cefazolin.





























Figure 3: The relationship between the observed (square) and model-based predicted (circle) bound and unbound 
cefazolin concentrations (mg/L) in 36 (pre)term neonates. B
max
 (protein binding defined as the maximum estimated 
concentration bound to albumin) and K
D
 (dissociation constant defined as the unbound concentration which cor-
responds to 50% of the maximum binding capacity) are illustrated.
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Chapter 6
The number of binding sites for cefazolin on the albumin molecule based on this 
analysis was calculated to be 0.6 (equation 3 and 4), which corresponds well with the 
number of binding sites for cefazolin on albumin previously found in literature (0.7) 
[7, 39, 40].
We documented relatively high cefazolin plasma concentrations based on a 50 
mg/kg/8h cefazolin dosing regimen, administered to all study patients. This is likely 
due to the absence of any bodyweight and/or age- adapted dosing. Simulation of 
the dosing regimen proposed by the Dutch Children’s Formulary resulted in lower 
cefazolin concentrations. However, based on Figure 4 and S2, the dose administered 
to neonates in group 3 when using the Dutch Children’s Formulary, still needs further 
reduction. A new bodyweight- and age-based dosing regimen is suggested, derived 
from the dosing regimen proposed by the Dutch Children’s Formulary, but with a 
dose reduction for group 3 in order to reach similar exposure in all four groups 
(Table 4). With this new model-based dosing regimen the target of 8 mg/L for 60% 
of the dosing interval was reached for >90% of the patients (i.e. 100%, 98.8%, 99.3% 
and 99% of the individuals of group 1, 2, 3 and 4, respectively).
When compared to the dosing regimen used in this study, a total daily dose 
reduction of 67%, 33% and 50% for patients in respectively group 1, 2 and 3 is 
proposed resulting in similar exposure in all groups. The proposed dosing regimen 
is hereby more in line with some of the recommendations presented in Table S1. As 
a consequence of cefazolin dose reduction, albumin binding places become available 
Guideline PNA (days) cBW (g) Dose (mg/kg) Interval (h)
Used in the current study - - 50 8
Dutch Children’s Formulary ≤ 7 days ≤ 2000g 25 12
≤ 7 days > 2000g 50 12
7-28 days 50 8
Proposed dosing regimen ≤ 7 days ≤ 2000g 25 12
≤ 7 days > 2000g 50 12
7-28 days ≤ 2000g 25 8
7-28 days > 2000g 50 8
PNA = postnatal age, cBW = current bodyweight
Table 4: Dosing recommendations for cefazolin in preterm and term neonates according to dosing regimens used in 
the current study, the Dutch Children’s Formulary and a new model-based proposed dosing regimen. For concentra-
tion-time profiles of these dosing regimens for neonates with different clinical characteristics we refer to Figure 4.
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Reference Age Weight Cefazolin dose and interval
NICU UZ Leuven 50 mg/kg/dose, q8h
Dutch Children’s Formu-
lary[15]





1-4 weeks PNA 50 mg/kg/dose, q8h
Neonatal and pediatric 
pharmacology, Yaffe and 
Aranda 2011[16] 











The Harriet Lane Handbook 
2012[18]
≤ 1 week PNA 20 mg/kg/dose, q12h






≤ 29 weeks PMA, 0-4 weeks PNA
  > 4 weeks PNA
25 mg/kg/dose, q12h
25 mg/kg/dose, q8 h
30-36 weeks PMA, 0-2 weeks PNA
  > 2 weeks PNA
25 mg/kg/dose, q12h
25 mg/kg/dose, q8 h
37-44 weeks PMA, 0-1 week PNA
  > 1 week PNA
25 mg/kg/dose, q12h
25 mg/kg/dose, q8h
≥ 45 weeks PMA, all 25 mg/kg/dose, q6h
Nelson’s Textbook of 
Pediatrics 2007[17]
< 1 week PNA 20 mg/kg/dose, q12h
> 1 week PNA 13-20 mg/kg/dose, q8h
The Sanford guide to 
antimicrobial therapy
2012-2013[20]
≤ 29 weeks PMA, 0-4 weeks PNA
  > 4 weeks PNA
50 mg/kg/dose, q12h
50 mg/kg/dose, q8h
30-36 weeks PMA, 0-2 weeks PNA
  > 2 weeks PNA
50 mg/kg/dose, q12h
50 mg/kg/dose, q8h
37-44 weeks PMA, 0-1 week PNA
  > 1 week PNA
50 mg/kg/dose, q12h
50 mg/kg/dose, q8h
≥ 45 weeks PMA, all 50 mg/kg/dose, q6h
Redbook 2012[21] 










Table S1: Overview of cefazolin dosing regimens for neonates and young infants. The dosing regimen used in the 
current study as well as the dosing regimen provided by the Dutch Children’s Formulary and different handbooks 

































PNA ≤ 7 days,  cBW ≤ 2000 g
GROUP 2:
PNA ≤ 7 days, cBW > 2000 g
GROUP 3:
PNA > 7 days, cBW ≤ 2000 g
GROUP 4:
PNA > 7 days, cBW > 2000 g
Dutch children’s Formularium
Proposed dosing regimen
Dosing regimen used in the current study
Figure 4: Concentration-time profiles based on 1000 Monte Carlo simulations using the final pharmacokinetic model 
following the dosing regimen used in this study (upper row), the dosing regimen proposed by the Dutch Children’s 
Formulary (middle row) and the new model-based proposed dosing regimen (bottom row) in 4 different groups 
based on current bodyweight and postnatal age. The black line represents the median of the simulated profiles and 
the grey area represents the 90% confidence interval of the simulated values. The black horizontal line corresponds 
to the minimal inhibitory concentration of 8 mg/L. The grey vertical lines indicate the time at which 60% of the 
dosing interval is reached (4.8 and 44.8 hours) for a dosing interval of 8 hours. The grey vertical dotted lines 
indicate the time at which 60% of the dosing interval is reached (7.2 and 43.2 hours) for a dosing interval of 12 
hours. PNA = Postnatal age, cBW = Current bodyweight.
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for other endogenous (e.g. bilirubin) or exogenous compounds competing for the 
same albumin binding places. In neonates, frequently showing hyperbilirubinaemia 
(increased bilirubin production and decreased glucuronidation) and/or receiving 
multi drug therapies, this is a relevant and population specific advantage. Recent PK 
reports of other beta-lactam antibiotics commonly used in neonatal intensive care 
units also suggested dose adaptations compared to previously used regimens. To 
further illustrate this, a reduction in drug dose and interval for amoxicillin [33] and 
an increase of initial dose with subsequent dose reduction depending on the micro-
biological isolate, for flucloxacillin [37] were suggested in neonates. This emphasizes 
the need for population specific PK studies in neonates. Since study methodologies 
can differ, a correct definition of the aimed PK target is required to achieve reliable 
dosing evaluations in this specific population [14, 41]. In general, we have to be aware 
that total daily dose reduction of an antimicrobial may lead to increased bacterial 
resistance and ineffectiveness [42]. Prospective validation of the new dosing regimen is 
therefore necessary, but this was not the intention of the present study. 
The strength of our analysis is the measurement of both total and unbound 
cefazolin concentrations in a relevant neonatal cohort. Additionally, the final 
pharmacokinetic model can be used to optimize dosing regimens for other pathogens 
in different settings by changing the target MIC value and/or the T>MIC. However, there 
are some limitations. First, the MIC values used were not prospectively determined. 
Secondly, the success of antibiotic prophylaxis depends not only on selection of 
the antimicrobial drug and drug dosing but also on the correct, well-timed drug 
administration and subsequent tissue distribution. Direct measurement of drug 
concentrations in the surgical site tissues [43, 44] may provide additional information to 
include in PK models, but is very challenging in this population [45].
We conclude that total and unbound cefazolin concentrations in neonates could 
be described by a one compartment PK model which includes saturable protein 
binding. Birth bodyweight and PNA were defined as the most important covariates 
contributing to cefazolin clearance variability. A new model-based neonatal cefazolin 
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Figure S1: Interindividual variability (ETA) in a) clearance versus birth bodyweight, b) clearance (Cl) versus postna-
tal age, c) volume of distribution (V) versus current bodyweight, d) Maximum protein binding (B
max
) versus albumin 
for the simple (left) and final covariate model (right).
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PNA ≤ 7 days, cBW ≤ 2000g
GROUP 1:
PNA ≤ 7 days, cBW ≤ 2000g
GROUP 2:
PNA ≤ 7 days, cBW > 2000g
GROUP 3:
PNA > 7 days, cBW ≤ 2000 g
GROUP 4:
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Figure S2: Individual predicted concentrations based on Monte Carlo simulations in 1000 individuals versus 4 
different groups based on current bodyweight (cBW) and postnatal age (PNA). Plot A represents the individual 
predicted concentrations at 60% of the dosing interval after the first dose which corresponds to 4.8 or 7.2 hours 
after the first dose for a dosing interval of 8 or 12 hours respectively. Plot B represents the individual predicted 
concentrations at 60% of the dosing interval after 4 or 6 doses which corresponds to 44.8 or 43.2 hours based 
on a dosing interval of 8 or 12 hours, respectively. The black horizontal line corresponds to the minimal inhibitory 
concentration of 8 mg/L. For each group 3 boxplots are shown following the dosing regimen applied in this study 
(left), the dosing regimen suggested by the Dutch Children’s Formulary (middle) and the new model-based proposed 
dosing regimen (right). Box plots illustrate median, interquartile range (5-95%) and outliers. The percentage of 
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Propylene Glycol Pharmacokinetics in Neonates 
Abstract
Aim
Propylene glycol (PG) is often applied as an excipient in drug formulations.  As 
these formulations may also be used in neonates, the aim of this study was to charac-
terize the pharmacokinetics of propylene glycol, co-administered intravenously with 
paracetamol (800mgPG/1000mg paracetamol) or phenobarbital (700mgPG/200mg 
phenobarbital) in preterm and term neonates.
Methods 
A population pharmacokinetic analysis was performed based on 372 PG plasma 
concentrations from 62 (pre)term neonates (birth weight (bBW) 630-3980g, 
postnatal age (PNA) 1-30days) using NONMEM 6.2. The model was subsequently 
used to simulate PG exposure upon administration of paracetamol or phenobarbital 
in neonates (gestational age 24-40 weeks).
Results
In a one compartment model, birth weight and PNA were both 
identified as covariates for PG clearance using an allometric function 
(CLi=0.0849x{(BWb/2720)
1.69x(PNA/3)0.201}). Volume of distribution scaled 
allometrically with current bodyweight (Vi=0.967x{(BW/2720)
1.45}), and was 
estimated 1.77 times higher when co-administered with phenobarbital compared 
to paracetamol. By introducing these covariates a large part of the interindividual 
variability on clearance (65%) as well as on volume of distribution (53%) was explained. 
The final model shows that for commonly used dosing regimens, the population 
mean PG peak and trough concentrations ranges between 33-144 and 28-218 mg/L 
(peak) and 19-109 and 6-112 mg/L (trough) depending on birth weight and age of the 
neonates for paracetamol and phenobarbital formulations, respectively. 
Conclusion
A pharmacokinetic model was developed for PG co-administered with 
paracetamol or phenobarbital in neonates. As such, large variability in PG exposure 
may be expected in neonates which are dependent on birth weight and postnatal age.
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Chapter 7
“What is already known about this subject”
Propylene glycol is commonly used as an excipient in dose forms and is ingested 
by neonates when administering different drugs. While propylene glycol is generally 
considered to be safe, toxic effects like bradycardia, lactic acidosis and convulsions 
have been reported. Information on the pharmacokinetics of propylene glycol in 
neonates is lacking to provide insights on the possible risk of toxicity.
“What this paper adds”
This study describes the pharmacokinetics of propylene glycol in preterm and 
term neonates co-administered with paracetamol and phenobarbital. A pharma-
cokinetic model was developed which identified birth weight and postnatal age as 
important covariates for clearance. The model was used to simulate exposure to 
propylene glycol co-administered with both drugs.
7.1. Introduction
Since a substantial number of drugs have poor solubility or stability, excipients 
are often needed. Propylene glycol (PG) is a frequently applied cosolvent to increase 
the solubility and/or stability of several drugs like e.g. phenobarbital, paracetamol, 
lopinavir, ritonavir or lorazepam, compounds which are also often administered in 
neonates [1]. Although propylene glycol is generally regarded as safe, concentration 
related toxicity has been reported in the adult, pediatric and neonatal population and 
may involve bradycardia, depression of the central nervous system, increase in anion 
gap, lactic acidosis, hepatic dysfunction or kidney injury [1-4]. 
Little is known on the pharmacokinetics of propylene glycol in children. In adults, 
it has been described that approximately 45% of the administered dose of propylene 
glycol is eliminated through the kidney. The other 55% is metabolized through 
alcohol dehydrogenase in the liver to lactate and pyruvate and eventually to carbon 
dioxide and water [5-7]. While the elimination half-life of propylene glycol is estimated 
to be 2-5 hours in adults [2, 8], prolonged elimination half-lives of 10.8-30.5 hours 
have been reported in preterm neonates (< 1.5 kg) [5, 9]. In particular neonates and 
infants are therefore potentially at increased risk for toxic effects due to a more pro-
nounced propylene glycol exposure [10]. In spite of this, current guidelines on the use 
of propylene glycol in drugs or food are limited and conflicting. Although the Food 
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and Drug Administration (FDA) as well as the European Medicine Agency (EMA) have 
developed guidelines concerning the safe use of propylene glycol, these guidelines 
vary largely between these agencies. The FDA established an acceptable daily intake 
of propylene glycol of 25 mg/kg bodyweight. EMA proposed a maximum daily dose of 
400 mg/kg for adults and 200 mg/kg for children [11]. This discordance in the different 
guidelines reflects the lack of information on the safe use of propylene glycol in 
general, and of specific advices for the pediatric and neonatal age ranges in particular. 
To date, to our best knowledge, no pharmacokinetic studies on propylene glycol 
have been performed in children nor in the full spectrum of neonates. Only a limited 
number of pediatric reports, exploring possible toxic effects of propylene glycol, are 
available [3, 12-15]. In this perspective, it is of relevance that the FDA recently warned on 
serious health problems in premature neonates receiving Kaletra®, which contains 
a combination of lopinavir and ritonavir dissolved in ethanol (356.3 mg ethanol/mL) 
and propylene glycol (152.7 mg/mL). Adverse events as cardiac, renal and respiratory 
problems were reported in premature neonates, likely due to a decreased ability to 
eliminate either ethanol, propylene glycol or both [16, 17]. 
Because of the conflicting guidelines and observations on the (in)tolerabililty to 
PG in neonates, the aim of this study was to characterize the pharmacokinetics of 
propylene glycol, when co-administered with intravenous paracetamol or phenobar-
bital in preterm and term neonates. 
7.2. Methods
7.2.1. Patients
This pharmacokinetic analysis was based on observations collected in 68 (pre)
term neonates from a previously published study [1] evaluating short-term clinical 
and biochemical tolerability to propylene glycol co-administered with intravenous 
paracetamol (Paracetamol Sintetica, Mendrisio, Italy) containing 800 mg propylene 
glycol per 1000 mg paracetamol solution or intravenous phenobarbital (Luminal 
Injektionlösung, Desitin Arzneimittel, Hamburg, Germany) containing 700 mg 
propylene glycol per 200 mg of phenobarbital. The study was conducted at the 
University Hospitals Leuven (Belgium) at the neonatal intensive care unit following 
approval by the local ethical board (B-32220084836) and study registration 
(PARANEO, EUdraCT 2009-011243-39, www.clinicaltrials.gov). Neonates were 
included after informed written parental consent. The decision to prescribe a source 
of intravenous PG, either paracetamol-PG or phenobarbital-PG, was made by the 
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attending physician and based on the clinical needs. For paracetamol, a loading dose 
of 20 mg/kg was given, followed by a maintenance dose of 5-10mg/kg every 6 hours, 
depending on postmenstrual age [1]. For phenobarbital, a loading dose of 20 mg/kg 
phenobarbital was given, followed by a maintenance dose of 5 mg/kg/day [18]. The 
number of samples in every individual neonate ranged from 1 to 11 collected between 
20 minutes until 20.5 hours after dose administration. Six patients were considered 
as outliers due to unexplainably high concentrations of propylene glycol, likely caused 
by analytical interferences after visual inspection of the individual chromatographies. 
The clinical characteristics of the included patients (N=62) are summarized in table I.
7.2.2. Analytical assay
Propylene glycol concentrations were determined by high performance liquid 
chromatography with photodiode array detection described by Kulo et al. [19]. The 
developed accurate, specific, sensitive and rapid method was validated for quanti-
fication of propylene glycol in low volume neonatal plasma (15-46 mg/L) and urine 
(20-175 mg/L). Samples with concentrations higher than this were re-analysed after 
dilution until they fell within the calibration range. The inter-assay and intra-assay 
precision was between 8.1 -14.1% and 2.3 -12.7% respectively while the lower limit 
of quantification was 0.25 mg/L.
7.2.3. Population pharmacokinetic analysis and Model evaluation
The population pharmacokinetic analysis was performed using the non-linear 
mixed effect modeling software NONMEM version 6.2. (Globomax LLC, Hanover, 
MD, USA). S-Plus, PsN and R were used for visualization and evaluation of the 
models. Development of the model was performed in four different steps: (i) choice 
Characteristics Paracetamol Phenobarbital Paracetamol + Phenobarbital
Number of patients 34 25 3
Gestational age (weeks) 38 (24-41) 34 (27-40) 36 (35-37)
Postmenstrual age (weeks) 38 (25-41) 34 (28-46) 36 (35-37)
Postnatal age (days) 3 (1-28) 2 (1-82) 3 (2-5)
Birth weight (g) 2990 (630-3820) 1965 (815-3980) 2490 (2245-2514)
Current bodyweight (g) 2990 (700-4100) 1965 (780-3980) 2435 (2145-2490)
Birth weight = weight at day of birth, current bodyweight = weight at day of blood sampling
Table 1: Clinical characteristics of the patients, receiving propylene glycol co-administered with paracetamol, pheno-
barbital or both, presented as median (range).
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of the structural model, (ii) choice of the statistical sub-model, (iii) covariate analysis, 
(iv) model evaluation. The descriptive and predictive performance between different 
models was evaluated by different diagnostic tools [20]. A decrease in objective 
function (OFV) of 3.9 points or more was considered as a statistically significant dif-
ference (p<0.05 based on X2 distribution) for structural and statistical models while 
a more stringent p value of 0.005 was used for the evaluation of covariate models. 
In addition, goodness-of-fit plots, including observed versus individual predicted, 
observed versus population predicted, conditional weighted residuals versus time and 
conditional weighted residuals versus population predicted, were used for diagnostic 
purposes. Furthermore, the total number of parameters, visual improvement of in-
dividual plots, confidence intervals of parameter estimates, and correlation matrix 
were assessed as diagnostic criteria during model development. Finally, ill-condition-
ing [21] and shrinkage [22], which may occur in pediatric analyses [20], were determined.
7.2.4. Structural model
A one and two compartment model was fitted to the data. The interindividual 
variability in the pharmacokinetic parameters was assumed to follow a log normal 
distribution. The value of a particular parameter in an individual i (post hoc value) is 
given by the following equation:
 (Equation 1)
in which TV is the typical value of the parameter and i is assumed to be a random 
variable with mean value zero and variance 2. The residual variability was best 
described by a proportional error model. This means for the jth observed concen-
tration of the ith individual the relation (Yij):
 (Equation 2)
where Cpred is the predicted concentration and ij is a random variable with a 




To visualize potential relationships between covariates and parameter estimates, 
plots of the individual post hoc parameter estimates and weighted residuals versus 
covariates were generated. The following covariates were evaluated: gestational age, 
postmenstrual age, postnatal age, birth weight (weight at day of birth) and current 
bodyweight (weight at day of blood sampling). Potential covariates were implemented 
into the model using a linear or allometric equation (equation 3).
 (Equation 3)
In this equation Pi represents the individual parameter estimate of the ith subject, 
Pp equals the population parameter estimate, Cov is the covariate and k is the 
exponent which was fixed to 1 for a linear function or estimated for an allometric 
function. 
Covariates were separately implemented into the model and considered 
statistically significant when the OFV decreased with at least 7.8 points (p value 
<0.005). When more than one covariate significantly reduced the OFV, the covariate 
causing the largest drop in OFV was left into the model. Additional covariates had to 
reduce this OFV further to be retained in the model. Subsequently, the contribution 
of each covariate was re-evaluated in the backward deletion for which a more 
stringent p value <0.001 (OFV 10.83 points) was used. To select the final covariate 
model, the individual and population predicted values were plotted against the most 
predictive covariate to evaluate whether the individual predicted parameters were 
equally distributed around the population predicted parameters [20]. The covariate 
model was further evaluated as discussed previously in the section Population 
Pharmacokinetic analysis. Finally, the results of the model validation procedure (see 
below) were also considered.
7.2.6. Internal validation
For the internal validation of the final pharmacokinetic model, two different 
evaluation tools were used. The first method was the bootstrap resampling method 
to evaluate model precision and stability. The bootstrap analysis was performed in 
S-plus, version 6.2.1 (Insightful software, Seattle, WA) with NM.SP.interface version 
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05.03.01 (© by LAP&P Consultants BV, Leiden, The Netherlands) in which 1000 
replicates were generated. Parameter estimates obtained in the bootstrap analysis 
were compared to the parameter estimates of the original dataset.
For the second internal evaluation method, the normalized prediction distribution 
error method (NPDE) was used, which is a simulation-based diagnostic to determine 
the accuracy of the model [23, 24]. The observed and simulated concentrations were 
compared using the NPDE package in R. A histogram of the NPDE distribution and 
scatterplots showing the NPDE versus time and versus predicted concentration were 
used to evaluate the final model.
7.2.7. Model-based simulations for propylene glycol co-administered with 
paracetamol or phenobarbital
Using the final PK model, simulations were performed in three different patients 
(birth weight 630g, 1500g and 3500g and gestational age 24, 32, 40 weeks) with a 
postnatal age of 1 and 28 days.  The current bodyweight at a postnatal age of 28 
days was 950g, 1950g and 4100 g, respectively. These three patients were selected 
to cover the entire population of the current study in terms of gestational age and 
bodyweight. The parameter estimates obtained in the final pharmacokinetic model 
were used to simulate concentrations of propylene glycol after administration of in-
travenous paracetamol (Paracetamol Sintetica, Mendrisio, Italy: 800mg PG/ 1000mg 
paracetamol) or intravenous phenobarbital (Luminal Injektionlösung, Desitin 
Arzneimittel, Hamburg, Germany: 700mg PG/ 200mg phenobarbital) in the dosing 
regimens applied in this study. For paracetamol, a loading dose of 20 mg/kg was given, 
followed by a maintenance dose of 10mg/kg every 6 hours [1]. For phenobarbital, a 
loading dose of 20 mg/kg phenobarbital was given, followed by a maintenance dose 
of 5 mg/kg/day [18]. 
7.2.8. Maximally acceptable levels of propylene glycol in neonates
Different approaches were applied to provide a basis for maximally acceptable 
concentrations of propylene glycol in neonates. First, the exposure to propylene 
glycol upon administration of propylene glycol as a result of paracetamol or phe-
nobarbital was compared to levels observed in a previously published study in 68 
preterm and term neonates in which tolerability of propylene glycol was evaluated 
and no toxic effects were reported [1]. In a second approach, a maximum concentra-
tion was defined on basis of the toxic effects related to the osmolar changes. The 
increase in osmolar gap can directly be linked to propylene glycol concentrations by 
the following relationship [2]: [osmolar gap = concentration of propylene glycol (mg/
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dL) / 7.6] while osmolar gap is considered the first indicator of propylene glycol accu-
mulation before propylene glycol toxicity appears related to other metabolic distur-
bances or clinical symptoms [6]. In a study of Yahwak et al. [25] in adults, an increase in 
osmolar gap of 10 mOsm/L was linked to elevated propylene glycol concentrations 
and an increase of 12 mOsm/L resulted in clinical changes suggestive of propylene 
glycol toxicity. Furthermore, in studies by Feldman et al. [26] and Giacoia et al. [27], a 
standard deviation of 8 mOsm/L in serum osmolality has been described in neonates. 
Based on these observations, we considered the maximum allowed propylene glycol 
plasma concentration to remain below 608 mg/L, which corresponds to a maximum 
change in osmolar gap of 8 mOsm/L. The proposed maximum concentration of 608 
mg/L is in close agreement with previously published results by Wilson et al. [6] in 
which metabolic abnormalities were reported for concentrations ranging between 
580 and 1270 mg/L [6]. However our proposed maximum concentration of propylene 
glycol of 608 mg/L should be viewed with caution since it is only based on findings 
reported in literature, for adult patients. It is therefore not validated in neonates. 
Finally, a third possible maximum safe concentration was identified by performing 






Value (CV%) Value (CV%) Value (CV%)
Fixed effects
CL (L/h) = CLp 0.060 (11.8) - -
CLp in CL= CLp x (bBW/median)m 
x (PNA/median)n
- 0.085 (4.9) 0.085 (5.24)
m - 1.69 (10.2) 1.68 (11.44)
n - 0.20 (31.9) 0.20 (37.62)
V (L) = Vp 0.90 (10.2) - -
Vp in V = Vp x (cBW/median)o x p - 0.97 (6.58) 0.97 (7.05)
o - 1.45 (10.4) 1.45 (11.28)
p (phenobarbital) - 1.77 (12.1) 1.79 (13.10)
Interindividual variability ( 2)
2 (CL) 0.69 (23.9) 0.12 (26.3) 0.11 (30.91)
2 (V) 0.64 (23.9) 0.18 (25.6) 0.17 (27.99)
Residual Variability ( 2)
2 (proportional) 0.036 (12.1) 0.036 (11.8) 0.036 (11.40)
CL = Clearance, CLp = population value for clearance, V = Volume of distribution, Vp = population value for 
volume, bBW = bodyweight at birth, cBW = current bodyweight, PNA = postnatal age
Table II: Model-based population pharmacokinetic parameter estimates and the values obtained after the bootstrap 
analysis.
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simulations based on the guidelines for propylene glycol administration in children es-
tablished by the EMA (200 mg/kg/day) and the FDA (25 mg/kg/day). To the very best 
of our knowledge, these guidelines are neither supported by observational data. In 
these simulations 100 mg or 12.5 mg of propylene glycol depending on the guidelines 
by the EMA or FDA, respectively was administered in three different neonates (bBW 
630 g, 1500 g and 3500g) every 12 hours since drugs containing propylene glycol 
are often given in this manner in clinical practice in neonates. It was simulated to be 




The pharmacokinetic analysis was based on 372 observations obtained from 
62 neonates. The number of samples taken per neonate ranged between 1-11. 
Thirty-four neonates received propylene glycol by intravenous administration of 
paracetamol compared to twenty-five neonates who received phenobarbital while 
three neonates receiving a combination of both paracetamol and phenobarbital. 
Patient characteristics are summarized in table I.
7.3.2. Structural pharmacokinetic model
A one compartment model parameterized in terms of clearance and volume of 
distribution with a proportional error model best described the plasma concentra-
tions of propylene glycol.
7.3.3. Covariate analysis
In the systematic covariate analysis, birth weight was found the most important 
covariate for clearance causing a drop in OFV of 82 points (p<0.001). Birth weight 
was best implemented on clearance using an allometric function in which a value of 
1.69 was estimated for the exponent. When evaluating other covariates, current 
weight was found the most important covariate for volume of distribution using an 
allometric function with an estimated exponent of 1.48 ( OFV 48 points, p<0.001). 
Furthermore, a significant difference in volume of distribution was seen between 
neonates receiving phenobarbital and paracetamol. The volume of distribution was 
estimated to be 1.77 times higher (95% confidence interval: 1.35-2.19) for neonates 
receiving phenobarbital ( OFV 18 points, p<0.001). Finally, further improvement 
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of the model fit was seen when postnatal age was introduced on clearance using 
an allometric function with an estimated exponent of 0.201. This last covariate was 
responsible for the smallest but still significant drop in the objective function (
OFV = 15 points, p<0.001). All parameter estimates of the final pharmacokinetic 
model are summarized in table II. The diagnostic plots are represented in figure 
1. By introducing these covariates a large part of the interindividual variability on 
clearance (65%) as well as on volume of distribution (53%) is explained (table II). This 
is reflected by the estimates of interindividual variability in clearance and volume of 
distribution which were reduced from 0.69 to 0.12 and 0.64 to 0.18, respectively.
7.3.4. Model validation
The values for the parameter estimates obtained during the bootstrap procedure 
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Figure 1: Diagnostic plots for the final pharmacokinetic model: (a) Observed versus individual predicted concentra-
tions, (b) Observed versus population predicted concentrations, (c) Conditional weighted residuals versus time, 
(d) Conditional weighted residuals versus population predicted concentrations.
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are shown in table II. The parameter estimates obtained after bootstrapping were 
within 8% of the values obtained in the final pharmacokinetic model. Of the total 
number of runs (N=1000), 100% was successful, only 34 runs did not have a covari-
ance step. 
The results of the NPDE analysis are depicted in figure 2. The histogram follows 
the normal distribution indicated by the black solid line (figure 2a). No trend is seen 
in the NPDE versus time (figure 2b) and the NPDE versus predicted concentrations 
(figure2c). The plot with the individual predicted parameter estimates and population 
parameter estimates for clearance and volume of distribution versus the most 
predictive covariate, birth weight and current bodyweight respectively, showed that 
the individual predicted parameter estimates are randomly scattered around the 
population parameter estimates (figures not provided). The number of ill-conditioning 
(8.28) was far below the critical value of 1000 meaning that the final pharmacokinetic 
model is not over-parameterized. Finally, -shrinkage expressed as a percentage was 
identified to be below 20% for clearance (14.8%) and volume of distribution (6.2%).
The model-based predicted clearance values for the final pharmacokinetic model 
versus birth weight for PNA 1, 7, 14, 21 and 28 days are shown in figure 3.
7.3.5. Model-based simulations for propylene glycol co-administered with 
paracetamol or phenobarbital
Concentration-time profiles of propylene glycol after standard dosing regimens 
of intravenous paracetamol (800mg PG/1000mg paracetamol) or phenobarbital 
(700mg PG/200mg phenobarbital) that were used in this study, were simulated in 



































Figure 2: Results of the NPDE analysis: (a) the histogram shows the NPDE distribution, the solid line indicates a 
normal distribution, (b) NPDE versus time after first dose, (c) NPDE versus predicted concentrations.
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age of 1 and 28 days (figure 4). The administered dose of paracetamol, phenobarbital 
and the corresponding dose of propylene glycol are given in table III. Figure 4 shows 
that population mean value for trough and peak concentration of propylene glycol 
co-administered with paracetamol for a neonate of 630 g at day 1 was estimated to 
be 109 and 144 mg/L, respectively, and for a neonates of 3500g at day 28 trough and 
peak concentration of propylene was estimated to be 19 and 33 mg/L, respectively. 
Drug Propylene glycol content Dosing guideline for drug Drug-associated daily 





800 mg PG/1000 mg 
paracetamol
Loading dose: 20 mg/kg 40





700 mg PG/200 mg 
phenobarbital
Loading dose: 20 mg/kg/day 70
(18)
Maintenance dose: 5 mg/kg/day 17.5
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Figure 3: Model-based predicted clearance values of propylene glycol versus birth weight for postnatal age (PNA) 
of 0, 7, 14, 21 and 28 days.
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The expected population mean peak and trough propylene glycol concentrations 
after administration of phenobarbital varied between 28-218 and 6-112 mg/L, respec-
tively, depending on birth weight (630g-3500g) and postnatal age  (1-28 days) of the 
neonate (table III, figure 4). 
7.4. Discussion
While propylene glycol is considered to be safe and inactive, upon high concen-
trations toxic effects like lactic acidosis, bradycardia and convulsions may occur. The 
risk of propylene glycol toxicity is higher in infants and neonates compared to adults 
since they have a lower metabolic capacity as well as an immature renal function 
resulting in a lower elimination capacity. The aim of this study was to characterize 
the pharmacokinetics of propylene glycol and its covariates in neonates following 
intravenous administration. 
The pharmacokinetic model developed in this study was based on 372 propylene 
glycol plasma concentrations obtained in 62 preterm and term neonates after 
administration of paracetamol, phenobarbital or both. Birth weight was found the 
most important covariate for clearance while an increase in clearance was seen with 
postnatal age. The population value for clearance of 0.0849 L/h reported here in 
neonates is very low compared to the clearance value reported in adults which was 
found to vary between 144-390 mL/min/1.73m2 (8.64-23.4 L/h/1.73m2) [5]. This may 
indicate that either the alcohol dehydrogenase enzyme pathway or primary renal 
elimination, or most likely both, are immature during the first month of life. For renal 
function this has been described before by studying amikacin clearance in neonates, 
which likely reflects glomerular filtration in neonates [28] . The model-based predicted 
clearance values of propylene glycol versus birth weight for postnatal age 1, 7, 14, 21 
and 28 are shown in figure 3. Large differences in clearance values are seen between 
neonates of 1 kg (0.013 L/h) and neonates of 4 kg (0.13 L/h) at day of birth. This 
10-fold difference in clearance is still seen one month after birth. Furthermore 
this figure illustrates that during the first two weeks of life the largest increase in 
clearance is observed. These results correspond well with the advice of the FDA 
to avoid Kaletra®, a propylene glycol containing oral solution in premature babies 
until 14 days after due date, or in full-term babies younger than 14 days postnatal 
age [16, 17]. Volume of distribution scaled with current weight and was estimated 1.77 
times higher in neonates receiving phenobarbital compared to neonates receiving 
paracetamol. The volume of distribution of a neonate of 1 kg (0.23L or 0.40L) (co-
administered with paracetamol or phenobarbital, respectively) was very different 
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compared to a neonate of 4 kg (1.69 L or 3L). This difference may possibly be 
explained by the fact that phenobarbital is often given to neonates after perinatal 
asphyxia which may lead to a change in the pharmacokinetic parameters e.g. higher 
volume of distribution. Unfortunately asphyxia could not be investigated as a covariate 
since no potential indicators (e.g. Apgar score, serum lactate concentration) were 
identified. The large variability in clearance and volume of distribution as a result of 
birth weight, PNA and current weight is reflected by the large range in expected 
peak and trough concentrations that can be expected upon commonly used doses of 
paracetamol and phenobarbital in neonates varying in birth weight between 630g and 
3500g and between a PNA of 1-28 days (figure 4). The stability and predictability of 
the final pharmacokinetic model was demonstrated by the bootstrap (table II) as well 
as the NPDE (figure 2), which are both advanced validation methods for paediatric 
pharmacokinetic models. 
 Although dose-related toxic effects have been reported upon administration of 
propylene glycol, only a limited number of pediatric reports are available in literature. 
Glasgow et al. [13] and MacDonald et al. [14] described hyperosmolality and clinical 
symptoms of propylene glycol toxicity in small infants (< 1500 g birth weight) due 












Birth weight 630 g
Current weight 950 g 
Gestational age 24 weeks
Patient 2:
Birth weight 1500 g
Current weight 1950 g 
Gestational age 32 weeks 
Patient 3:
Birth weight 3500 g
Current weight 4100 g 



































Figure 4: Model-based simulated concentration-time profiles of propylene glycol for three neonates (birth weight 
630g, 1500g and 3500 g) after administration of paracetamol (800mg propylene glycol/1000mg paracetamol, upper 
panel) and phenobarbital (700mg propylene glycol/200mg phenobarbital, lower panel) in doses according to table 
III. The grey lines illustrate the concentration-time profiles for the neonates at birth. The black lines represent the 
concentration-time profiles at a postnatal age of 28 days (current weight 950g, 1950g and 4100g).
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to very high propylene glycol exposure (3000mg/kg) in multivitamins injections. In 
retrospective studies of Shehab et al. [3] and Whittaker et al. [15] it was concluded 
that neonates at the neonatal intensive care unit are indeed exposed to potentially 
toxic doses of propylene glycol due to administration of commonly used drugs (e.g. 
phenobarbital, lorazepam, phenytoin, paracetamol) cosolved in propylene glycol but 
data on toxicity were not reported. In a study of Chicella et al. [12] a propylene 
glycol containing lorazepam formulation was administered to 11 infants between 1-15 
months of age. In this study, there were neither clinical nor laboratory abnormalities 
observed, but accumulation of propylene glycol occurred during continuous infusion 
of lorazepam. Consequently, propylene glycol containing formulations should be 
used with caution in the pediatric and certainly in the neonatal age range especially 
when this results in high PG exposure. Based on literature, the first indicator of a 
risk for subsequent propylene toxicity is propylene glycol accumulation and changes 
in osmolar gap. Accumulation may subsequently result in biochemical changes and 
eventually toxic effects like e.g. bradycardia, hepatic or renal injury, depression of 
the central nervous system. 
To provide a basis to interpret the simulated concentrations of PG co-administered 
with paracetamol or phenobarbital in neonates, different approaches were provided 
in the methods section. However to identify maximum safe concentrations, more 
pharmacokinetic and pharmacodynamic studies are needed in neonates, particularly 
with drugs containing high concentrations of propylene glycol. To illustrate this 
concept, simulations were performed to illustrate the potential exposure of 
propylene glycol co-administered with lorazepam (828mg PG/2mg lorazepam). 
Based on the final pharmacokinetic model of propylene glycol co-administered with 
paracetamol, substantially higher concentrations of PG are obtained depending on 
the dose of lorazepam. Simulated propylene glycol concentrations upon lorazepam 
in a dose of 0.015 mg/kg/h [18] (daily dose of 149 mg/kg/day of propylene glycol) varied 
between 540 mg/L for a neonate of 630g at day 1 and 123 mg/L for a neonate of 
3500g at day 28. Upon a dose of lorazepam of 0.1 mg/kg/day as described by Chicella 
et al. [12], concentrations of propylene glycol varying between 798-3563 mg/L were 
obtained, depending on birth weight and postnatal age. It should be noted that these 
concentrations are generated under the assumption of linear pharmacokinetics of 
propylene glycol, while higher daily doses of propylene glycol were administered 
to the neonates (149 mg/kg/day or 996 mg /kg/day) with lorazepam compared to 
paracetamol or phenobarbital. As a result of the assumption of linear pharmacokinetics, 
the estimates of the exposure to propylene glycol must be considered conservative. 
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In case of non-linearity in pharmacokinetics, even higher exposures are expected. 
At least, PG accumulation upon the lorazepam dosing in neonates is in line with PG 
accumulation and toxicity described in adults [2, 6]. 
7.5. Conclusion
A pharmacokinetic model with birth weight and postnatal age as covariates for 
clearance was developed for propylene glycol co-administered with paracetamol or 
phenobarbital in preterm and term neonates. As such, large variability in exposure of 
propylene glycol may be expected in neonates which are dependent on birth weight 
and postnatal age. The model can be used to simulate concentrations of propylene 
glycol co-administered with paracetamol and phenobarbital in neonates. As the exact 
safe concentrations are still undefined, more studies are needed to characterize the 
pharmacokinetics of propylene glycol in neonates and children.
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Abstract
Background 
Despite limited information on the pharmacokinetics of excipients, propylene 
glycol (PG) is often used as a excipient both in adults and children. The aim of this 
study is to characterize renal and hepatic elimination of propylene glycol in preterm 
and term neonates. 
Methods
The pharmacokinetic analysis of PG was performed in NONMEM 6.2. on the 
basis of PG concentrations in plasma and/or urine samples for a total of 69 (pre)term 
neonates (birth weight 630-3980g, gestational age 24-41 weeks, postnatal age 1-29 
days) who received PG co-administered with IV paracetamol (5-10 mg/kg/6 hours), 
phenobarbital (5 mg/kg/day) or both. To capture the time dependent trend in renal 
excretion of PG, different models based on time after first dose, urine volume and 
creatinine amount in urine were tested.
Results
A one compartment model parameterized in terms of renal clearance, hepatic 
clearance and volume of distribution was found to adequately describe the observa-
tions in both plasma and urine. After the first dose, renal elimination of propylene 
glycol was 15% of total clearance, which increased over time to 25% at 24 hours after 
the first dose of PG. This increase was best described using a hyperbolic function 
based on time after the first dose. 
Conclusions
Renal elimination of PG in (pre)term neonates is low, particularly compared to 
the reported percentage of 45% in adults, but may increase with time after first dose 
of PG. To study whether this increase is caused by an auto-induced increase in renal 




Propylene glycol is a frequently used excipient in many drug formulations to 
increase solubility and/or stability of drugs. Although excipients may be expected to 
be inactive compounds, toxic effects related to propylene glycol such as bradycardia, 
lactic acidosis, hepatic and renal dysfunction, increase in anion gap, have been 
described in adults, children and neonates [1-5]. As a consequence, both the Food 
and Drug Administration (FDA) and the European Medicine Agency (EMA) have 
established guidelines considering maximum daily doses of propylene glycol. However, 
no conformity is seen between the guidelines of both agencies [6]. While this may 
be explained by a lack of specific information relating to the safe use of propylene 
glycol, it is emphasized that the available knowledge on the pharmacokinetics of 
propylene glycol mainly focuses on adults. However children and certainly neonates 
are at increased risk for the toxic effects of propylene glycol due to accumulation 
of propylene glycol [7-9], which is reflected by the prolonged elimination half-life in 
preterm neonates (10.8-30.5 hours) [10] compared to adults (2-5 hours) [1, 11]. 
In adults, it is known that 45% of propylene glycol is eliminated through the renal 
route and 55% is metabolized in the liver by alcohol dehydrogenase (ADH) to lactate 
and pyruvate [8, 12, 13]. Previously it has been reported that the activity of alcohol de-
hydrogenase is reduced in neonates reaching adult levels at about 5 years of age [14]. 
Due to immaturity of the renal function, renal clearance of propylene glycol may also 
be expected to be lower in neonates compared to adults. Assuming that maturation 
processes in the liver and kidneys may differ in rate and nature, one pathway or the 
other may be more relevant for a specific age group resulting in for instance age-spe-
cific drug-drug interactions for the pathway concerned. Even though based on plasma 
observations the pharmacokinetics of propylene glycol have recently been character-
ized in preterm and term neonates [15],  no information is available on the contribution 
of renal elimination to the overall clearance of propylene glycol in neonates. The aim 
of this study was therefore to characterize the pharmacokinetics of propylene glycol 
differentiating between renal elimination and hepatic metabolic pathways based on 
propylene glycol observations in both plasma and urine in preterm and term neonates.
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8.2. Methods
8.2.1. Patients and Data
The analysis was based on data of 69 preterm and term neonates consisting of 
previously published observations of propylene glycol in plasma [3, 15] and observations 
of propylene glycol in urine. Urine samples could only be collected in neonates with 
a urinary bladder catheter already in place for clinical indications. An overview of 
the clinical characteristics is given in table 1. Propylene glycol was co-administered 
with either intravenous paracetamol (Paracetamol Sintetica, Mendrisio, Switzerland) 
containing 800 mg propylene glycol per 1000 mg paracetamol solution or intravenous 
phenobarbital (Luminal Injektionlösung, Desitin Arzneimittel, Hamburg, Germany) 
containing 700 mg propylene glycol per 200 mg of phenobarbital or both. For 
paracetamol, a loading dose of 20 mg/kg was given followed by a maintenance dose 
of 5-10 mg/kg every 6 hours. This corresponds to a dose of propylene glycol varying 
between 16-40 mg/kg/day. For phenobarbital, a loading dose of 20 mg/kg was given 
followed by a maintenance dose of 5 mg/kg/day. This corresponds to a dose of 70 mg/
kg/day of propylene glycol when a loading dose is given and 17.5 mg/kg/day when a 
maintenance dose is given. In 46 neonates, plasma samples of propylene glycol which 
was co-administered with paracetamol, phenobarbital or both, was available while in 
16 neonates both urine and plasma samples of propylene glycol co-administered with 
paracetamol were available. In 7 neonates, only urine samples of propylene glycol 
co-administered with paracetamol were available. Urine samples were available in 6 
hour fractions collected over 24 hours. In one patient, urine was collected every 6 
hours with a maximum of 48 hours instead of 24 hours after administration of the 
first dose. The study was conducted in Leuven NICU following approval by the local 
ethical board of the University Hospitals Leuven (B-32220084836).
8.2.2. Analytical method
Propylene glycol was determined in low volume neonate plasma (15-46 mg/L) and 
urine (20-175 mg/L) by high performance liquid chromatography with photodiode 
array detection as described by Kulo et al [16]. Samples with concentrations higher 
than the validation range were re-analyzed after appropriate dilution until they fell 
into the validation range. Plasma samples were diluted with drug-free human plasma 
and urine samples with water.
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8.2.3. Pharmacokinetic analysis: Model development
The non-linear mixed effect modeling software (NONMEM 6.2) (Globomax LLC, 
Hanover, MD, USA) using the first-order conditional estimation method with the 
interaction option (FOCE-I) was used to perform the population pharmacokinetic 
analysis. Tools like S-Plus version 6.2.1  (Insightful software, Seattle, WA) with NM.SP.
interface version 05.03.01 (© by LAP&P Consultants BV, Leiden, The Netherlands), 
PsN and R (version 2.10.1) were used to visualize and evaluate the model. 
The model was developed in four different steps: (i) choice of the structural 
model, (ii) choice of the statistical sub-model, (iii) choice of the covariate model, 
(iv) model evaluation. A decrease in objective function (OFV) of 3.9 points or more 
was considered statistically significant (p<0.05 based on X2 distribution, for nested 
models). In addition, the following goodness-of-fit plots were evaluated for diagnostic 
purposes: (i) observed versus individual predicted concentrations, (ii) observed versus 
population predicted concentrations, (iii) conditional weighted residuals versus time, 
(iv)conditional weighted residuals versus population predicted concentrations. Finally, 
the total number of parameters, visual improvement of individual plots, correlation 
matrix, confidence intervals of parameter estimates, ill-conditioning [17] and shrinkage 
[18] were assessed.
Characteristics All patients Patients with 
plasma data only
Patients with both 
plasma and urine 
data 
Patients with urine 
data only
Number of patients 69 46 16 7
Number of samples
 per patient







Gestational age (weeks) 37 (24-41) 35 (25-40) 37.5 (24-41) 37 (30-39)
Postmenstrual age (weeks) 37 (25-46) 34 (25-46) 38 (26-41) 38 (30-39)
Postnatal age (days) 3 (1-82) 1 (1-82) 3 (1-28) 2 (2-11)
Birth weight (g) 2720 (630-3980) 2200 (700-3980) 3050(630-3600) 2650 (1160-3315)
Current bodyweight (g) 2720 (700-4100) 2490 (700-3980) 3030 (630-4100) 2560 (1160-3315)
Urine Volume (mL/6 hours) 48 (14-115) - 48 (14-0.115) 5 (17-113)
Birth weight = bodyweight at day of birth. Current bodyweight = bodyweight at day of blood sampling. PG = 
propylene glycol
Table 1: Clinical characteristics (median (range)) of the studied patient population receiving propylene glycol (PG) 
co-administered with intravenous paracetamol, phenobarbital or both.
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Structural model
For the structural model, a one compartment model was developed using 
NONMEM VI, subroutine ADVAN6, TOL=3. The concentrations of propylene glycol 
in plasma were expressed as mg per L. The excretion of propylene glycol in urine 
was expressed as a cumulative amount in mg and calculated by multiplying the urinary 
concentration (mg/L) with urine volume.
Statistical submodel
For the statistical submodel, the interindividual variability was tested assuming a 
log-normal distribution in an individual i (post hoc value) and is given by the following 
equation:
 (Equation 1)
in which TV is the typical value of the parameter and i is assumed to be a random 
variable with mean value zero and variance 2. For the intra-individual variability 
and residual error, proportional (equation 2), additive (equation 3) and combination 




where Yij is the jth observation in the ith individual, Cpred,ij is the predicted concen-
tration and ij is a random variable from a normal distribution with a mean of zero 
and estimated variance of 2.
Covariate analysis
A comprehensive covariate analysis was performed in which the following co-
variates were evaluated: gestational age, postmenstrual age, postnatal age, birth 
weight (weight at day of birth), current bodyweight (weight at day of blood or urine 
sampling), time after first dose, urine volume, urine volume/kg, amount of creatinine 
in urine (mg). Covariates were implemented into the model using a linear or power 




In this equation Pi represents the individual parameter estimate of the ith subject, 
Pp equals the population parameter estimate, Cov is the covariate and k is the 
exponent, which was fixed to 1 for a linear function or estimated for a power function. 
Specific covariate models that were also tested to capture the time-dependent trend 
in renal elimination of PG are described below under Characterization of changes 
in renal clearance of propylene glycol over time. A covariate was considered to be 
statistically significant when causing a decrease in objective function of 7.8 points 
(p-value <0.005). When more than 1 covariate significantly reduced the OFV, the 
most significant covariate was retained into the model. This model was subsequently 
considered as the basis for the inclusion of additional covariates. The contribution 
of each covariate was then re-evaluated in the backward deletion for which a more 
stringent p-value <0.001 ( OFV 10.8 points) was used. In addition, the individual and 
population predicted parameters were plotted against the most predictive covariate 
to evaluate whether the individual predicted parameters were equally distributed 
around the population predicted parameters [19]. Finally the covariate model was 
evaluated as mentioned previously under Pharmacokinetic analysis: model develop-
ment, whereby the results of the Model validation were also considered.
Characterization of changes in renal clearance of propylene glycol over time
As a systematic trend in propylene glycol amounts in urine over time after first 
dose was observed, different models were tested.
Model I. Implementation of an (intermediate) Michaelis-Menten model [20] for 
renal clearance of propylene glycol.
Model II. Implementation of urine volume normalized to kilograms current body-
weight as a covariate on renal clearance (equation 5).
Model III. Implementation of both time after first dose and current bodyweight as 
covariates on renal clearance of propylene glycol (equation 5).
Model IV: Implementation of a hyperbolic model based on time after first dose on 
renal clearance (equation 6):
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 (Equation 6)
In equation 6, CLRi equals the individual renal clearance of the ith subject, CLmax 
represents the maximum renal clearance of propylene glycol, Time represents time 
after first dose, Time50 is the time after first dose at which half of the maximum 
clearance is reached and k is the estimated exponent. Based on observations in adults 
[8, 12, 13], CLmax was fixed at 0.45/0.55 of the hepatic clearance, which indicates that 
renal elimination also increases in correspondence with changes in hepatic clearance. 
Model V. Implementation of amounts of creatinine, determined in each of the 
6-hourly urine fractions, as a covariate on renal clearance of propylene glycol.
8.2.4. Model Validation
A bootstrap was performed in S-plus, version 6.2.1. (Insightful software, Seattle, 
WA) with NM.SP.interface version 05.03.01 (© by LAP&P Consultants BV, Leiden, 
The Netherlands) in which 1000 replicates were generated. The parameter estimates 
obtained in the bootstrap were subsequently compared to the parameter estimates 
of the original dataset. 
In addition, due to the small number of subjects in whom urine data were available, 
a n-1 jackknife was performed to evaluate the stability of the model when one subject 
with urine data at a time was removed from the dataset.
Finally the normalized prediction distribution error method (NPDE) was used 
as a simulation-based diagnostic. The dataset was again simulated 1000 times, after 
which the observed and simulated concentrations were compared using the NPDE 
package in R [21, 22]. 
8.2.5. Simulations
Simulations were performed in NONMEM 6.2 based on the final pharmacoki-
netic model to simulate renal and hepatic clearance of propylene glycol across the 
individuals of the current study (birth weight 630g, 1500g, 2500g and 3500g and 
with a postnatal age of 1 and 28 days). In the simulations, four consecutive doses of 
propylene glycol co-administered with paracetamol were given. Simulations were 
performed with the exclusion of the interindividual and residual variability in order 




8.3.1. Patients and data
Patient and data characteristics are summarized in table 1. The pharmacokinetic 
analysis was based on 372 plasma concentrations of propylene glycol co-administered 
with intravenous paracetamol, phenobarbital or both and 79 urine samples of 
propylene glycol co-administered with paracetamol (table 1). Postnatal age for all 
patients varied between 1 and 29 days, except for one patient with a postnatal age 





Figure 1: Schematic representation of the pharmacokinetic model of propylene glycol.
8.3.2. Pharmacokinetic analysis: Model development
Structural Model
Based on propylene glycol samples in both plasma and urine, a one compartment 
model was used, parameterized in terms of hepatic clearance (CLH), renal clearance 
(CLR) and volume of distribution (V1). A schematic representation of the model is 
given in figure 1. A different proportional error was estimated for plasma and urine 
concentrations. 
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Covariate Model
A/ Hepatic clearance of propylene glycol
For hepatic clearance, birth weight was found as the most important covariate 
causing a drop in OFV of 81.5 points (p<0.001), when implemented using a power 
function. Subsequently, current bodyweight was identified as most important 
covariate on volume of distribution also using a power function, causing a drop in 
OFV of 50 points (p<0.001). Furthermore, the volume of distribution was estimated 
to be 1.71 times higher between neonates receiving phenobarbital compared to 
neonates receiving paracetamol, as was reported before [15]. This may possibly be 
explained by the fact that phenobarbital is often given to neonates after perinatal 
asphyxia which may cause differences in pharmacokinetic parameters like an increase 
in volume of distribution [15]. Finally postnatal age (PNA) was found as significant 
covariate on hepatic clearance. In this analysis, PNA was best implemented using a 
linear function, causing a drop in OFV of 20 points (p<0.001). After introducing these 
covariates, the observed plasma concentrations were well described by the model 
(figure 2, upper panels).
B/ Renal clearance of propylene glycol
When evaluating the amounts of propylene glycol in urine, a systematic trend in 
conditional weighted residuals versus time (figure 3) was seen, which could not be 
explained by bodyweight or PNA. To elucidate this time-dependent trend, which 
indicates that the excretion of propylene glycol in urine increases over time after first 
dose, five different models were tested as explained in the methods section. 
As a first approach, a non-linear pharmacokinetic model was tested by 
implementation of an (intermediate) Michaelis-Menten model on renal clearance 
(Model I). Even though the time-dependent trend could indicate non-linear 
pharmacokinetic behavior of renal excretion of propylene glycol, this model did not 
result in an improved fit. As a second approach, urine volume (normalized to current 
bodyweight) was added as a covariate. This linear implementation of urine volume 
on renal clearance showed a significant improvement of the model illustrated by the 
decrease in objective function ( OFV 26 points, p<0.001) and improvement of the 
diagnostic plots. In model III, both time after first dose and current bodyweight were 
implemented as covariates on renal clearance using power functions. Compared to 
model II, a higher drop in objective function was seen in model III ( OFV 69 points, 
p<0.001), which was also reflected by visual improvement of the diagnostic plots. In 
model IV, implementation of the hyperbolic model based on time after first dose in 
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model IV, resulted in a drop in objective function of 67 points (p<0.001). In model V, 
no correlation was found between the amount of propylene glycol and creatinine in 
urine. Therefore implementation of creatinine did not result in an improved fit. 
Based on the results, model III and model IV were identified as the best models 
to describe the time-dependent trend in the excretion of propylene glycol in urine. 
Although model IV had a slightly higher objective function compared to model III (
OFV = 2 points, p>0.05)), model IV was chosen as the best model since model IV was 
able to describe the data evenly well with one parameter less compared to model 
III. This hyperbolic function included an exponent and a parameter to describe the 
time after the first dose when 50% of the maximum renal clearance is reached, which 



















































































Population Predicted Cumulative Amounts (mg)
Figure 2: Observed versus individual predicted concentrations/amounts (left panels) and population predicted 
concentrations/amounts (right panels) of propylene glycol for plasma (upper panels) and urine (lower panels) obser-
vations for the final model.
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Value (CV%) Value (CV%) Value (CV%) Value (CV%)




 (L/h) = CL
H 
p 0.045 (15.0) - -  -
CL
H 
p in CL = CL
H 
p x (bBW/median)m 
x (1+(PNA/median)xn)
- 0.056 (8.1) 0.055 (9.4) 0.056 (8.1)
m - 1.68 (10.5) 1.69 (11.7) 1.68 (10.5)
n - 0.12 (41.9) 0.13 (46.0) 0.12 (41.9)
V (L) = Vp 0.92 (9.6) - -
Vp in V = Vp x (cBW/median)o x p - 1.01 (6.5) 1.01 (6.5) 1.01 (6.5)
o - 1.46 (10.2) 1.46 (10.6) 1.46 (10.1)
p - 1.71 (11.8) 1.71 (13.0) 1.71 (11.8)
CL
R
 (L/h) = CL
R
 p 0.0098 (11.8) - - -
CL
R
 = CLmax x ((time)q/ ((time50)q 
+(time)q))
- - - -






Time50 - 42.2 (49.8) 51.4 (75.7) 42.1 (50.9)
q - 0.69 (17.3) 0.71 (21.7) 0.66 (17.7)
Interindividual variability ( 2)
2 CL 1.01 (25.9) 0.16 (31.4) 0.15 (36.3) 0.16 (31.5)
2 V 0.61 (23.4) 0.17 (24.2) 0.16 (24.9) 0.17 (24.3)
2 CLU 0.35 (32) 0.33 (32.5) 0.31 (37.6) 0.34 (33.1)
Residual variability ( 2)
2 plasma (proportional) 0.037 (12.1) 0.034 (12.5) 0.034 (12.8) 0.034 (12.6)
2 urine (proportional) 0.069 (25.5) 0.032 (33.0) 0.031 (36.6) 0.032 (33.3)
CL
H
= hepatic clearance, CL
H 
p = population value for hepatic clearance, V = Volume of distribution, Vp = popula-
tion value for volume of distribution, CL
R
 = renal clearance, CL
R
 p = population value for renal clearance, CLmax 
= maximum renal clearance = 0.45/0.55 x CL, bBW = bodyweight at birth, cBW = current bodyweight, PNA = 
postnatal age, time = time in hours after administration of the first dose of propylene glycol, time50 = time at 
which 50% of the maximum clearance is reached.
Table II: Population pharmacokinetic parameter estimates of the simple model without covariates, the final pharma-
cokinetic model, the bootstrap analyis and n-1 jackknife analysis.
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The parameter estimates of the final pharmacokinetic model are summarized 
in table 2. Figure 2 depicts (a) the observed versus the individual predicted 
concentrations/amounts and (b) the observed versus the population predicted 
concentrations/amounts for plasma and urine observations. In figure 3, the conditional 
weighted residuals versus time for the urine samples are illustrated for the simple 
without covariates and the final model. By introducing these covariates, 69% of the 
interindividual variability in hepatic clearance, 53% in volume of distribution and 3% 
in renal clearance was explained (table 2). In figure 4, the population estimates of 
renal and hepatic clearance versus birth weight for a postnatal age of 1 and 28 days 
are illustrated. Renal excretion of propylene glycol in neonates proved 15, 20, 23 
and 25% of total clearance at 6, 12, 18 and 24 hours after the administration of the 
first dose respectively. At 30, 36, 42 and 48 hours after administration of the first 
dose, these percentages would be 27, 28, 29 and 30%, respectively. In figure 5, total 
clearance, hepatic clearance and renal clearance of propylene glycol is presented in 
four different neonates (birth weight 630g, 1500g, 2500g and 3500g) at a postnatal 
age of 1 and 28 days.
8.3.3. Model Validation
The results of the bootstrap analysis (N=1000) showed that the median 
estimated values based on re-sampled data were within 9% of the estimated values 
of the final pharmacokinetic model except for the estimated value of time at which 
50% of the maximum renal clearance is reached, which was within 18%. All CV 
percentages were below 50%, except for the estimated value of time at which 50% of 
the maximum renal clearance was reached for which the CV percentage amounted 
75%. As this may be explained by the small number of individuals in which urine data 









































Figure 3: Conditional weighted residuals versus time for amounts of propylene glycol in urine for the simple (left 
panel) and the final (right panel) model.
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Figure 4: Model-based predicted hepatic (black line) and renal (grey lines) clearance of propylene glycol versus 
birth weight for typical neonates with a post-natal age of 1 day (upper panel) and of 28 days (lower panel). The 




were available, a n-1 jackknife was performed, in which parameter estimates are 
recomputed leaving out the urine data of 1 patient at a time. In a total of 23 datasets, 
the values for the parameter estimates obtained were within 3% of the estimates of 
the final pharmacokinetic model. The CV percentage of the estimated value of time 
at which 50% of the maximum clearance was reached was 50.9% while the other CV 
percentages of the estimated parameters were all below 50%. 
The results of the normalized prediction distribution error (NPDE) method 
analysis for the plasma and urine concentrations showed that the model can predict 
the median concentrations in plasma and urine since the histograms follow the 
normal distribution. Furthermore no trend was seen in the NPDE versus time and 
NPDE versus predicted concentrations (figure 6). 
On the basis of the condition number of 32.9, it was concluded that the model was 
not over-parameterized. The percentage of -shrinkage was identified to be 21% on 
hepatic clearance, 9% on volume of distribution and 37% on renal clearance. The plots 
illustrating the most predicted covariate, birth weight, current bodyweight and time 
after first dose versus the individual and population predicted parameter estimates 
for hepatic clearance, volume of distribution and renal clearance, respectively, 
showed that the individual parameter estimates were randomly scattered around the 
population parameter estimates (Supplement figure 1).
8.4. Discussion
Although propylene glycol is often used as an excipient in drug formulations and is 
regarded to be safe, toxic effects (e.g. bradycardia, lactic acidosis, convulsions) have 
been reported in the adult and pediatric age range upon administration of propylene 
glycol. In adults it is known that about 45% of propylene glycol is eliminated through the 
renal function and 55% of the administered dose of propylene glycol is metabolized in 
the liver to lactate and pyruvate [8, 12, 13]. Due to immaturity of the renal function, renal 
clearance of propylene glycol may be expected to be lower in neonates compared to 
adults. Therefore the aim of this study was to characterize the contribution of renal 
clearance versus hepatic clearance of propylene glycol in neonates based on excreted 
amounts of PG in urine.
Based on the final pharmacokinetic model, renal elimination of propylene glycol in 
neonates was low compared to hepatic elimination and increased over time after first 
dose of PG. The latter was best described using a hyperbolic function based on time 
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Figure 5: Hepatic (grey) and renal  (striped) clearance of propylene glycol for four typical neonates with birth 
weight 630g, 1500g, 2500g and 3500g and a postnatal age of 1 day (upper panels) and of 28 days (lower panels).
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after first dose. Based on this hyperbolic model, renal elimination of propylene glycol 
was estimated to be 15, 20, 23 and 25% of total clearance at 6, 12, 18 and 24 hours 
after the administration of the first dose respectively (figure 4 and 5). At 48 hours 
after the first dose, this percentage of renal elimination of propylene glycol increased 
even further to 30%. Despite this increase over time after dose, renal elimination of 
propylene glycol in neonates still remains substantially lower compared to adults, for 
which renal clearance of propylene glycol was reported to be 45%. The consequence 
of this finding is that maturational changes in the ratio between renal and metabolic 
clearance may influence the magnitude of drug-drug interactions. As in neonates 
hepatic clearance of propylene glycol proves the most important elimination route, 
drug-drug interactions for the alcohol dehydrogenase enzyme will become more 
important in neonates compared to adults. In this perspective, the advice of the 
FDA to avoid Kaletra®, a propylene glycol containing solution, in premature babies 
until 14 days after their due data or in full-term neonates younger than 14 days 
of postnatal age is of relevance. Kaletra® is a solution, which contains a combina-
tion of lopinavir and ritonavir solved in ethanol (356.3 mg ethanol/mL Kaletra®) 
and propylene glycol (152.7 mg/mL Kaletra®). Adverse events as heart, kidney and 
breathing problems were reported in premature neonates, which were likely due 
to a decreased ability to eliminate either ethanol or propylene glycol or both [23, 24]. 
Since both alcohols are metabolized by ADH in the liver, the high concentration of 
ethanol may possibly interfere with the metabolism of propylene glycol since ethanol 
has the highest affinity for ADH. While in adults this probably will be compensated 
by the renal route, in neonates this route is still immature which may result in accu-
mulation of propylene glycol. As such, the results of this study may indicate that due 
to maturational changes, some drug interactions are of more relevance for specific 
age categories.
In the current analysis, it was found that the elimination of propylene glycol 
increased with time after first dose, independently of bodyweight or postnatal age 
of the neonate. To describe this increase in renal elimination of propylene glycol 
different models were tested: I) Model describing non-linear pharmacokinetics using 
an (intermediate) Michaelis-Menten model, II) Model with urine volume normalized 
to current bodyweight implemented as covariate on renal clearance, III) Model with 
both time after first dose and current bodyweight, implemented as covariates on 
renal clearance, IV) Model using a hyperbolic model based on time after first dose, 
V) Model with amount of creatinine as covariate on renal clearance of propylene 
glycol. Implementation of urine volume in the second model (Model II) caused a 
significant decrease in objective function which can be explained by the fact that 
similar to excretion of PG, urine volume increased over time as well. This time 
dependent increase in urine volume may potentially be induced by the osmotic 
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effects of propylene glycol leading to higher volumes of urine when more propylene 
glycol is excreted by the renal route. Subsequently, to evaluate whether this time 
dependent increase in renal elimination of propylene glycol is due to renal maturation 
or specifically caused by propylene glycol, the amount of creatinine was determined 
in urine (model V). No increase in renal elimination of creatinine was seen over time 
implicating that other factors are causing this trend. A potential explanation for these 
findings is an auto-induced increase in renal clearance of propylene glycol, including 
either glomerular filtration, active tubular secretion or both. Another explanation 
may be found in failure of the tubular reabsorption upon propylene glycol use, causing 
this time-dependent increase of propylene glycol in urine. Finally, the model using 
a hyperbolic function based on time after first dose (model IV) was identified as 
the best model. In this model, it was taken into account that the increase in renal 
clearance of propylene glycol will level of at a certain bodyweight or age as seen in 
adults for which renal clearance of propylene glycol is estimated to be around 45% 
compared to hepatic clearance which was estimated to be 55% [8, 12, 13]. As a result, 
in model IV renal elimination of propylene glycol was estimated as a fraction of 
hepatic elimination, which also indicates that besides the increase over time after 
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Figure 6: NPDE results for plasma and urine observations of the final model for propylene glycol. The histograms 
show the NPDE distribution for propylene glycol in plasma (upper panel) and urine (lower panel) with solid lines 
indicating a normal distribution. The distribution of the NPDE versus time after the first dose of propylene glycol 
and the NPDE versus the propylene glycol concentrations are also illustrated.
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as hepatic clearance with birth weight and postnatal age. The time at which 50% 
of the maximum renal clearance is reached, was estimated to be 42.2 hours. This 
value should however be considered with caution since it is based on limited data. 
To evaluate this time-dependent increase in renal elimination of propylene glycol, 
which has not been described before in any age group, further research is needed, 
particularly in preterm neonates who are exposed for several days to drugs containing 
high concentrations of propylene glycol (e.g. lorazepam).
The hepatic clearance of propylene glycol in preterm and term neonates was 
best described using birth weight and postnatal age as covariates. Birth weight, 





















































Supplement figure 1: Individual predicted (black dot) and population predicted (grey dot) parameter estimates for 
hepatic clearance (a), volume of distribution (b) and renal clearance (c) versus the most predictive covariate birth 
weight, current weight and time after first dose.
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representing antenatal maturation of hepatic clearance was implemented using 
a power function. Maturation after birth of hepatic clearance was quantified by 
postnatal age, implemented using a linear function. The identification of these 
covariates confirmed the results of a previous analysis where only plasma data of 
propylene glycol were available [15]. The influence of both covariates on hepatic 
clearance is illustrated in figure 4 and figure 5. Both figures illustrate clearly how 
hepatic clearance of propylene glycol is increasing with birth weight and postnatal age 
and indicate that caution is needed when propylene glycol is administered to preterm 
neonates at the first days of life. The sum of hepatic and renal clearance of propylene 
glycol as illustrated in figure 5 correspond well with the total clearance of propylene 
glycol previously found in preterm and term neonates using plasma samples [15].
Finally, the amount of propylene glycol given in this study following the administra-
tion of paracetamol or phenobarbital varied between 16 and 70 mg/kg/day. Although 
for some of the patients the daily dose of propylene glycol was higher than the 
maximum daily dose suggested by the FDA (25 mg/kg/day), it was much lower than 
the maximum daily intake proposed by the EMA. These guidelines should however 
be considered with caution since the guideline proposed by the FDA is based on the 
administration of propylene glycol as a food additive and it has not been revised since 
1974. Moreover both guidelines are to our knowledge not based on observational 
data.
8.5. Conclusion
Based on the current analysis of propylene glycol data in plasma and urine in 
preterm and term neonates, renal and hepatic elimination rates of propylene glycol 
were determined. Hepatic elimination of propylene glycol proved to be the most 
important elimination route in (pre)term neonates. Renal elimination of propylene 
glycol increased over time after first dose and proved to be 15, 20, 23 and 25% of 
the total clearance at 6, 12, 18 and 24 hours after administration of the first dose, 
respectively. To evaluate whether this increase indicates an auto-induced increase in 
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A semi-physiological function for GFR maturation
Abstract 
Purpose
Since glomerular filtration rate (GFR) is responsible for the elimination of a large 
number of water-soluble drugs, the aim of this study was to develop a semi-physio-
logical function for GFR maturation from neonates to adults.
Methods
In the pharmacokinetic analysis (NONMEM VI) based on data of gentamicin, 
tobramycin and vancomycin collected in 1760 patients (age 1 day-18 years, body-
weight 415g-85kg), a distinction was made between drug-specific and system-
specific information. Since the maturational model for clearance is considered to 
contain system-specific information on the developmental changes in GFR, one GFR 
maturational function was derived for all three drugs.
Results
Simultaneous analysis of these three drugs showed that maturation of GFR 
mediated clearance from preterm neonates to adults was best described by a body-
weight-dependent exponent (BDE) function with an exponent varying from 1.4 
in neonates to 1.0 in adults (ClGFR= Cldrug*(BW/4kg)
BDE with BDE=2.23*BW-0.065). 
Population clearance values (Cldrug) for gentamicin, tobramycin and vancomycin were 
0.21L/h, 0.28L/h and 0.39L/h for a full term neonate of 4kg, respectively.
Discussion
Based on an integrated analysis of gentamicin, tobramycin and vancomycin, a 
semi-physiological function for GFR mediated clearance was derived that can poten-





Children may differ from adults in their response to drugs due to differences 
in pharmacokinetic (PK) and/or pharmacodynamic (PD) relationships [1-3]. A pre-
requisite to developing rational dosing schemes for the pediatric age range (from 
neonates to adults), is to understand how developmental changes influence this PK 
and PD relationship [4]. Given the large number of drugs used and the wide range in 
age and bodyweight in the pediatric population, a major effort would be needed to 
obtain this information for all drugs used in children. Therefore novel approaches to 
support pediatric data analysis, to develop predictive pharmacokinetic models and 
to develop rational dosing schemes in children are required. A promising approach 
would be the characterization of maturation in important metabolic and excretion 
routes across the pediatric life-span from preterm neonates to adults [4, 5]. On the 
basis of model drugs, these maturation functions can be derived and subsequently 
be used to predict the PK for other drugs that are metabolized or excreted through 
the same pathway [6, 7].
Glomerular filtration rate (GFR) is responsible for the elimination of a large 
number of water-soluble drugs and drug metabolites. In adults, GFR is well defined 
with a value of around 120 ml/min [8]. Concerning the pediatric age range, it is known 
that nephrogenesis starts at week 5-6 of gestation and continues until 36 weeks of 
gestation [8-11]. Furthermore, during the first weeks of life, a rapid increase is seen in 
GFR which is mainly due to hemodynamic changes [8]. Adult levels, as expressed per 
body surface area, are reached at approximately 6-12 months of age [8]. However, 
partly due to the expression of GFR per body surface area, the application of these 
functions in the analysis of renally excreted drugs in different age categories is com-
plicated underlining the need for novel functions quantifying GFR across the pediatric 
life-span. GFR can be determined on the basis of the concentrations of endogenous 
(creatinine) or exogenous compounds (inulin, radio-isotopes). Nevertheless, several 
limitations are linked with each of these methods in the pediatric age range. Therefore 
the most pragmatic method to assess maturation in GFR is the determination of the 
clearance of a (model) drug that is almost entirely eliminated through GFR and that 
is widely used in clinical practice across the pediatric age range [12-14]. The advantage 
of the use of clearance of renally excreted drugs as a measure to determine GFR, is 
that this information can be gathered in daily clinical practice. The latter is of course 
of major importance in the pediatric and neonatal age range to keep the burden for 
each patient to a minimum. 
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The aim of this analysis was to develop a semi-physiological function to describe 
maturation in GFR on the basis of simultaneous population pharmacokinetic modeling 
of gentamicin, tobramycin and vancomycin, which are almost entirely eliminated 
through GFR. Since this analysis is based on three different drugs, a novel system-
based pharmacology approach was applied [5]. More specifically, within the model 
a distinction was made between drug-specific and system-specific properties [5]. 
Consequently, the pediatric covariate model on clearance was considered to contain 
system-specific information on the developmental changes in GFR and therefore 
the same covariate model on clearance was implemented for all three drugs. The 
population values for clearance and volume of distribution and the covariate model 
on volume of distribution were considered as drug-specific values and estimated for 
each drug separately. 
9.2. Methods
9.2.1. Patients and Data
Data of gentamicin, tobramycin and vancomycin were included in this analysis, 
which were available from previously published studies [15-18] and from retrospec-
tive data collection at the intensive care units of the Erasmus MC-Sophia Children’s 
Hospital, Rotterdam, the Netherlands. In total, data from 1812 subjects were 
available, which were divided into 4 different age categories according to FDA guide-
lines [19]: 1) neonates (0-1 month), 2) children  1 month-2 years, 3) children 2-12 years, 
4) children 12-18 years. Fifty-two patients (N=14 neonates, N=22 patients aged 
between 1-23 months, N=15 patients aged between 2-11 years, N=1 patients aged 
between 12-18 years) with creatinine values three times higher than the age-related 
reference values [20-24], were excluded from the analysis as they were considered to be 
patients with severe renal dysfunction. Beside peak and trough samples taken before 
and 1 hour after initiation or completion of the dose, there were often samples 
available at other time points. Available data are briefly discussed below while more 
details on the studies can be found in the original articles [15-18]. An overview of the 
different datasets is given in table I. 
Gentamicin [15, 16]
For gentamicin, data of two different studies were combined into one dataset 
resulting in a total of 1705 samples available from 717 patients (682 neonates, 26 
infants 1-24 months, 5 children 2-12 years, 4 children 12-18 years, with a bodyweight 




A total of 1273 tobramycin concentrations available from 614 patients were 
included in this analysis (463 neonates, 67 infants 1-24 months, 48 children 2-12 
years, 36 children 12-18 years, with a bodyweight range between 485g – 85kg). 
This tobramycin dataset consisted of data of preterm and term neonates aged up 
to 4 days of age obtained from a study performed by de Hoog et al.[17] and data of 
patients ranging between a postnatal age of 9 days and 18 years of age obtained 
from a retrospective analysis performed at the intensive care units of the Erasmus 
MC-Sophia’s Children Hospital, Rotterdam, the Netherlands. Patients were included 
in the retrospective data analysis when they were younger than 18 years and when 
bodyweight, age and serum creatinine concentration (not exceeding three times the 
age-related reference value as explained above) was available. 
Vancomycin [18]
For vancomycin 1168 concentrations were available from a total of 429 patients 
(283 neonates, 87 infants 1-24 months, 42 children 2-12 years, 17 children 12-18 
years, with a bodyweight range between 415g – 85kg). Two hundred and sixty 
nine preterm neonates between 1 and 30 days of age were included from a study 
performed by Allegaert et al. [18] and 160 patients ranging between 4 days and 17 years 
of age were obtained from a retrospective analysis performed at the intensive care 
units of the Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands. 
For the retrospective data analysis, the same criteria as explained under tobramycin 
were used. 
Drug Gentamicin Tobramycin Vancomycin
Number of subjects 717 614 429
Number of blood samples 1705 1273 1168
Age 2 days (1 day-15 yrs) 3 days (2 days-18 yrs) 16 days (1 day-17 yrs)
Subjects (n) per age group (range)
 1 (1-28 days) 682 (GA 23-43) 463 (GA 23-43) 283 (GA 23-34)
 2 (1-23 months) 26 67 87
 3 (2-11 years) 5 48 42
 4 (12-18 years) 4 36 17
Bodyweight 2600g (440g-80kg) 2010g (485g-85kg) 1800g (415g-85kg)
Serum creatinine (μmol/L) 72 (12-104) 72 (5-130) 51 (7-144.1)
GA = Gestational age (weeks)
Table I: Overview of the study and patient characteristics (median (range))
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9.2.2. Pharmacokinetic modeling
The population pharmacokinetic analysis was performed with the non-linear mixed 
effect modeling software NONMEM 6.2. (Globomax LLC, Hanover, MD, USA) using 
the first-order conditional estimation method with the interaction option (FOCEI). 
Tools like S-Plus version 6.2.1 (Insightful software, Seattle, WA) with NM.SP.interface 
version 05.03.01 (© by LAP&P Consultants BV, Leiden, The Netherlands), PsN and R 
(version 2.10.1) were used to visualize and evaluate the model. Four different steps 
were used to develop the model: (i) choice of the structural model, (ii) choice of the 
statistical sub-model, (iii) choice of the covariate model, (iv) model validation. 
Structural and statistical model
For the structural model, both one and two compartment models were tested. 
Concerning the statistical model, the inter-individual variability was assumed to be 
log-normal distributed in an individual i (post hoc value) and is given by the following 
equation:
 (Equation 1)
in which TV is the typical value of the parameter and i is assumed to be a random 
variable with mean value zero and variance 2. For the intra-individual variability and 
residual error (statistical submodel), proportional (equation 2), additive (equation 3) 




where Yij is the jth observation in the ith individual, Cpred,ij is the predicted con-
centration and ij is a random variable from a normal distribution with a mean of zero 
and estimated variance of 2.
Discrimination between structural and statistical models was based on different 
diagnostic tools [25]. A difference in objective function (OFV) of 3.9 points or 
more was considered as statistically significant (p<0.05 based on X2 distribution). 
Furthermore, the goodness-of-fit plots (observed versus individual predicted 
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concentrations, observed versus population predicted concentrations, conditional 
weighted residuals versus time, conditional weighted residuals versus population 
predicted concentrations) of all data, stratified by drug and age categories were used 
for diagnostic purposes. Finally the total number of parameters, visual improvement 
of individual plots, correlation matrix, confidence intervals of parameter estimates, 
ill-conditioning [26] and shrinkage [27] were assessed. Ill-conditioning was tested by 
calculating the condition number by dividing the largest eigenvalue by the smallest 
eigenvalue.
Covariate model
The pharmacokinetic model was developed by simultaneously analyzing the 
data of gentamicin, tobramycin and vancomycin. On the basis of a systems-based 
pharmacology approach, within the model a distinction was made between system-
specific and drug-specific information [5, 6]. Using this approach, it was assumed 
that the covariate model contains system-specific information derived from the 
developmental changes in clearance across the pediatric age range from neonates 
to adults of the underlying physiological systems, in this case GFR. As a result, the 
covariate relationships on clearance for all three drugs were not tested separately 
for each drug but the same covariate relationship was tested on clearance of all 
three drugs [7]. The population value for clearance and volume of distribution and the 
covariate models on volume of distribution were considered to contain drug-specific 
information and were therefore estimated by NONMEM for each drug separately.
The following covariates were tested: bodyweight, age, serum creatinine 
concentrations (< three times the age-related upper limit of the reference value 
in order to exclude severe renal dysfunction) and co-administration of ibuprofen, 
indomethacin, diuretics, amoxicillin and aminoglycosides. Since during the first five 
days of life serum creatinine values are considered to reflect maternal renal function 
[10, 28], these creatinine values were excluded from the analysis. According to the 
origin of the data [15-18], serum creatinine was measured using the enzymatic or 
uncompensated Jaffé method. In order to evaluate the influence of creatinine as a 
covariate on clearance different approaches were used: 
(1) Evaluation of creatinine value normalized to age. According to the measuring 
technique, enzymatic or Jaffé respectively, different age-related reference values 
were used [20-24]. 
(2) Evaluation of creatinine clearance. Different formulas were used to estimate 
creatinine clearance (mL/min) in the ith individual: Cockroft-Gault formula, Schwartz 
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formula and Modification of Diet in Renal Disease (MDRD) formula.
Cockroft-Gault:
 (Equation 5)




where k=0.33 for preterm babies in the first year of life, k=0.445 for full term 
infants and k=0.55 for infants and children between 1 and 12 years of age, Scr is the 
serum creatinine (mg/dL) and length was expressed in cm and was determined using 
the growth charts of the World Health Organization. 
MDRD formula:
 (Equation 7)
where age is expressed in years and SCr in mg/dL. 
Creatinine clearance was tested as covariate on clearance using the above 
mentioned formulas as well as the combination of the Schwartz formula < 12 years 
of age and the Cockroft-Gault or MDRD formula > 12 years of age.
Continuous covariates were separately entered into the model using a linear or 




where Pi indicates the individual or post hoc value of the parameter for the ith 
subject, Pp is the population value of the parameter and COV is the appropriate 
covariate. In case of a power function, k represents the exponent value, while for 
a linear relationship k is fixed to 1. For creatinine, linear or power functions were 
tested in the denominator since a negative relationship was seen between creatinine 
concentrations and clearance.
In addition, as it often has been reported that the exponent k (Equation 8) 
on clearance is higher in neonates and young children (scaling exponent >1) [29, 30] 
compared to older children and adults (scaling exponent <1), a recently developed 
bodyweight-dependent exponent function (BDE) was tested in which the scaling 
exponent varied with bodyweight [31-33]. In an analysis undertaken by Wang et al.[31], 
this BDE model (Equation 9) was first used, in which the exponent for propofol 
clearance was found to vary between 1.35 for neonates and 0.57 for adults. The 
bodyweight-dependent exponent function (BDE) used in this analysis is given in 
Equation 9: 
 (Equation 9)
in which CLGFR is clearance in the ith individual with bodyweight BW; CLdrug is the 
clearance of the drug (gentamicin, tobramycin, vancomycin) in a full term neonate 
with a bodyweight of 4 kg; BW is bodyweight of an individual i; L1 is the intercept 
in the scaling exponent and M is the exponent which allows the scaling exponent to 
change with bodyweight. 
The significance of a covariate was statistically evaluated by the use of the objective 
function. In the forward inclusion a p value <0.005 was considered as statistically 
significant while a more stringent p value <0.001 was used in the backward deletion. 
In addition, the reduction in interindividual variability in the parameter studied 
was evaluated upon inclusion of the covariate in the model. When two or more 
covariates were found to significantly improve the model, the covariate that reduces 
the objective function the most was retained into the model and served as a basis 
for subsequent inclusion of additional covariates. The choice of covariate model 
was further evaluated as discussed previously under structural and statistical model 
whereby the results of the model validation were also considered. 
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9.2.3. Model validation
Validation of the model was performed using the normalized prediction distribu-
tion error method [34, 35]. The dataset was simulated 500 times in NONMEM and the 
observed and simulated concentrations were compared using the NPDE package in 
R. A histogram of the NPDE distribution and the scatterplots showing the NPDE 
versus time and versus predicted concentrations were subsequently used to evaluate 
the final model. 
9.3. Results
9.3.1. Patients and Data
The analysis was based on a total number of 4146 observations from three 
different drugs (gentamicin, tobramycin and gentamicin) collected in 1760 patients 
varying in age between 1 day and 18 years of age and with a bodyweight that varied 
between 0.415 and 85 kg. A summary of the clinical characteristics is given in Table I.
9.3.2. Pharmacokinetic modeling: system-based approach 
In the pharmacokinetic analysis based on the simultaneous analysis of gentamicin, 
tobramycin and vancomycin data, a two compartment model parameterized in terms 
of clearance (CL), intercompartmental clearance (Q), volume of distribution of the 
central compartment (V1) and volume of distribution of the peripheral compartment 
(V2) was superior over a one compartment model. Since no covariance step could 
be obtained, the model was simplified by equalizing Q and V2 to CL and V1, which 
was supported by the results of the two compartment model. The interindividual 
variability was only included on clearance values of gentamicin, tobramycin and 
vancomycin as it could not be estimated on volume of distribution of the three 
drugs, probably because of overparameterization. The residual variability was best 
described using a combined error model. 
As mentioned in the methods section, the model consisted of drug-specific and 
system-specific parameters. The covariate model on clearance for these three drugs 
was considered system-specific information while the population values for clearance 
and volume of distribution and the covariate model on volume of distribution was 
considered as drug-specific information. Concerning the system-specific part 
of the model, a power function on the basis of bodyweight as covariate in which 
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the exponent varied with bodyweight (Equation 9) was found to best describe the 
developmental changes in clearance of the three different drugs across the entire 
pediatric life-span. As shown in equation 9, clearance was standardized to a full term 
neonate with a bodyweight of 4 kg, while it is emphasized that given the nature of 
this function also the median weight of the population or 70 kg could have been 
chosen. Implementation of this bodyweight-dependent exponent model on clearance 
of the three different drugs caused a drop in objective function of 3607 points (p < 
0.005). The scaling exponent BDE was found to change in neonates from 1.42 for a 
neonate of 1000g to 1.34 for a neonate of 2500g to 1.3 for a neonate for 4000g to 
1.0 in adults of 18 years old with a bodyweight of 70kg. A higher objective function 
(104 points) was found when bodyweight was implemented using a power function 
(Equation 8) on clearance of the three drugs. Bodyweight was also identified as most 
important covariate on volume of distribution of the central compartment for all 
three drugs. Bodyweight was implemented using a power function for gentamicin 
and tobramycin, while a linear function was identified for vancomycin causing in 
total a drop in objective function of 2438 points (p < 0.005). By implementing these 
covariates, a large part of the interindividual variability on clearance of gentamicin 
(62%), tobramycin (87%) and vancomycin (77%) was explained. Although the influence 
of creatinine on the clearance of the three different drugs was thoroughly evaluated 
using different methods as described in section Methods, creatinine nor creatinine 
clearance was not identified as a covariate in the final pharmacokinetic model. 
This may be explained by two different reasons: 1) only children with creatinine 
concentrations below 3 times the age-related reference values were included, 2) two 
different methods (Jaffé and enzymatic method) were used to measure creatinine in 
the different studies. Consequently when serum creatinine values are considered to 
be normal with one technique, this holds not true for the other technique.
 The parameter estimates of the final pharmacokinetic model with the system-
specific function for GFR mediated clearance are given in table II. The individual post 
hoc and population predicted clearance values versus bodyweight are illustrated in 
figure 1a, 1b, 1c. These figures show that for each drug the individual post hoc values 
are equally distributed around the population clearance values even though one 
function is used to capture maturational changes in clearance of each of the three 
drugs. The observed versus population predicted concentrations per drug and per 
age category are depicted in figure 2 while in figure 3 the individual and population 
predicted clearance values of the final system-specific pharmacology model are 
illustrated versus bodyweight. Based on the correlation matrix, a high correlation 
was seen between L1 and M (>95%). The condition number (428) was far below the 
critical value of 1000 which indicates that the model was not overparameterized. 
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To evaluate the performance of this system-specific pharmacology model, it was 
compared with independent reference models which were developed separately for 
each drug using a systematic covariate analysis. In accordance to the system-specific 
pharmacology model, a bodyweight dependent exponent model was found to best 
describe the developmental changes in clearance for each drug. Furthermore body-
weight was also found as covariate on volume of distribution. Figure 4 illustrates the 
population predicted clearance values versus bodyweight for the final system-specific 
pharmacology model and the independent reference models for the three different 
drugs. 
9.3.3. Model validation
The system-specific model was internally validated using the normalized prediction 
distribution error method. The results of the NPDE analysis of the final system-
specific model (figure 5) show that the model can predict the median concentrations 
accurately, even though a slightly over prediction of the variability was also seen. 
Finally, no trend was observed between the NPDE versus time and versus predicted 
concentrations.
9.4. Discussion
In order to support data analysis, to develop predictive models and to develop 
rational drug dosing schemes in children, new approaches are needed. One of 
the approaches, which is applied in the current investigation, is to characterize 
the developmental changes of important metabolic and excretion pathways from 
neonates until adults by the use of model drugs. Since maturation of renal function is 








































Figure 1: Individual post hoc (grey) and population predicted (black) clearance values (L/h) versus the most pre-
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Figure 2: Observed versus population predicted concentrations of the final system-specific pharmacology model for 
gentamicin, tobramycin and vancomycin, split by four age categories.
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age dependent, resulting in differences in glomerular filtration rate at different stages 
of development, the aim of this study was to characterize the maturation of GFR 
throughout the pediatric age range on the basis of three different renally excreted 
model drugs. To perform this analysis a system-specific pharmacology model [5] was 
developed in which a distinction was made between drug-specific and system-specific 
information. In this model, the developmental changes in clearance of all three drugs 
from preterm neonates to adults were considered system specific information and 
were characterized on the basis of one bodyweight-dependent exponent model [31-33] 
in which the exponent was found to vary with bodyweight from 1.4 in neonates to 
1.0 in adults for all drugs. While this approach resulted in adequate description of the 
data for the entire pediatric life-span (figure 3), it is emphasized that the description 
of the developmental changes in renal clearance, performed in this analysis can also 
be viewed as empirical because an (advanced) allometric function is used. We prefer 
however the use of the term semi-physiological because this approach meets in the 
middle of a standard population pharmacokinetic analysis and a full physiologically 
based pharmacokinetic analysis because both drug specific and system specific 
information are estimated in one model.
The performance of this system-specific pharmacology model was compared 
with independent reference models which were developed separately for each 
drug using a systematic covariate analysis. In figure 4 clearance values are plotted 
versus bodyweight for the system-specific pharmacology model and for the 
independent reference models for the three different drugs. While for tobramycin 
and vancomycin, similar clearance values are observed over the entire pediatric age 
Figure 3: Individual (grey) and population predicted (black) clearance values for gentamicin, tobramycin and vanco-
mycin versus bodyweight (kg) for the final system-specific pharmacology model.
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Parameter Final pharmacokinetic covariate model (CV%)
Fixed effects
System specific parameters: (Eq. 9)
 L1 2.23 (6.23)













 (L) 1.45 (2.94)
V1tobra 
4kg
 (L) 1.90 (1.99)
V1vanco 
4kg
 (L) 2.22 (2.63)
V1genta =V
4kg
 x (BW/4kg)k2 (Eq. 8)
 k2 0.759 (4.35)
V1tobra = V
4kg
 x (BW/4kg)k3 (Eq. 8)
 k3 0.735 (2.56)
V1vanco = V
4kg 
x (BW/4kg)k4 (Eq. 8)
 k4 1 FIX
Qgenta = CLgenta -
Qtobra = CLtobra -
Qvanco = CLvanco -
V2genta = V1genta -
V2tobra = V1tobra -
V2vanco = V1vanco -
Interindividual variability
2 on CLgenta 0.143 (12.5)
2 on CLtobra 0.158 (16.5)
2 on CLvanco 0.171 (10)
Residual variability
2 (proportional) 0.0886 (5.21)
2 (additive) (mg/L) 0.0494 (22.7)
CL = clearance, CL
4kg
 = clearance for a full term neonate of 4kg, Q = intercompartmental clearance, V1= volume 
of distribution of the central compartment, V2 = volume of distribution of the peripheral compartment, BW = 
bodyweight (g), L1 = coefficient of the bodyweight dependent exponent function, M = bodyweight dependent 
exponent, k2 = the exponent of bodyweight on V1 of gentamicin, k3 = the exponent of bodyweight on V1 of 
tobramycin, k4 = the exponent of bodyweight on V1 of vancomycin
Table II: Population parameter estimates of the final system-specific pharmacology model with the system-specific 
function for GFR mediated clearance and drug-specific information on gentamicin, tobramycin and vancomycin.
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range, a difference between the two approaches is observed for gentamicin at the 
higher clearance values. For example the estimates for clearance for a neonate of 
4 kg were for gentamicin 0.21 and 0.20 L/h, for tobramycin 0.28 and 0.29 L/h and 
for vancomycin 0.39 and 0.38 L/h for the system-specific and independent reference 
model, respectively. For a child of 20 kg, the estimates for clearance were 1.38 and 
1.07 L/h for gentamicin, 1.84 and 2.08 L/h for tobramycin and 2.56 and 2.29 L/h for 
vancomycin, while for an individual of 60kg the estimates for clearance were 4.00 and 
2.54 L/h for gentamicin, 5.34 and 6.07 L/h for tobramycin and 7.43 and 6.34 L/h for 
vancomycin for the system-specific and independent reference model, respectively. 
This difference for gentamicin in the higher clearance values between the two 
different approaches can probably be explained by the fact that for gentamicin data 
of only 9 individuals were available in the age range between 2 and 18 years (figure 2). 
Compared to the independent reference model of gentamicin, in the system-specific 
pharmacology model this information is supported by information on tobramycin and 
vancomycin for which much more information was available between in the age range 
between 2 and 18 years. It is therefore anticipated that for gentamicin the system-
specific pharmacology model may be more reliable than the independent reference 
model for the higher bodyweight ranges.
In this analysis, the developmental changes in GFR were described from neonates 
until adults using only bodyweight as covariate on clearance. In an article of Rhodin et 
al.[36], maturation of renal function was described from premature neonates to adults 
using a pooled dataset of 8 different studies in which GFR was evaluated based on 
clearance of Cr-EDTA, mannitol, inulin, iohexol and sinistrin. Both bodyweight and 
postmenstrual age were identified as covariates to describe the maturational changes 
in GFR. Bodyweight was included on clearance using an allometric function with an 
exponent of 0.75 while postmenstrual age was included using a sigmoidal hyperbolic 




























Figure 4: Population predicted clearance values versus bodyweight for the final system-specific pharmacology model 
(grey) and independent reference models (black) for the three different drugs.
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basis of statistical principles, bodyweight was identified as most important covariate 
on clearance. More specifically, it was found that bodyweight was best implemented 
on clearance using a bodyweight-dependent exponent model in which the exponent 
based on bodyweight was found to range from 1.4 in neonates to 1 in adults (figure 6). 
These findings confirm the results of previous studies in which it was also shown that 
the scaling exponent on clearance is higher in neonates and young children compared 
to older children and adults [29, 30, 32]. Moreover the difference in scaling exponent 
signifies that the largest increase in clearance of these different drugs, which in their 
turn reflect GFR, is seen in the first weeks of life until 1 year after birth [8] (figure 1). 
As suggested before, this can be due to hemodynamic changes leading to an increase 
in renal blood flow and decrease in vascular resistance [9, 37].
Previously, a pharmacokinetic model was developed describing the developmental 
changes in clearance of amikacin in preterm and term neonates on the basis of birth 
bodyweight and postnatal age, representing antenatal and postnatal maturation of 
the kidney, respectively [29]. In that model, that proved of predictive value for other 
renally excreted antibiotics in neonates [38, 39] a decrease in clearance was seen when 
ibuprofen was co-administered. Since the combination of birth weight and postnatal 
age is not applicable for older children, bodyweight and age were studied as covariates. 
In the current study in which clearance of three different renally excreted drugs 
was described from neonates until adults, bodyweight was included on clearance 
using the bodyweight-dependent exponent model, because it proved superior over 
age. Although the final system-specific pharmacology model based on bodyweight 
was able to describe the observed concentrations without bias in all age categories, 
including neonates, for all drugs (figure 2), it needs to be evaluated whether the 
model based on birth weight and postnatal age [29] for the neonatal population would 
be superior in precision over the current model. Finally ibuprofen was not identified 
in this current study as a covariate on clearance. Probably this is due to the limited 

































Figure 5: NPDE results of the final system-specific pharmacology model for the three different drugs. Left panel: 
Histogram of the NPDE distribution with the solid line representing a normal distribution, middle panel: NPDE 
versus time, right panel: NPDE versus predicted concentrations.
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can not be excluded that separate models are needed to describe more accurately the 
developmental changes in neonates, in the current study we were able to successfully 
describe the developmental changes over the entire pediatric age range.
In this analysis, an influence of serum creatinine or creatinine clearance could 
not be identified, even though different approaches were tested (methods). This 
seems an unexpected finding because patients with creatinine values up to three 
times the age-related reference values [20-24] were included in the analysis. Potentially, 
this result may in part be explained by the fact that two different methods (Jaffé 
and enzymatic method) were used to measure creatinine concentrations in the 
different studies. Due to interferences with proteins, ketoacids, cephalosporins and 
bilirubin, the Jaffé method overestimates creatinine concentrations compared to the 
enzymatic method [40-42]. In adults it is seen that serum creatinine concentrations are 
overestimated by the Jaffé method by about 30% compared to the enzymatic method 
[43, 44]. In neonates and children this overestimation could not be exactly quantified 
or changes continuously [22, 45]. Moreover, this difference in creatinine measurement 
also affects the formulas used to calculate creatinine clearance to estimate GFR 
[42]. Consequently these formulas need to be adapted based on the used measuring 
technique. Finally, the numbers of patients with a three times increased serum 
creatinine concentration across the entire age range was low (5%), which should be 
considered when interpreting this result. Therefore, it seems that care should be 
taken to apply the model to children with a creatinine concentration between the 
two- and three times the age-related reference value. We should however notice 
that the final system-specific pharmacology model is able to describe the observed 
concentrations of all different age ranges of the three drugs adequately and without 
bias, even though creatinine was not included in the final model. Moreover without 
inclusion of creatinine on clearance, a large part of the interindividual variability was 
explained for the three drugs (gentamicin: 62%, tobramycin: 87%, vancomycin: 77%). 
This analysis based on the use of three different renally excreted drugs to 
characterize GFR from neonates until adults has in addition to a number of advantages 
(e.g. information can be obtained directly from clinical practice causing no additional 
burden for patients) also some restrictions. First of all, it should be emphasized that 
the model developed in this study describes the developmental changes in GFR in 
patients without severe renal impairments. To evaluate maturation of GFR in patients 
with an impaired renal function, new studies need to be performed. Furthermore, 
it should be taken into account that data are obtained from patients staying at the 
intensive care units for which factors of critical illness or augmented renal clearance 
may have an influence on renal function. 
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In conclusion, in this study, we were able to develop a system-specific pharmacology 
model describing maturation in GFR from neonates to adults based on three different 
renally excreted drugs using a bodyweight-dependent exponent function. In a next 
step, it will be evaluated whether this model can be used to predict other renally 
excreted drugs, which has been shown before for a neonatal GFR model [29, 39]. In 
addition, it would be useful to analyze the sensitivity of this relationship to other 
model parameterizations and to characterize the exact influence of differences 
in pharmacokinetic and physicochemical properties. Furthermore, besides the 
extension of this system-specific pharmacology model to other renally excreted 
drugs the possibility to describe the developmental changes in tubular processes 
across the entire pediatric age using this system-specific GFR model can be explored 
when analyzing clearance of a drug undergoing both GFR and tubular excretion. By 
applying a more system-based approach the development of pharmacokinetic models 
will be advanced and the development of evidence-based and individualized dosing 
regimen in children be facilitated. 
Figure 6: The relationship between the allometric exponent in the final system-specific pharmacology model and 
bodyweight (kg) in the bodyweight-dependent exponent model (Equation 9).
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9.5. Conclusions
In this study the developmental changes in GFR mediated clearance in neonates, 
infants, toddlers, children and adolescents were described by describing the 
pharmacokinetics of three renally excreted drugs, gentamicin, tobramycin and 
vancomycin. Based on a distinction between drug-specific and system-specific 
parameters, a semi-physiological function for GFR mediated clearance was derived 
that can potentially be used to facilitate sparse data analysis and evidence based 
dosing regimens of renally excreted drugs in children.
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Section VI








10.1 Towards a system-based pharmacology approach to 
predict developmental changes in renal drug clearance 
To date, dosing guidelines in children are often empirically derived from dosing 
guidelines in adults based on linear extrapolations based on bodyweight. However, 
children can not be considered small adults. During development, changes in body 
composition, cardiac output and blood flow are seen as well as developmental 
changes in drug metabolizing enzymes, liver and kidneys. All of these factors may 
influence the pharmacokinetics of drugs. Furthermore differences in pharmacological 
response may be seen between children and adults due to differences in expression of 
receptors or differences in disease status, which influence the pharmacodynamics. The 
magnitude of these changes may not be solely reflected by differences in bodyweight. 
Therefore it is of utmost importance to characterize these developmental changes in 
pharmacokinetics (PK) and pharmacodynamics (PD) to develop evidence-based and 
individualized dosing regimen [1]. The absence of this information poses otherwise 
significant risks to over- or underdosing leading to adverse or even toxic effects or 
therapeutic failure, respectively [2,3].
Renal clearance is responsible for the elimination of a large number of 
water-soluble drugs and metabolites and is therefore of large importance when 
characterizing the pharmacokinetics of drugs. Renal clearance includes glomerular 
filtration, tubular secretion and reabsorption and each of these processes is subject 
to different developmental changes [4]. To estimate the renal clearance of drugs in 
children, a thorough understanding of these developmental changes in the different 
subprocesses contributing to renal function is needed. Therefore the aim of the 
research described in this thesis was to characterize the developmental changes 
in renal function over the entire pediatric age range. To this end, a system-based 
pharmacology approach was applied implicating that within the models for the 
different subprocesses contributing to renal function a distinction was made between 
system-specific and drug-specific properties [5]. 
In chapter 2 of this thesis we have highlighted the potential value of population 
pharmacokinetic and pharmacodynamic modeling in pediatrics. Performance of 
clinical studies in children is associated with several ethical, practical and economical 
issues. Since it is unethical to perform clinical studies in healthy children, studies 
are performed in children suffering from a disease. As a consequence only a limited 
number of patients are available. Moreover the small blood volume should be taken 
into account limiting the number and volume of blood samples. To overcome these 
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issues with regard to the analysis of pediatric data, the population approach should 
be applied. This population approach using non-linear mixed effect modeling allows 
for the analysis of dense, sparse, balanced or unbalanced data, making the application 
highly suitable in pediatric clinical practice. Additionally, it permits the exploration of 
the influence of different covariates such as bodyweight, age and other covariates, to 
explain the variability in drug response. Finally, using this approach, PK-PD studies can 
be designed in the most efficient manner in order to obtain the maximum information 
on the PK-PD parameters with the highest precision. Once a population PK and/or 
PD model is developed, internal and external validations should be performed [6]. If 
the model performs well in these validation procedures, model simulations can be 
used to define a dosing regimen which in turn needs to be tested and challenged 
in a prospective clinical trial [6]. This methodology will improve the efficacy/safety 
balance of dosing guidelines, which will be of benefit to the individual child. The 
population approach using non-linear mixed effect modeling was applied in this thesis 
to describe the developmental changes in renal clearance for different drugs across 
the pediatric age range.
10.2. Developmental changes in GFR in preterm and term 
neonates by describing the pharmacokinetics of renally 
excreted antibiotics
Previously it has been described that during the first month of life, a rapid rise in 
glomerular filtration is seen. Therefore in chapter 3 of this thesis the developmental 
changes in glomerular filtration were described using data of amikacin in 874 preterm 
and term neonates (birth bodyweight 385-4650g, postnatal age 1-30 days, gestational 
age 24-43 weeks). Amikacin was used as a paradigm compound to reflect GFR because 
it is almost entirely eliminated through GFR, Postmenstrual age proved to be the 
most significant covariate on clearance based on the systematic covariate analysis. 
However, birth bodyweight and postnatal age, representing antenatal and postnatal 
maturation of the kidney, respectively, proved to be superior over postmenstrual age 
alone. Birth bodyweight was implemented on clearance using a power function with 
an exponent of 1.34 and postnatal age was implemented using a linear function with 
a slope of 0.2. Furthermore a decrease (16%) in clearance was seen when ibuprofen 
was co-administered. Based on the final pharmacokinetic model, which was validated 
both internally and externally, simulations were performed to illustrate exposure to 
amikacin in preterm and term neonates following currently used dosing regimens. 
Based on the simulations it could be concluded that the currently used dosing 
regimens should be revised as they may possibly increase the risk of toxicities since 
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target through values between 1.5-3 mg/L were often not reached. Consequently 
a new model-based dosing regimen was developed for preterm and term neonates 
aged between 1 and 30 days, and based on current bodyweight, postnatal age and 
co-administration of ibuprofen. 
In chapter 4, this new model-based dosing regimen was prospectively evaluated 
in 579 preterm and term neonates (median birth bodyweight 2285g (range 420-
4850g), postnatal age 2 days (range 1-30 days), gestational age 34 (range 24-41 weeks)). 
The analysis showed that across the entire neonatal age range the observed amikacin 
concentrations were accurately predicted by the final pharmacokinetic model without 
bias. Moreover the accuracy of the model was confirmed by the NPDE.  Based on 
the Monte Carlo simulations, it was shown that peak concentrations above 24mg/L 
were reached in almost all patients with different bodyweight, postnatal age and use 
of ibuprofen. Trough concentrations below 3 mg/L were found for 78-100% of the 
individuals when ibuprofen was co-administered and for 45-96% of the individuals 
when ibuprofen was not co-administered.
Based on the prospective study, it can be concluded that the novel model-based 
dosing algorithm for amikacin leads to optimized peak and trough concentrations 
in preterm and term neonates with varying birth bodyweight, current bodyweight, 
postnatal age and ibuprofen co-administration. The model-based approach for dosing 
drugs in the highly variable population of neonates, as applied here for amikacin, 
substantially contributes to the individualization of dosing drugs in neonates. 
To develop rational, evidence-based and individualized dosing regimen for specific 
drugs, pharmacokinetic and/or pharmacodynamic models need to be developed and 
validated [6,7] as seen in chapter 3. However to facilitate model development for 
groups of drugs, a more system-based pharmacology approach is needed [5]. This 
approach was applied in chapter 5, in which it was evaluated whether the covariate 
model for amikacin, describing the developmental changes in GFR in preterm and 
term neonates (chapter 3), could be extrapolated to other renally excreted drugs. 
To perform this analysis five different neonatal datasets on netilmicin, tobramycin, 
vancomycin and gentamicin were used. Using this approach a distinction was made 
between system-specific and drug-specific information [5]. The covariate model that 
included birth bodyweight, postnatal age and co-administration of ibuprofen was 






Subsequently the descriptive and predictive performance of the models using 
the amikacin covariate model was compared to the independent reference models, 
which were developed based on a systematic covariate analysis. Based on the 
analysis, it was concluded that the descriptive and predictive properties of the 
models developed using the amikacin covariate model were good and fairly similar 
to the independent reference models, as expressed by the goodness-of-fit plots and 
the normalized prediction distribution error method. Finally, the same covariates 
as in the covariate model of amikacin, i.e. birth bodyweight and postnatal age, 
were identified as the most important descriptors of clearance in the independent 
reference models. Consequently it was concluded that pediatric covariate models 
contain system-specific information describing the developmental changes in the 
underlying physiological processes. This approach in which information of one drug 
is extrapolated to another drug eliminated through the same route will lead to 
optimization of study design, sparse data analysis and will facilitate the development 
of individualized and evidence-based dosing regimen. 
10.3. Developmental changes in renal function (GFR and 
tubular processes) in preterm and term neonates by 
describing the pharmacokinetics of cefazolin
Chapter 6 of this thesis focused on describing the pharmacokinetics of cefazolin 
in preterm and term neonates. In adults it is know that cefazolin is eliminated by both 
GFR and active tubular secretion [8,9] and that protein binding varies between 70-90% 
[10,11,12,13]. However in children and certainly in neonates only limited information is 
available on the pharmacokinetics of cefazolin. Therefore in chapter 6 of this thesis 
the pharmacokinetic properties of cefazolin were described in 36 preterm and term 
neonates (birth bodyweight 540-4200g, postnatal age 1-30 days, gestational age 24-40 
weeks). Based on total and unbound cefazolin concentrations, a one compartment 
model was developed in which total and unbound concentrations were linked by 
estimation of the protein binding (Bmax) and the dissociation constant (KD) which 
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were estimated to be 136 mg/L and 46.5 mg/L, respectively. Birth bodyweight and 
postnatal age were found as most important covariates on clearance of cefazolin 
using a power and linear function, respectively. Furthermore, it was found that 
albumin was linearly correlated with Bmax. Based on this final model, Monte Carlo 
simulations were performed to illustrate the exposure to cefazolin following the 
currently used dosing regimens. According to the results, it was suggested to adjust 
the dosing regimen proposed by the Dutch Children’s Formulary [14] to attain unbound 
concentrations during 60% of the dosing interval above a concentration of 8 mg/L, 
which corresponds to the minimal inhibitory concentration according to The Clinical 
and Laboratory Standards Institute (CLSI) for susceptibility of Staphylococcal species 
[15] and to guarantee a similar exposure in all patients. 
10.4. Renal and hepatic elimination of propylene glycol in 
preterm and term neonates
Drug formulations often contain excipients to increase solubility and/or stability 
of drugs. One of the frequently used excipients is propylene glycol (PG). Propylene 
glycol is normally considered to be safe. However toxic effects have been reported in 
the adult, pediatric and neonatal population and may include bradycardia, depression 
of the central nervous system, increase in anion gap, lactic acidosis, hepatic 
dysfunction and kidney injury [16,17,18,19]. As a consequence both the Food and Drug 
Administration (FDA) and the European Medicine Agency (EMA) have established 
guidelines considering the maximum daily dose of propylene glycol. However, a 
large discrepancy is seen between both guidelines. While the FDA established an 
acceptable daily intake of 25mg/kg bodyweight, the EMA proposed a maximum daily 
dose of 400mg/kg in adults and 200mg/kg in children [20]. This discordance in both 
guidelines indicates the lack of information on the safe use of propylene glycol in 
adults but also in the pediatric age range. To date, no pharmacokinetic studies in 
the pediatric age range were available on propylene glycol. Only a limited number 
of reports was found in literature informing on the toxic effects of propylene glycol 
[18,21,22,23,24,25]. Therefore in chapter 7, the pharmacokinetics of propylene glycol co-
administered intravenously with paracetamol (800mg PG/1000mg paracetamol) or 
phenobarbital (700mg PG/200mg phenobarbital) were described in 62 preterm and 
term neonates (birth bodyweight 630-3680g, postnatal age 1-30 days, gestational age 
24-41 weeks). A one compartment model was developed in which birth bodyweight 
and postnatal age were found as most important covariates on clearance. Current 
bodyweight was found as most important covariate on volume of distribution and 
proved 1.77 times higher when co-administered with phenobarbital compared to 
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paracetamol. Based on this final pharmacokinetic model, simulations were performed 
to illustrate propylene glycol exposure when co-administered with paracetamol and 
phenobarbital. Based on the simulations, it was shown that the population mean 
propylene glycol peak and trough concentrations ranged between 33-144 and 28-218 
mg/L (peak) and 19-109 and 6-112 mg/L (trough) for paracetamol and phenobarbital, 
respectively, depending on birth bodyweight and age of the neonates.
In chapter 8 of this thesis, renal and hepatic elimination of propylene glycol 
was quantified in these preterm and term neonates. In adults, it is known that 45% 
of propylene glycol is eliminated through the renal route and 55% is metabolized 
in the liver by alcohol dehydrogenase (ADH) to lactate and pyruvate [26,27]. Due to 
immaturity of the renal function, renal clearance of propylene glycol may be expected 
to be lower in neonates compared to adults. Even though the pharmacokinetics of 
propylene glycol have been characterized in preterm and term neonates in chapter 
7, no distinction could be made between renal and hepatic elimination of propylene 
glycol in that analysis. It is however important to characterize the magnitude of both 
pathways in neonates because when it appears that one pathway or the other is more 
dominant in neonates this may play a role in the significance of age-specific drug-drug 
interactions. Therefore in chapter 8, renal and hepatic elimination of propylene 
glycol was characterized. The pharmacokinetic analysis was performed based on 
concentrations of propylene glycol in both plasma and/or urine collected in 69 (pre)
term neonates (birth bodyweight 630-3980g, postnatal age 1-30 days gestational age 
24-41 weeks). Birth bodyweight and postnatal age were identified as most important 
covariates on hepatic clearance. Since a time-dependent trend was seen in the renal 
excretion of propylene glycol, different models were tested based on time after first 
dose, urine volume and amount of creatinine in urine. Renal clearance was 15% of the 
total clearance after the first dose but increased over time to 25% at 24hours after 
the first dose. This increase was best described by a hyperbolic function based on 
time after the first dose. Although renal clearance increased with time after first dose 
up to 25%, renal clearance in neonates was substantially lower compared to adults 
for which renal clearance of propylene glycol was reported to be about 45% of the 
total clearance. As a consequence, since in neonates hepatic clearance of propylene 
glycol is determined as the most important elimination route, this may implicate that 
drug-drug interactions at the alcohol dehydrogenase enzyme are more important in 
neonates compared to adults. Furthermore, this may potentially also indicate that 
renal failure is of less importance in neonates compared to adults considering the 
total elimination of propylene glycol. It is concluded that, to evaluate whether the 
increase in renal clearance of propylene glycol indicates an auto-induced increase in 




10.5. Developmental changes in GFR from neonates until 
adults described using different renally excreted antibiotics
Glomerular filtration is responsible for the elimination of a large number of water-
soluble drugs and their metabolites. GFR is well defined in adults and is estimated to 
be around 120 mL/min [4]. More uncertainty rises in the pediatric age range as GFR 
is supposed to reach adult levels at about 6 months – 1 year of age [4]. However an 
exact quantification of GFR throughout the pediatric age range is missing. Therefore, 
the aim in chapter 9 was to describe the developmental changes in GFR from (pre)
term neonates until adults (N=1760 patients, bodyweight 415g-85kg, age 1 day-18 
years) by describing the pharmacokinetics of gentamicin, tobramycin and vancomycin, 
which are drugs that are almost entirely eliminated through GFR. Since the analysis 
was based on data of three different drugs combined into one analysis, a system-
based pharmacology approach was used. This means that, as explained in chapter 
5, a distinction was made between system-specific and drug-specific properties. 
The covariate model tested on clearance was considered to contain system-specific 
information reflecting the developmental changes in GFR applicable to all drugs while 
the population value was considered to be a drug-specific parameter. Across the 
entire pediatric age range, from premature neonates until adults, bodyweight was 
found as most significant covariate on clearance and volume of distribution. The 
effect of bodyweight was best described on clearance using an allometric function 
in which the exponent changed with bodyweight from 1.4 in neonates to 1 in adults. 
This indicates that the largest increase in clearance of these different drugs, reflecting 
GFR, is seen during the first weeks of life. This maturation function, developed in 
chapter 9, may possibly be used to describe evidence-based and individualized 
dosing regimen for renally excreted drugs over the entire pediatric age range.
10.6. Perspectives
The aim of the research described in this thesis was to describe the developmental 
changes in renal function. Renal function consists of glomerular filtration, tubular 
secretion and reabsorption. In this thesis we primarily focused on describing the 
developmental changes in glomerular filtration on the basis of analyses on drugs that 
are primarily excreted through GFR. Once the developmental changes in GFR are 
described, this information can be used to describe the developmental changes in 




Glomerular filtration is rapidly rising during the first weeks of life. Moreover, also 
large differences in GFR are seen between preterm and term neonates. Therefore 
in the first part of this thesis we focused on describing the developmental changes in 
GFR in neonates. Subsequently the maturation of the renal function was described 
across the entire pediatric age range. As explained in the introduction of this thesis 
(chapter 1), several methods can be used to measure GFR. The most practical 
manner to assess GFR in healthy individuals is by measuring creatinine clearance. 
Since creatinine is an endogenous compound, the burden to evaluate GFR can be 
kept to a minimum for each individual. However, a few remarks should be considered 
when creatinine is used to evaluate GFR. First of all, creatinine is not only filtered by 
GFR but also in part secreted by tubular secretion [4,28]. In addition, the measurement 
of creatinine clearance based on plasma samples can be complicated since the 
formation of creatinine depends on muscle mass, age and gender [4]. Furthermore in 
the first days of life creatinine values reflect maternal renal function [29,30,31]. Finally, the 
Schwartz formula which is often used to estimate GFR in children based on serum 
creatinine and body length, often leads to overprediction of GFR [32]. Consequently, 
due to the reasons mentioned above, creatinine is not the best marker to assess 
GFR. Other markers like inulin or radioisotopes [33,34] have amongst other things 
the disadvantage that these compounds are exogenous implicating that the burden 
for each individual will be increased when evaluating GFR compared to creatinine. 
Therefore to perform these analyses the pharmacokinetics were described of 
amikacin, netilmicin, tobramycin, vancomycin and gentamicin, which are drugs that 
are almost entirely eliminated through GFR. Since GFR was evaluated by describing 
data of renally excreted drugs, data could be directly obtained from clinical practice 
without administering diagnostics or other compounds specific for this analysis. The 
latter is of course of major importance for children so that the burden for each patient 
can be kept to a minimum. However, this also implicates that the developmental 
changes in glomerular filtration were characterized in non-healthy or sick patients. 
In chapter 3 the GFR model for neonates was developed based on data of 
amikacin obtained in 874 preterm and term neonates, covering an extensive range 
in gestational age, birth bodyweight and postnatal age. This analysis in which a 
tremendous amount of data of amikacin was used to characterize developmental 
changes in GFR in preterm and term neonates was never performed before as 
previous analyses were based on a smaller number of patients and a more narrow 
age range compared to our analysis. Moreover, the model developed in chapter 3 
was both internally and externally validated. Consequently this model, describing 
the developmental changes in GFR based on amikacin clearance, could then be used 
to describe clearance of other renally excreted drugs in neonates (chapter 5). This 
extrapolation to the other renally excreted drugs was performed to populations 
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with the same clinical characteristics and disease status compared to the amikacin 
dataset since all patients were admitted to the neonatal intensive care unit and were 
treated with aminoglycosides or glycopeptides when sepsis was suspected. However, 
since critical illness (i.e. sepsis) may have an influence on clearance, these models 
should not be applied in other patient populations until the accuracy of the model 
has been evaluated in those populations. In a previous study by Ince et al. [35] it was 
reported that critical illness severely reduced the CYP3A4-mediated clearance of 
midazolam. Therefore, the effects of critical illness on the developmental changes 
in glomerular filtration should be further analyzed, even though renal excretion can 
not be compared to CYP3A4 metabolism. Moreover the use of this kind of drugs 
(aminoglycosides, glycopeptides) may cause renal toxicity after repetitive dosing 
[36]. Furthermore, the model performance should also be evaluated in patients on 
extracorporeal membrane oxygenation (ECMO) treatment. Previously it has been 
shown that the very invasive ECMO treatment influences the pharmacokinetic 
parameters of various drugs [37,38,39,40,41,42]. In a study of Dodge et al. [43], it was 
concluded that neonates on ECMO receiving gentamicin had a higher volume of 
distribution and a lower clearance of gentamicin compared to neonates off ECMO. In 
conclusion, this means that the model developed in chapter 3 should not be applied 
to other patient populations until the accuracy and predictability of this model is 
evaluated in this population. The model can however be seen as a primary basis in 
which a large amount of data was used. Moreover, besides the fact that the model 
was both internally and externally validated, it was also used to predict other renally 
excreted drugs. 
As explained in the introduction of this thesis, the objective of this thesis was to 
describe the developmental changes in renal function by the use of a more system-
based pharmacology approach. The key feature of this approach is that a distinction 
was made between system-specific and drug-specific properties. This approach was 
first applied in chapter 5 of this thesis. The amikacin covariate model for neonates, 
which was considered to be system-specific, was extrapolated to netilmicin, 
tobramycin, vancomycin and gentamicin, which are drugs that are almost entirely 
eliminated through GFR (chapter 5). The applicability of this GFR model, based on 
amikacin was also illustrated in an analysis performed by Zhao et al. [44], in which the 
model of amikacin was used to predict clearance of vancomycin. Based on that study, 
it was concluded that the model describing the developmental changes in GFR based 
on amikacin can be used to predict dosage regimens of other renally excreted drugs 
by GFR in preterm and term neonates.  However, it should be emphasized that the 
final pharmacokinetic models for amikacin, netilmicin, tobramycin, gentamicin and 
vancomycin as developed in section II of this thesis are only of significance in a specific 
age range namely preterm and term neonates. The exponential increase in clearance 
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with birth bodyweight (exponent of 1.34) seen in preterm and term neonates will 
not be applicable to older children and adults as the renal function will be gradually 
flattening. Therefore, in the last section of this thesis (chapter 9) the developmental 
changes in GFR were quantified over the entire pediatric age range based on three 
renally excreted drugs using a bodyweight-dependent exponent model, in which the 
exponent changes depending on bodyweight. This bodyweight-dependent exponent 
function permits that the exponent gradually changes according to bodyweight and is 
able to characterize more rapid changes in neonates compared to adults.  Previously 
similar bodyweight-dependent exponential covariate models were developed to 
scale clearance of propofol [45,46], busulfan [47], midazolam [48] and morphine [49] from 
neonates until adults. In all these models, a higher exponent was found in neonates 
and young children (exponent >1) compared to older children and adults as found in 
the model describing the developmental changes in GFR from neonates (exponent 
of 1.4) until adults (exponent of 1). In our opinion, the innovative and progressive 
aspect of the model quantifying the developmental changes in GFR over the pediatric 
age range, described in this thesis, is that it was based on the combination of three 
renally excreted drugs, gentamcin, tobramycin and vancomycin allowing for the 
distinction between drug and system-specific properties [5]. It should however, be 
highlighted that further research is needed to evaluate the generalizability of the 
models describing the developmental changes in glomerular filtration in neonates 
(section II) and from neonates until adults (chapter 9). Since in the current analyses, 
all drugs have fairly similar physicochemical and pharmacokinetic drug properties, the 
influence of different physicochemical and pharmacokinetic drug properties to the 
extrapolation to other drugs should be characterized on the basis of physiologically-
based modeling. This was also done in an analysis by Krekels et al. [50], in which 
the influence of differences in physicochemical properties was evaluated on the 
extrapolation possibilities of the glucuronidation function developed using morphine 
data. Finally, in a next step, as performed for amikacin in neonates (chapter 3), the 
final pharmacokinetic models should be used to evaluate the currently used dosing 
regimens for amikacin, gentamicin, tobramycin, netilmicin and vancomycin in neonates 
and over the entire pediatric age range. If it appears that the currently used dosing 
regimen should be revised, new model-based dosing regimens should be developed 
and tested in a prospective analysis in a similar manner as amikacin (chapter 4). 
Although renal function consists of glomerular filtration, active tubular 
secretion and reabsorption, we primarily focused on describing the maturation in 
glomerular filtration. Once the developmental changes in GFR were characterized, 
we hypothesized that this information could be used to describe the developmental 
changes in tubular processes by studying drugs that are excreted by both GFR and 
tubular processes. Development of tubular processes starts from 36 weeks of 
241
Conclusions and Perspectives
gestation and continues during childhood [4]. In comparison with glomerular filtration, 
development of tubular processes is delayed [4,51,52]. For the glomerular filtration rate, 
it is known that adult levels are reached at approximately 6-12 months of age while 
for the tubular processes adult levels are not reached until 1-5 years of age [52]. Since 
large differences are seen in renal function between preterm and term neonates 
during the first month of life, we decided to initially start with the quantification of 
the developmental changes in tubular secretion in preterm and term neonates, as 
performed for GFR using amikacin as a model drug. Since cefazolin is a drug which 
is both eliminated by GFR and active tubular secretion [8,9], this drug was used as a 
paradigm compound to quantify the maturational changes in tubular secretion in 
neonates. To perform this analysis it was supposed that when clearance of cefazolin 
was higher than the clearance of GFR, it was due to active tubular secretion. 
Consequently based on these assumptions, the semi-physiological GFR model 
based on amikacin clearance from chapter 3 was directly incorporated on cefazolin 
clearance. This implicated that birth weight was implemented on clearance using an 
allometric function with an exponent of 1.34 as well as postnatal age using a linear 
function with a slope of 0.213 (chapter 3). Although the population clearance value is 
considered a drug-specific parameter, it was fixed to the value obtained in the final 
pharmacokinetic model of amikacin (equation 2). The reason for this approach was 
that we found in chapter 5, in which the amikacin covariate model reflecting GFR in 
(pre)term neonates was extrapolated to four other renally excreted drugs, that all 
initial population values were very similar for all these different drugs. Therefore, in 
this analysis the initial population clearance value was not estimated but fixed to the 
value (0.0493 L/h for a neonate with a birth bodyweight of 1750g and a PNA of 2 
days) obtained in final pharmacokinetic model of amikacin. 
 (Equation 2)
The remaining part was then considered to describe clearance through active 
tubular secretion. Consequently, to quantify these developmental changes in active 
tubular secretion, a systematic covariate analysis was performed based on free 
cefazolin concentrations collected in the 36 preterm and term neonates used for 
the analysis in chapter 6. Similar to GFR, birth bodyweight and postnatal age were 
identified as most relevant covariates for active tubular secretion. By fixing the 
developmental changes of GFR to the results obtained with amikacin, we were able to 
isolate and quantify the developmental changes in tubular secretion. Table I gives an 
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Table I: Population pharmacokinetic parameter estimates of the simple model, the final pharmacokinetic model and 
the bootstrap analysis.














p x (bBW/median)m 
x (1+(PNA/median)xn)
0.0493 FIX 0.0493 FIX 0.0493 FIX
m 1.34 FIX 1.34 FIX 1.34 FIX




 (L/h) = CL
Tub 







p x (bBW/median)o 
x ((PNA/median)p)
- 0.147 (15.0) 0.146 (16.0)
o - 1.99 (28.8) 2.03 (31.0)
p - 0.271 (43.5) 0.266 (47.7)
V (L) = Vp 1.86 (8.1) -
Vp in V = Vp x (cBW/median)q - 1.98 (5.5) 1.97 (6.1)
q - 1.19 (13.1) 1.21 (14.8)
Interindividual variability ( 2)
2 CL 0.243 (31.9) 0.12 (37.2) 0.108 (40.1)
2 V 0.253 (31.1) 0.0649 (33.3) 0.06 (36.9)
Residual variability ( 2)
2 (proportional) 0.0469 (27.5) 0.0473 (27.3) 0.047 (28.5)
CL
GFR
= clearance through glomerular filtration, CL
GFR
 p= population value for clearance through GFR, CL
Tub
= 
Clearance through tubular processes, CL
Tub
p= population value for clearance through tubular processes, V = Volume 
of distribution, Vp = population value for volume of distribution, bBW = bodyweight at birth, cBW = current 
bodyweight, PNA = postnatal age, median values for the covariate model on GFR are based on the GFR model 
based on amikacin, median values for the covariate model on tubular processes and volume of distribution are 
based on the currently used cefazolin dataset
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overview of the parameter estimates of the simple and final pharmacokinetic model 
together with the values obtained from the bootstrap analysis. The model-based 
total clearance (sum of clearance through GFR and tubular processes), clearance 
through GFR and clearance through tubular processes of cefazolin versus birthweight 
for PNAs of 1, 14 and 28 days is illustrated in figure 1. Figure 1, in which clearance 
through tubular processes is illustrated versus birth bodyweight for PNAs 1, 14 and 
28, indicates that the largest increase in tubular secretion is seen during the first 14 
days. This may be explained by the upregulation of transporters (organic anion or 
cation transporters) in the kidney during the perinatal period to compensate the 
increased concentrations of various compounds after birth. Furthermore, this figure 
illustrates a lower clearance of cefazolin by tubular processes compared to glomerular 
filtration in neonates below 3.5 kg during the first 14 days. However, in neonates with 
a birth bodyweight above 3.5 kg the tubular clearance of cefazolin seem to transcend 
the glomerular filtration. Nevertheless on day 28, glomerular filtration is the most 
important elimination route of cefazolin in all neonates, which corresponds well with 
previously reported results that renal tubular development is delayed compared to 
GFR. The applicability of this model in which the developmental changes in tubular 
secretion were characterized in preterm and term neonates should subsequently be 
tested using other renally excreted drugs, which are undergoing both glomerular 
filtration as tubular processes. Finally in next step the maturational changes in tubular 
secretion should be described from neonates until adults. To perform that analysis 
and to be able to characterize the developmental changes in tubular secretion over 
the pediatric age range, the model described in chapter 9 can be used as a basis as 
this model is describing the developmental changes in GFR across the pediatric age 
range. 
Figure 1: Model-based predicted total clearance (= sum of clearance through GFR and tubular processes) (left), 
clearance through GFR (based on the developmental changes in GFR seen with amikacin (equation 2) (middle) 
and clearance through tubular secretion (based on free cefazolin concentrations) (left) of cefazolin versus birth 
bodyweight for postnatal age of 1 (black line), 14 (dotted line) and 28 days (grey line).
Clearance of cefazolin through GFR Clearance of cefazolin through tubular secretation





























































In summary we can claim that the developmental changes in glomerular filtration 
were described from preterm and term neonates to adults using a system-based 
pharmacology approach [5]. This implicated that a distinction was made between 
system-specific and drug-specific properties making it possible to extrapolate 
information of one drug to another drug. Further studies need to be performed 
to evaluate to what extent this approach is applicable to other drugs with different 
physicochemical drug properties. The preferred approach to perform this analysis is 
by the use of physiologically-based pharmacokinetic modeling approaches because 
this allows for simulations for a variety of drugs and physiological situations. 
Furthermore, the developmental changes in the other subprocesses that contribute 
to renal clearance (tubular secretion and reabsorption) should be characterized 
across the entire pediatric age range. To perform the latter analyses, the models 
describing the developmental changes in GFR can be used as a basis. The transition 
to a more system-based pharmacology approach and the combination of different 
strategies (extrapolation to other drugs, adult data or non-clinical data) will result in 
an approach focusing on the underlying system instead of focusing on the drugs and 
may facilitate development of pharmacokinetic models and evidence-based dosing 
regimens in the pediatric population.
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11.1. Voorspelling van de verandering in de ontwikkeling van 
renale klaring in kinderen aan de hand van een systeem 
farmacologische benadering 
Doseervoorschriften bij kinderen worden vaak afgeleid uit doseervoorschriften 
bij volwassenen op basis van verschillen in lichaamsgewicht of lichaamsoppervlak. 
Aangezien kinderen niet beschouwd kunnen worden als kleine volwassenen, leidt 
dit echter vaak tot over- of onderdosering. Gedurende de ontwikkeling van het 
kind vinden er vele veranderingen plaats als gevolg van veranderingen in de grootte 
van het lichaam, veranderingen in de lichaamssamenstelling, en veranderingen in 
lever en nierfunctie. Dit heeft invloed op twee processen die bepalend zijn voor 
de werking van geneesmiddelen, de farmacokinetiek en de farmacodynamiek. De 
farmacokinetiek heeft betrekking op de absorptie, de verdeling en de eliminatie van 
geneesmiddelen in het lichaam, en bepaalt het verloop van de concentratie van het 
geneesmiddel als functie van de tijd. De farmacodynamiek heeft betrekking op de 
processen die ten grondslag liggen aan de werking van het geneesmiddel (de binding 
aan het doeleiwit, de activatie en de transductie mechanismen) en bepalend zijn 
voor de intensiteit van het effect als functie van de concentratie. Doseerregimes bij 
kinderen, die zijn afgeleid zijn uit doseerregimes bij volwassenen gebruik makend 
van lineaire extrapolaties op basis van lichaamsgewicht, houden geen rekening met 
deze veranderingen. Het is daarom noodzakelijk om de factoren die bepalend zijn 
voor de veranderingen in farmacokinetiek en farmacodynamiek van geneesmiddelen, 
die gebruikt worden bij kinderen, te karakteriseren. Dit zal uiteindelijk leiden 
tot wetenschappelijk onderbouwde en geïndividualiseerde doseerregimes. Om 
onderzoek naar de veranderingen in farmacokinetiek en farmacodynamiek bij 
kinderen te stimuleren, is er zowel in Europa als in de Verenigde Staten een nieuwe 
regelgeving met betrekking tot geneesmiddelonderzoek bij kinderen tot stand 
gekomen. Deze regelgeving houdt in dat onderzoek in kinderen verplicht is voor 
nieuwe, op de markt te brengen geneesmiddelen. Ondanks de positieve gevolgen 
van deze regelgeving voor de dosering van nieuwe geneesmiddelen bij kinderen, is er 
vooralsnog geen oplossing voor geneesmiddelen die al op de markt zijn, waardoor in 
de praktijk vele geneesmiddelen nog steeds off-label gebruikt worden bij kinderen.
Vele wateroplosbare geneesmiddelen en geneesmiddel-metabolieten worden 
geëlimineerd via de nieren. Renale klaring  bestaat uit een samenspel van drie 
verschillende processen, glomerulaire filtratie, tubulaire secretie en tubulaire 
reabsorptie. Tijdens de ontwikkeling van het kind treden er belangrijke veranderingen 
op in elk van deze deelprocessen. Om veranderingen in de renale klaring van 
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geneesmiddelen in kinderen te karakteriseren, is een grondige kennis vereist van de 
veranderingen in elk van deze deelprocessen. 
Het doel van het onderzoek in dit proefschrift was om de ontwikkelings-
veranderingen in de nierfunctie te karakteriseren in verschillende leeftijdsgroepen. 
Daarbij is toegewerkt naar een systeem farmacologische benadering, waarbij 
veranderingen in de nierfunctie werden bestudeerd aan de hand van veranderingen 
in de excretie van modelstoffen. Bij het opstellen van de wiskundige modellen 
werd een onderscheid gemaakt tussen enerzijds systeem-specifieke en anderzijds 
geneesmiddel-specifieke eigenschappen.
In hoofdstuk 2 van dit proefschrift, wordt een overzicht gegeven van de 
voordelen van de zogenaamde “populatie” analyse. Het uitvoeren van klinische 
studies in kinderen wordt beperkt door ethische, praktische en economische 
factoren. Bovendien wordt het als onethisch beschouwd om onderzoek uit te voeren 
bij gezonde kinderen waardoor vrijwel uitsluitend studies kunnen worden uitgevoerd 
in kinderen die lijden aan een ziekte. Dit heeft tot gevolg dat slechts een beperkt 
aantal kinderen beschikbaar is voor onderzoek. Bovendien is het bloedvolume bij 
kinderen beperkt waardoor het aantal en het volume van de bloedmonsters die 
kunnen worden afgenomen beperkt is. De beste methode om met deze beperkingen 
om te gaan, is door gebruik te maken van de populatie analyse. Deze methode maakt 
het mogelijk farmacokinetische en farmacodynamische processen te beschrijven op 
basis van beperkte en onevenwichtig opgebouwde datasets. Deze methode is daarom 
bijzonder geschikt voor het uitvoeren van onderzoek in kinderen. Bovendien is het 
mogelijk om de invloed van verschillende covariabelen zoals lichaamsgewicht, leeftijd 
en comedicatie te bestuderen om de variabiliteit tussen verschillende individuen te 
verklaren. Dat is belangrijk omdat op basis van de gevonden covariabelen de dosering 
kan worden geïndividualiseerd. Alvorens over te gaan tot toepassing in de praktijk, 
is het noodzakelijk dat het gevonden populatiemodel wordt geëvalueerd in een 
prospectieve klinische studie. Het onderzoek in dit proefschrift maakte gebruik van 
de populatie analyse, waarbij op basis van veranderingen in de renale uitscheiding 
van verschillende model-geneesmiddelen, de ontwikkelingsveranderingen in renale 
klaring bij kinderen in kaart werden gebracht. 
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11.2. Ontwikkelingsveranderingen in glomerulaire filtratie 
in preterme en a terme neonaten op basis van een 
farmacokinetische analyse van de renale excretie van 
antibiotica
Hoewel de nierfunctie goed gekarakteriseerd is in volwassen, zijn er slechts 
beperkte gegevens beschikbaar over ontwikkeling van de nierfunctie bij kinderen. 
Gedurende de eerste levensmaand wordt een snelle stijging gezien in de glomerulaire 
filtratie waarbij, rekening houdend met lichaamsoppervlak, volwassen waarden worden 
bereikt op een leeftijd van 6 maand tot 1 jaar. Tubulaire processen, daarentegen, 
lijken zich veel langzamer te ontwikkelen, waarbij volwassenen waarden worden 
bereikt bij een leeftijd tussen de 1-5 jaar. Omdat glomerulaire filtratie een belangrijke 
component is van de renale klaring van de meeste geneesmiddelen, was het primaire 
doel van ons onderzoek het karakteriseren van de ontwikkelingsveranderingen in 
glomerulaire filtratie. Om de glomerulaire filtratie te schatten, kunnen verschillende 
methoden worden toegepast waarbij de klaring van endogene (creatinine) of exogene 
(inuline, radio-isotopen) componenten wordt bepaald. Aan elk van deze methoden 
zijn verschillende nadelen verbonden, wat de routinematige toepassing bij kinderen 
en zeker bij neonaten moeilijk maakt.
Bijgevolg in het onderzoek dat is beschreven in dit proefschrift werd een 
methode gehanteerd, waarbij de glomerulaire filtratie geschat werd door bepaling 
van de klaring van een geneesmiddel dat volledig via glomerulaire filtratie wordt 
geëlimineerd. Het beschrijven van glomerulaire filtratie aan de hand van de klaring 
van een geneesmiddel heeft bovendien als voordeel dat de nodige informatie kan 
worden verkregen in de klinische praktijk zonder dat de patiënten hiervoor extra 
belast moeten worden. Het onderzoek dat wordt beschreven in hoofdstuk 3, heeft 
betrekking op de farmacokinetiek van amikacine in 874 preterme en a terme neonaten 
(geboortegewicht 385-4650g, postnatale leeftijd 1-30 dagen, zwangerschapsduur 
23-43 weken). Amikacine werd gebruikt als model-geneesmiddel om de maturatie 
in glomerulaire filtratie weer te geven aangezien het bijna volledig geëlimineerd 
wordt door glomerulaire filtratie. Op basis van een systematische covariaatanalyse 
kon worden vastgesteld dat postmenstruele leeftijd de meest significante covariaat 
was voor de variatie in klaring. De combinatie van geboortegewicht en postnatale 
leeftijd, die respectievelijk de prenatale en postnatale maturatie reflecteren, bleek 
echter superieur te zijn over postmenstruele leeftijd. Op basis van deze bevindingen 
werd geconcludeerd dat in de onderzochte leeftijdsgroep, de veranderingen in 
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klaring van amikacine best beschreven werden met een exponentiële functie op basis 
van geboortegewicht met een exponent van 1.34 en een lineaire functie met een 
richtingscoëfficiënt van 0.2 op basis van postnatale leeftijd. Tenslotte werd vastgesteld 
dat de klaring van amikacine 16% lager was wanneer ibuprofen ook werd toegediend 
aan deze neonaten. Het huidige lichaamsgewicht werd gevonden als belangrijkste 
covariabele op verdelingsvolume. Om vast te stellen of het model kan worden gebruikt 
om concentraties te voorpellen, werd het model uitvoerig gevalideerd. Daarbij 
werd zowel een interne als een externe validatie verricht. Voor de externe validatie 
werden twee externe datasets gebruikt. Externe datasets worden gedefinieerd als 
datasets die afkomstig zijn van patiënten, die geen onderdeel vormden van de groep 
patiënten waarvan de data werden gebruikt om het model te ontwikkelen. Met 
behulp van verschillende analyses werd vastgesteld dat op basis van het model dat 
werd  ontwikkeld in hoofdstuk 3, de concentraties van de patiënten in de externe 
datasets kunnen worden voorspeld op basis geboortegewicht, postnatale leeftijd, 
toediening van ibuprofen en huidig lichaamsgewicht. Nadat was gebleken dat op basis 
van het model goede voorspellingen kunnen worden gemaakt, werden simulaties 
uitgevoerd om de blootstelling aan amikacine in preterme en a terme neonaten te 
voorspellen op basis van de huidige in de praktijk toegepaste doseerregimes. Op 
basis van deze simulaties kon worden vastgesteld dat de huidige doseerrichtlijnen 
moeten worden herzien omdat deze naast gebrek aan effect ook aanleiding kunnen 
geven tot een verhoogd risico op toxiciteit omdat de gewenste dalconcentraties 
tussen 1.5-3 mg/L vaak niet werden bereikt. Op grond  hiervan werd een nieuw 
doseerregime ontwikkeld op basis van de gevonden covariabelen in het finale model 
van amikacine (huidig lichaamsgewicht, postnatale leefijd en gelijktijdige toediening 
van ibuprofen) voor preterme en a terme neonaten met een leeftijd tussen 1 en 30 
dagen. Tot slot werd geopperd dat dit model eventueel ook kan gebruikt worden 
om de farmacokinetiek van andere renaal geklaarde geneesmiddelen te beschrijven, 
omdat het ontwikkelde model in hoofdstuk 3 de glomerulaire filtratie reflecteert. 
In hoofdstuk 4 werd het nieuwe doseerregime voor amikacine, zoals dat werd 
ontwikkeld in hoofdstuk 3, geëvalueerd in de klinische praktijk. In deze prospectieve 
studie werden 579 preterme en terme neonaten geïncludeerd (geboortegewicht 
420-4850g, postnatale leeftijd 1-30 dagen, zwangerschapsduur 24-41 weken). In 
een eerste analyse werden de waargenomen amikacine piek- en dalconcentraties 
vergeleken met de concentraties die werden voorspeld op basis van het finale model 
uit hoofdstuk 3. Deze analyse toonde aan dat over het gehele neonatale leeftijdsbereik 
de waargenomen amikacine concentraties nauwkeurig werden voorspeld zonder 
bias. Bovendien werd de juistheid bevestigd door het uitvoeren van de NPDE. 
Om de blootstelling aan amikacine te evalueren in preterme en terme neonaten 
werden tot slot ook Monte Carlo simulaties uitgevoerd. Op basis hiervan, werd 
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aangetoond dat piekconcentraties boven de gewenste waarde van 24 mg/L bereikt 
werden in bijna alle patiënten met verschillend lichaamsgewicht, postnatale leeftijd 
en gebruik van ibuprofen. Dalconcentraties onder 3 mg/L werden bereikt bij 78-100% 
van de neonaten wanneer ibuprofen werd toegediend en 45-96% van de neonaten 
wanneer geen ibuprofen werd toegediend. Op basis van deze prospectieve studie, 
kan er besloten worden dat het nieuwe doseerregime voor amikacin, dat gebaseerd 
werd op het farmacokinetisch model, ontwikkeld in hoofdstuk 3, vaker leidt tot de 
gewenste piek- en dalspiegels voor amikacine bij preterme en a terme neonaten met 
een verschillend lichaamsgewicht, geboortegewicht, postnatale leeftijd en gebruik 
van ibuprofen. Deze benadering, zoals toegepast in hoofdstuk 3 en 4 voor amikacine 
in preterme en a terme neonaten, vormt de basis voor een verdere individualisatie 
van doseerregimes bij neonaten.
Zoals beschreven in hoofdstuk 3 en 4, kunnen rationele, wetenschappelijk 
onderbouwde en geïndividualiseerde doseerschema’s worden ontwikkeld op basis 
van gevalideerde farmacokinetische en/of farmacodynamische modellen. Dit is 
echter een heel tijdsrovend en intensief proces, wat het onmogelijk maakt dit uit te 
voeren voor elk geneesmiddel en in elke leeftijdscategorie. Om die reden werd in 
hoofdstuk 5 een systeem farmacologische benadering gebruikt, waarbij systeem-
specifieke informatie die is verkregen op basis van de analyse van een geneesmiddel, 
wordt geëxtrapoleerd naar andere geneesmiddelen die via dezelfde weg geëlimineerd 
worden. Met andere woorden, werd in hoofdstuk 5 nagegaan of het covariaten model 
van amikacine, wat de ontwikkelingsveranderingen beschrijft in glomerulaire filtratie, 
kan worden geëxtrapoleerd naar andere geneesmiddelen die voornamelijk via 
glomerulaire filtratie worden uitgescheiden. Om deze analyse uit te voeren, werden 
vijf verschillende datasets gebruikt die betrekking hebben op de renale excretie van 
netilmicine, tobramycine, vancomycine en gentamycine in kinderen. Het uitgangspunt 
bij deze analyse was als volgt: het covariaten model, op basis van geboortegewicht, 
postnatale leeftijd en toediening van ibuprofen, werd beschouwd als een systeem-
specifieke beschrijving van de leeftijdsafhankelijke veranderingen in glomerulaire 
filtratie. De populatiewaarden klaring en verdelingsvolume worden daarentegen 
beschouwd als geneesmiddel-specifieke parameters. Dat betekent dat de waarden 




Om de beschrijvende en voorspellende waarde van het systeem farmacologisch 
model, dat is ontwikkeld op basis van amikacine te evalueren, werden de modellen 
vergeleken met zogenaamde referentie modellen die ontwikkeld werden op basis van 
een systematische covariaatanalyse voor elke stof afzonderlijk. Op basis van deze 
vergelijking, kon worden vastgesteld dat de modellen ontwikkeld met het covariaten 
model van amikacine de data even goed beschreef als de onafhankelijke referentie 
modellen. Bovendien werden bij de referentie modellen dezelfde covariabelen, 
geboortegewicht en postnatale leeftijd, geïdentificeerd als meest belangrijke 
covariabelen op klaring. Op basis hiervan kan worden geconcludeerd dat pediatrische 
covariaten modellen systeem-specifieke informatie bevatten die onderliggende 
fysiologische processen beschrijven. Deze benadering, waarbij informatie van het 
ene geneesmiddel geëxtrapoleerd wordt naar het andere dat geëlimineerd wordt via 
dezelfde route, zal leiden tot optimalisatie van het studie opzet en zal de ontwikkeling 
van geïndividualiseerde en wetenschappelijk onderbouwde doseerschema’s 
bevorderen.
11.3. Ontwikkelingsveranderingen in de glomerulaire filtratie 
en tubulaire secretie in preterme en a terme neonaten op 
basis van een farmacokinetische analyse van de renale 
excretie van cefazoline
Zoals hierboven beschreven, bestaat renale klaring niet alleen uit glomerulaire 
filtratie maar ook uit tubulaire processen: tubulaire secretie en reabsorptie. Cefazoline 
is een geneesmiddel dat zowel via glomerulaire filtratie als via actieve tubulaire 
secretie wordt geëlimineerd. Hoofdstuk 6 van dit proefschrift heeft betrekking 
op de farmacokinetiek van cefazoline in preterme en a terme neonaten. Op basis 
van zowel totale als vrije cefazoline concentraties in 36 neonaten (geboortegewicht 
540-4200g, postnatale 1-30 dagen, zwangerschapsduur 24-40 weken) werd een één 
compartimenten farmacokinetisch model ontwikkeld waarbij samenhang tussen 
totale en vrije concentraties werd beschreven door het schatten van parameters die 
de mate van de eiwitbinding (Bmax = 136 mg/L) en de dissociatieconstante (KD = 46.5 
mg/L) beschrijven. In het ontwikkelde model waren geboortegewicht en postnatale 
leeftijd de belangrijkste covariabelen voor klaring van cefazoline. De verandering in 
cefazoline klaring werd best beschreven met een exponentiële functie op basis van 
geboortegewicht en een lineaire functie voor postnatale leeftijd. Bovendien werd 
een lineaire relatie gevonden tussen de albumine concentratie en de Bmax voor de 
plasma eiwitbinding. Op basis van dit finale model, werden Monte Carlo simulaties 
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uitgevoerd om de blootstelling aan cefazoline te voorspellen wanneer de huidige 
doseerregimes worden opgevolgd. Op basis van de resultaten, wordt voorgesteld 
om het doseerregime zoals beschreven in het Nederlands Kinderformularium, 
enigszins aan te passen opdat gedurende 60% van het doseerinterval de waarden 
van de vrije concentraties boven 8 mg/L zijn. Deze 8 mg/L komt overeen met de 
minimaal inhiberende concentratie voor de vatbaarheid van Staphylococcen volgens 
het “Clinical and Laboratory Standards Institute”. Met deze kleine aanpassing van 
het Nederlandse doseerregime, nl. toevoeging van één extra doseergroep, kon een 
vergelijkbare blootstelling in alle patiënten worden verzekerd. 
11.4. Renale en hepatische eliminatie van propyleen glycol in 
preterme en a terme neonaten
Geneesmiddelen bevatten vaak hulpstoffen om de stabiliteit of de oplosbaar-
heid van de actieve componenten te vergroten. Propyleen glycol is één van de veel 
gebruikte hulpstoffen. Hoewel hulpstoffen als inactief en veilig zouden moeten 
kunnen worden beschouwd, werden toch bijwerkingen en toxische effecten gerap-
porteerd zoals bradycardie, depressie van het centraal zenuwstelsel, lactaatacidose, 
lever- en nierlijden na toediening van hoge en/or langdurige doses propyleen glycol bij 
volwassenen, kinderen en neonaten. Hoewel er richtlijnen bestaan, opgesteld door 
zowel de “Food and Drug Administration” (FDA) als de “European Medicine Agency” 
(EMA) die betrekking hebben op de maximale dagdosis van propyleen glycol, zijn er 
grote verschillen in deze richtlijnen van beide instanties. De maximale dagdosis voor 
propyleen glycol volgens de FDA is 25 mg/kg lichaamsgewicht terwijl de EMA een 
maximale dagdosis van 400 mg/kg in volwassen en 200 mg/kg in kinderen voorstelt. 
Deze verschillen tussen beide richtlijnen is een gevolg van het gebrek aan klinische 
informatie voor het veilig gebruik van propyleen glycol in volwassenen en kinderen. 
Bij volwassenen zou ongeveer 45% van propyleen glycol geëlimineerd worden via 
de nieren en 55% gemetaboliseerd worden door de lever door het enzym alcohol-
dehydrogenase waarbij het wordt omgezet naar lactaat en pyruvaat. Tot op heden 
zijn er echter geen gegevens uit farmacokinetische studies bij kinderen beschikbaar 
omtrent propyleen glycol. Er is enkel een beperkt aantal meldingen beschikbaar in 
de literatuur waarbij de toxische effecten na toediening van propyleen glycol worden 
gerapporteerd. Doordat de nieren nog niet volledig ontwikkeld zijn en de renale 
rijping niet noodzakelijk simultaan verloopt met de hepatische rijping, is de verwach-
ting dat de renale klaring bij kinderen en zeker bij neonaten laag is in vergelijking 
met volwassenen. Om die reden was het doel in Sectie III van dit proefschrift om de 




Hoofdstuk 7 heeft betrekking op de farmacokinetiek van propyleen glycol, 
wanneer toegediend in combinatie met paracetamol of fenobarbital, in 62 preterme 
en a terme neonaten (geboortegewicht 630-3680g, postnatale leeftijd 1-30 dagen, 
zwangerschapsduur 24-41 weken). Op basis van de data werd een één comparti-
menten model ontwikkeld met zowel geboortegewicht en postnatale leeftijd als de 
belangrijkste covariabelen op klaring. De meest belangrijke covariabele op het ver-
delingsvolume bleek huidig lichaamsgewicht te zijn. Bovendien werd vastgesteld dat 
het verdelingsvolume 1.77 keer hoger was voor propyleen glycol wanneer dit werd 
toegediend met fenobarbital in vergelijking met paracetamol.  Om de blootstelling 
aan propyleen glycol in neonaten te evalueren wanneer toegediend in combinatie met 
paracetamol of fenobarbital werden simulaties uitgevoerd. Op basis van de simulaties 
werd vastgesteld dat afhankelijk van geboortegewicht en postnatale leeftijd van de 
neonaten, de propyleen glycol concentraties varieerden tussen 33-144 en 28-218 
mg/L (piekconcentraties) en 19-109 en 6-112 mg/L (dalconcentraties) wanneer toege-
diend met respectievelijk paracetamol en fenobarbital. 
In hoofdstuk 8 van deze thesis kon zowel de hepatische als renale klaring van 
propyleen glycol gekwantificeerd worden in 69 neonaten (geboortegewicht 630-
3980g, postnatale leeftijd 1-30 dagen, zwangerschapsduur 24-41 weken) gebruik 
makend van propyleen glycol concentraties in zowel plasma als urine. Geboorte-
gewicht en postnatale leeftijd werden gevonden als belangrijkste covariabelen op 
hepatische klaring. Omdat een tijdsafhankelijkheid werd gezien werd in de renale 
excretie van propyleen glycol, werden verschillende modellen getest om deze ver-
andering te kunnen beschrijven, waaronder: modellen gebaseerd op tijd na eerste 
dosis, op urine volume of op de hoeveelheid creatinine in de urine. Uiteindelijk bleek 
dat de renale klaring 15% was van de totale klaring na de eerste dosis maar dat deze 
steeg tot 25% 24 uur na de eerste dosis. Deze stijging werd best beschreven door 
middel van een hyperbolische functie op basis van tijd na de eerste dosis. Hoewel 
dit onderzoek laat zien de renale klaring van propyleen glycol in neonaten toeneemt 
met tijd na de eerste dosis, is de renale klaring substantieel lager in neonaten in ver-
gelijking met volwassenen, waar de renale klaring van propyleen glycol 45% van de 
totale klaring bedraagt. Omdat bij neonaten de hepatische eliminatie van propyleen 
glycol het belangrijkst is, heeft dit tot gevolg dat geneesmiddelinteracties ter hoogte 
van het alcoholdehydrogenase enzym belangrijker zijn in neonaten in vergelijking met 
volwassen. Om vast te stellen of deze stijging in renale klaring een auto-geïnduceerde 




11.5. Ontwikkelingsveranderingen in glomerulaire filtratie van 
neonaten tot volwassen op basis van een farmacokinetische 
analyse van de renale excretie van antibiotica
Hoewel glomerulaire filtratie goed gedefinieerd is in volwassen en geschat wordt 
op ongeveer 120 ml/min, is er slechts een beperkte kennis van de maturatie van 
glomerulaire filtratie over de verschillende leeftijdscategorieën. Glomerulaire filtratie 
wordt verondersteld volwassenen waarden (uitgedrukt per lichaamsoppervlak) te 
bereiken op een leeftijd tussen 6 maand tot 1 jaar, maar een exacte kwantificatie 
ontbreekt. Dit lijkt te worden bevestigd in hoofdstuk 3 waar de veranderingen in 
glomerulaire filtratie in preterme en a terme neonaten werden beschreven. Echter 
in deze studie wordt geen rechtstreekse vergelijking met volwassenen gemaakt. Het 
doel van het onderzoek in hoofdstuk 9 is de ontwikkeling van een systeem-specifiek 
model voor de maturatie in de glomerulaire filtratie in de leeftijdsgroep van neonaten 
tot volwassen (N = 1760). Dit model werd ontwikkeld op basis van een analyse van 
de farmacokinetiek van drie renaal geëlimineerde geneesmiddelen, m.n. tobramycine, 
gentamycine en vancomycine. Door opnieuw een onderscheid te maken tussen 
systeem-specifieke en geneesmiddel-specifieke eigenschappen, konden de data van 
deze drie geneesmiddelen gezamenlijk worden geanalyseerd in één analyse. Daartoe 
werd een uniek covariaten model toegepast voor de beschrijving van de variatie in 
renale klaring. De populatie waarden werden op hun beurt weer beschouwd als 
geneesmiddel-specifieke eigenschappen en geschat voor elk geneesmiddel apart. Op 
basis van deze analyse in 1760 individuen (lichaamsgewicht 415 g - 85 kg, leeftijd 1 dag 
- 18 jaar) werd lichaamsgewicht gevonden als meest significante covariabele op zowel 
de klaring als het verdelingsvolume. Het effect van lichaamsgewicht op klaring werd 
best beschreven door gebruik te maken van een allometrische functie waarbij de 
exponent varieerde met lichaamsgewicht van 1.4 in neonaten tot 1.0 bij volwassenen. 
Dit is in overeenstemming met andere studies waarbij de waarde van de exponent 
bij neonaten en jonge kinderen hoger was dan bij oudere kinderen en volwassen. Dit 
wijst erop dat de grootste stijging in de glomerulaire filtratie, optreedt gedurende 
de eerste levensweken. Deze maturatie functie, ontwikkeld in hoofdstuk 9, kan 
mogelijk gebruikt worden om wetenschappelijk onderbouwde en geïndividualiseerde 
doseerschema’s te ontwikkelen voor renaal geëlimineerde geneesmiddelen over het 




Gedurende de groei en ontwikkeling vinden veel veranderingen plaats in het 
lichaam. Aangezien de geneesmiddelblootstelling door deze veranderingen in groei 
en ontwikkeling wordt beïnvloed, moeten deze worden gekarakteriseerd. In dit 
proefschrift hebben we onderzoek gedaan naar de ontwikkelingsveranderingen in 
glomerulaire filtratie van neonaten tot volwassenen, op basis van een analyse van de 
veranderingen in farmacokinetiek van (model)-geneesmiddelen die bijna uitsluitend 
via glomerulaire filtratie worden geëlimineerd. In eerste instantie hebben we ons 
hierbij gericht op karakteriseren van glomerulaire filtratie in preterme en a terme 
neonaten, aangezien in deze groep grote veranderingen worden gezien. Op basis 
van het ontwikkelde farmacokinetisch model, werd vervolgens na een uitgebreide 
interne en externe validatie, een nieuw doseerregime opgesteld voor amikacine in 
preterme en a terme neonaten. Vervolgens werd in een klinische studie het nieuwe 
doseerregime, afgeleid uit de farmacokinetische analyse, geëvalueerd. 
Om te vermijden dat voor elk geneesmiddel een tijdsrovende systematische 
farmacokinetische en/of farmacodynamische analyse moet worden uitgevoerd, werd 
vervolgens een nieuwe benadering toegepast, de zogenaamde systeem farmacologische 
benadering. Dit betekende dat informatie van het ene geneesmiddel geëxtrapoleerd 
werd naar het andere geneesmiddel,  door een onderscheid te maken tussen 
systeem-specifieke eigenschappen en geneesmiddel-specifieke eigenschappen. Tot 
slot werden de ontwikkelingsveranderingen in glomerulaire filtratie gekarakteriseerd 
van neonaten tot volwassen, waarbij tevens deze systeem farmacologische 
benadering werd gebruikt. Dit had tot gevolg dat 3 verschillende geneesmiddelen, 
tobramycine, gentamycine en vancomycine konden gecombineerd worden in één 
analyse. In bovenstaande analyses is het echter wel belangrijk om op te merken dat 
deze systeem farmacologische benadering werd toegepast op de renale excretie van 
geneesmiddelen met vergelijkbare fysicochemische eigenschappen. Om de exacte 
invloed van verschillen in fysicochemische en farmacokinetische eigenschappen te 
evalueren, is het belangrijk meer studies uit te voeren om na te gaan in hoeverre deze 
nieuwe benadering kan worden toegepast. Deze analyse wordt best uitgevoerd door 
gebruik te maken van “fysiologische gebaseerde farmacokinetische modeling” omdat 
met deze benadering het mogelijk is simulaties uit te voeren met geneesmiddelen 
met verschillende fysiologische en farmacokinetische eigenschappen. Tot slot is het 
ook belangrijk de ontwikkelingsveranderingen te beschrijven over de verschillende 
leeftijdscategorieën in de andere subprocessen die bijdragen tot renale klaring 
namelijk tubulaire secretie en reabsorptie. Hierbij kunnen de modellen, beschreven 
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in dit proefschrift, die de ontwikkelingsveranderingen beschrijven in glomerulaire 
filtratie gebruikt worden als basis. 
De transitie naar een systeem farmacologische benadering en de combinatie van 
verschillende strategieën (extrapolatie naar andere geneesmiddelen, gebruik van 
data uit volwassenen of niet klinische data) zal uiteindelijk leiden tot benaderingen 
die zich meer focussen op het functioneren van onderliggende systemen dan op 
geneesmiddelen. Dit zal uiteindelijk de ontwikkeling van farmacokinetische modellen 
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